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LIFE SCIENCES, TECHNOLOGY,
AND THE LAW SYMPOSIUM
UNIVERSITY OF MICHIGAN LAW SCHOOL
ROOM 250, HUTCHINS HALL
FRIDAY, MARCH 7, 2003
WELCOME AND INTRODUCTORY REMARKS
MATT MOCK: Good Morning! My name is Matthew Mock and I
am Editor-in-Chief of the Michigan Telecommunications and Technology
Law Review. Welcome to our Symposium: Life Sciences Technology and
the Law. Before we begin I would like to take a moment to thank our
sponsors for their generous support. This event is made possible by do-
nations from the following members of the University of Michigan
family: the Law School; the Life Sciences, Values and Society Program;
the Life Science Institute; the Business School; the Office of the
President; the Office of the Provost and Executive Vice President for
Academic Affairs; and the Chemistry Department. I want to thank all of
these members, and any of their representatives who are in attendance
today.
And now, without further ado, I would like to introduce our opening
speaker. Dr. Alan Saltiel received his A.B. in Zoology from Duke
University and his Ph.D. in Biochemistry from the University of North
Carolina. In 1984, after a distinguished postdoctoral research fellowship,
he moved to The Rockefeller University as Assistant Professor. In 1990,
he joined Parke-Davis Pharmaceutical Research, and was later promoted
to Distinguished Research Fellow and Senior Director of Cell Biology at
Parke-Davis. He was named Adjunct Associate Professor of Physiology
at the University of Michigan School of Medicine in 1990 and was
promoted to Adjunct Professor in 1994. In 2001, Dr. Saltiel moved to the
newly created Life Sciences Institute at the University of Michigan as
Professor of Medicine and Physiology. In 2002, he was named director
of the Institute and John Jacob Able Professor in the Life Sciences. He
has received numerous awards, including the Rosalind Yallow Research
and Development Award from the American Diabetes Association, the
Herschel Award, the John Jacob Able award from the American Society
of Pharmacology and Experimental Therapeutics, and was elected to
honorary membership in the American Society of Clinical Investigation.
He has served on a number of advisory panels and editorial boards,
including the Journal of Biological Chemistry, Endocrinology, Diabetes,
the Journal of Clinical Investigation, and others. He has nine issued
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patents and has published over two hundred original papers. And now it
is my pleasure to introduce Dr. Saltiel.
[Applause]
DR. ALAN R. SALTIEL: Thank you very much Matthew. It's
really a pleasure to be here and a pleasure to be at this conference with
you. I want to thank all of you for coming, on behalf of the Life Sciences
Institute, and to welcome you to the law school and to this important
conference. I think we have in front of us what promises to be a very
interesting day. I'm particularly impressed by the wide range of perspec-
tives that we'll hear from today, scientists, lawyers, legal scholars,
university administrators, and biotech industry representatives.
I want to start off the symposium by telling you a little bit about the
Life Sciences Institute. The make-up and the mission of the institute are
germane to today's activities because we are planning a new kind of aca-
demic endeavor that will bring together different scientific disciplines to
bear on important scientific questions, particularly in the field of medi-
cine. Our institute will consist of faculty drawn from a variety of
disciplines. These will include chemistry, structural and computational
biology, genetics, cell biology, and physiology.
Our building plan includes open architecture, with big labs that are
designed to facilitate maximum interactions. Our hope is that the faculty
who reside in this wonderful space will seek out collaborations and find
synergistic ways to attack problems such as diabetes, cancer, inflamma-
tory disease, and other problems in medicine. I'll give you one example
from my own field, diabetes. I can see a situation in which geneticists
will hunt for genes that endow susceptibility to diabetes, and then col-
laborate with cell biologists and biochemists, and possibly even
chemical biologists and chemists to try to design molecules that might
attack the proteins that are responsible for this kind of disease. Thus,
what we are hoping to build is an exciting endeavor, with potential for
impacting in a basic way human health.
This kind of approach that we're planning to take typifies a situation
in which we follow the science wherever it leads. We plan to do this de-
spite the boundary crossing that's involved in this kind of process. This
is really what the new scientific problems of our area demand, the ability
to focus on the complex diseases and diseases that are very difficult, par-
ticularly those associated with aging.
Now just as today's scientific problems require a variety of perspec-
tives, so do contemporary legal, social, and ethical problems that have
emerged as a result of our new, enhanced understanding of the processes
of life. Indeed, some of the very basic tenets of our social fabric are chal-
lenged by today's scientific progress. You're taking up some of these
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issues today, and I applaud you for this. Scientists acting alone surely
cannot resolve or necessarily even identify these seismic shifts. Simi-
larly, a discussion by lawyers and legal scholars surely need scientists to
be involved, because the implications of discoveries that are made in
science can't really be understood or appreciated without the involve-
ment of the actual discoverers themselves. Finally, we all know that
university administrators and legal scholars and business leaders have a
crucial role to play in putting new discoveries to practice in the real
world. Thus, if you take a look at all of this together, I think it's clear
that we must have a dialogue across the disciplines and across the set-
tings of our social institutions, including law, policy and business itself,
if we're able to keep pace with our scientific progress in the laboratory.
Again, as I mentioned before, I applaud the planning that's assem-
bled such a diverse and exciting stellar group to talk about life science,
the technology, and the law. I wish you a tremendous day. I hope you




Thank you Dr. Saltiel. Good morning. My name is Larry LaVanway,
and I'm the Executive Editor and Conference Chair for the MTTLR
Volume Nine. I want to thank Dr. Saltiel for taking the time to speak
here today. We really do appreciate it. And now I'd like to present our
keynote speaker.
Dr. Philip Reilly is President of the American Society of Law, Medi-
cine, and Ethics, and currently sits on the Board of Directors. From 1994
to 1997, he was on the Board of Directors of the American Society for
Human Genetics. He's also been the CEO of Interleukin Genetics since
1999. Prior to joining Interleukin as a CEO, he held the position as
Executive Director of the Eunice Kennedy Shriver Center for Mental
Retardation, a not-for-profit organization in Massachusetts. He held that
position until 1999. Dr. Reilly has also had several teaching positions,
most notably an Assistant Professor spot at Tufts University School of
Medicine, and another Assistant Professor position at Harvard School of
Medicine, and an Adjunct Professor position in both legal studies and
biology at Brandeis University. Dr. Reilly is a member of the American
College of Medical Genetics, the Massachusetts Bar Association, and the
American Association for the Advancement of Science. He has served on
many national committees chartered to explore public policy issues
raised by advances in genetics and is frequently asked to comment on
Fall 20031
178 Michigan Telecommunications and Technology Law Review [Vol. 10:175
these topics by the national media. He's an author of four books and has
published more than one hundred articles in scholarly journals. His most
recent book, Abraham Lincoln's DNA and Other Adventures in
Genetics,' published by Cold Harbor Spring Laboratory Press, has been
chosen by the city of Ann Arbor's reading program for its book of the
year for 2003. On a personal note, I know it happens to be a good read
for both the scientist and the layperson. Dr. Reilly also holds a B.A. from
Cornell University, a J.D. from Columbia University, and an M.D. from
Yale. It is my pleasure to present our keynote for the 2003 MTTLR
symposium, Dr. Philip Reilly.
[Applause]
DR. PHILIP R. REILLY: Good morning. It's a pleasure to be with
you this morning to explore that interface between science and law that
was so appropriately referred to by the first speaker. As you know, C. P.
Snow, five decades ago, wrote articles about the so-called two cultures. I
think that concern about the divide between those who create knowledge
and those who apply it, is as great as ever.
In thirty minutes, I cannot possibly hope to ground those of you who
are nonscientists in the facts upon which I would build the argument that
we are, in fact, in the midst of the revolution of knowledge in biology,
and particularly genomics and proteomics. So to some extent you'll have
to take that for granted.
But I'm guessing that many people in the room are nonscientists. So
I thought I would take just a couple of minutes to try and transfer to you
some of my sense for the magic of our understanding of DNA. After all,
what other symbol in modern science has become as iconographic as the
double helix? Almost everybody, literate American, I think if you say
double helix, an image comes to their mind about that coil that Francis
Crick's wife sketched out fifty years ago as the first symbolic
representation of the DNA molecule. So just before I get into my talk,
just think about this for a second. You began life as a single cell, the
union of a sperm and egg, each a vector carrying information-
approximately 3.2 billion letters of the DNA molecule. A molecule that
uses an alphabet that's only four letters long. You write your briefs or
read your casebooks with a language of twenty-six letters and yet you've
been created through an evolutionary scheme that needed only four
letters to create things as exclusive as yourselves. So how might that be?
Well the answer, in part of course, is that the message is very long, 3.2
billion letters is a lot of letters. And unlike our alphabet where three Ts
or three As or three Gs wouldn't mean very much, in the language of
1. PHILIP R. REILLY, ABRAHAM LINCOLN'S DNA AND OTHER ADVENTURES IN
GENETICS (2000).
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DNA repeat sequences of information can, in fact, carry a message out
into the cytoplasm to help make a protein, which is what makes us
function.
There's a lot of really fascinating things about the DNA molecule.
Just think about how you pack 3.2 billion letters of information in a sin-
gle cell. The packing ratio of the DNA molecule is about seven thousand
to one. When you think about it as a layman, you think of a string, when
in fact it's this huge bunch of spaghetti at the microscopic level. And
somehow it behaves in a very orderly fashion. It's really quite astound-
ing. In fact to me, a never-ending source of wonder. Think about, for
example, the fact that in just nine months you go from a single cell to a
well organized infant of about ten trillion cells. And from the moment
you're conceived you have all the genetic programming you need to
make it through adolescence itself, a miracle. And to go onto age and
middle age and reproduce yourselves. It's all right there in the first cell.
One of the reasons that we're here today is that we now have the
ability to ask exquisitely refined questions, not only about your DNA but
pretty much anybody's DNA. And, in fact, one of the underlying themes
that I'm not really going to discuss is that the cost of acquiring genetic
information, be it about corn or people, or the way the drug works in the
body, is falling very, very rapidly. So one of the silent barriers to dealing
with the information is disappearing.
Just a couple of other reflections. DNA teaches us some wonderful
things about humanity. One thing it teaches us is that we're all so alike.
So if I take the DNA from any two people sitting in this room and com-
pare it, on a sequence level you're 99.9% alike. Well why are you so
much smarter and better looking than the people sitting next to you?
Well the answer, of course, is in part the environment, but in part the
0.1%. This 0.1% of 3.2 billion is 3.2 million. So we're both profoundly
alike and profoundly different at the DNA level, which is to me a source
of great mystery, actually. And maybe some day someone will figure out
a way to use the fact that we're 99.9% alike to break down the lingering
nineteenth century stereotypes of the colonial era that described and set
the archetypes of race in the Western world, which from a biological
perspective is not completely meaningless, but has much less meaning
than it should have.
So what I want to do is try to proceed with some reflections very
closely keyed to the remarks made in the brochure of the symposium,
actually that describes it, and wonder if together I could help set the
stage for the more important work that comes later, which is the work of
the three panels, which I think promises to be very interesting. So this is
what those who've created this conference wrote in their brochure. You
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can read it, I'll just paraphrase it. Just the notion of a revolution, if you
will. A notion that even legal thinking would be profoundly challenged
by advances in the life sciences. I wrote at the bottom of this slide, "Do
you agree or disagree?" And probably what I should've also added is,
"Do you feel you're ready to agree or disagree?" Back to my question
about the divide between science and policy makers. I, at least, agree
that it is a revolution. And I could've put a lot of different messages up
on this slide, but I tried to keep at least the first one to you.
Trying to imagine how a lawyer might see it. It is a fact that in one
year in the late '90s, more bills were introduced into the nation's state
legislatures about the regulation of genetic information than any other
single topic. More than 650 bills at one point by one count. Now most of
them did not become law and most of them, I would argue, were dealing
with problems that had not yet manifested. But still I think this is a pro-
found reflection of the way the public has begun to perceive the power of
this information. I could've put up another slide. There has been, for ex-
ample, a profound effect on thinking about genetics in the world of
modem art. I'm involved in editing a series of books now about the role
of the DNA molecule as an icon in modem art. It's almost impossible to
see a TV show or read a journal article where there isn't some often-
humorous reference to the power of genes and often a misleading one.
But on a less legally-focused area, it's true, genetic information is af-
fecting aspects of human existence that are the most closely held to us,
in our emotions and our hearts, how we reproduce, the very food we eat,
and perhaps most importantly for the lawyers, how we take the measure
of one another. And one of the themes I'd like to introduce is this notion
of how we value information and what it means, and how it impacts
what we perceive about other people.
The last statement on the slide is a bit controversial. There are many
scientists that would disagree with that. But I actually still think that in
the nature/nurture argument, and clearly it's not an argument because
everything is genes unfolding in an environment, that we still tend to
underestimate, in some cases, the roles genes play. That's a politically
incorrect statement, but I actually think it's going to turn out to be true.
So what are some of the things we'll be able to do? And I'm glad
there's some scientists here to keep me honest. I'm actually highly con-
fident about every single one of the assertions I'm going to make in the
next two slides. I think there is almost no chance that these won't come
to pass. Many have come to pass already. And each one of these I think
you could quickly, and I'll try to do so, raise some interesting legal or
constitutional questions about the ability to assess reproductive risks for
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many diseases and intervene and perhaps neutralize them. Then I have
these letters PGD, which stands for Preimplantation Genetic Diagnosis.
So imagine, for example, an Ashkenazi Jewish couple both of whom
are carriers for the Tay-Sachs disease, who are opposed to first trimester
abortion, for ethical reasons. They could theoretically-in fact it's being
done-they could engage in the technology of in vitro fertilization. If
you're not infertile, we use the same technology then. To have a single
cell, out of an eight cell pre-human embryo, tested to see whether that
embryo pre-implanted, would be destined to have Tay-Sachs disease or
not. And if it was not, then implant it, and guarantee the parents that if
the child came to term Tay-Sachs disease would be one problem in life
that it would not have. That's very simple when you're talking about a
disease as devastating as Tay-Sachs disease, which is uniformly fatal by
age five or six and a terrible disorder. But what happens when we can
assess risks, whatever they are, for much more uncertain, or much less
certain, categories of risk, such as learning disability and things like
that?
Our ability to greatly expand the assessment of newborns, by that I
mean a DNA-based analysis, which is currently biochemically-based
analysis and will be DNA based in the next decade. Currently every baby
born in the United States and much of the Western world has a test. All
the people in this room born in the United States who are under the age
of thirty-five have had their blood taken and have been tested for genetic
disorders. You just don't know it because your memory traces don't go
back that far. And we are going to expand that list of disorders.
Currently, in Massachusetts, it's gone from five to thirty. I could easily
imagine it being three hundred. Again, the issue is what's a genetic
disorder? What is the right of the state to have the information? By the
way, all this testing is done pursuant to mandatory state law, with some
religious exemptions in certain states. Most exemptions citizens don't
know about anyway and they're not imposed. This ability to identify a
potential for risk in advance is an ability that gives people a lot of
concern because it might have an impact on how, again, we measure
other people. In this case, in schools, by the insurance industry or the
workplace. There's been a lot of discussion about that and I won't get
into it here.
The stem cell controversy that you've followed in the halls of
Congress and elsewhere relates very much to the right to life controversy
and how we value human life before it exists independently. It's just one
of the areas that I think we're going to see a lot more debate about in the
future.
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We already have created animals that are in fact pharmaceutical, that
are bioreactors. Genzyme, for example, in Massachusetts, has a herd of
goats that "makes" human proteins. Female goats secrete milk and can
be very easily extracted from the milk and scaled out and purified. And a
lot cheaper in the long run than building a very large building.
One other area that I'm particularly interested in and has lots of in-
ternational implications-huge debates underlie every one of these
statements that I'm making to you-we're now seeing the first real evi-
dence published in the leading scientific journals that the per hectare
yield of basic grains, things like soy, corn and rice, is benefited if certain
genes are moved into those genomes and then into seeds of those crops
to confer resistance to pesticides. That has huge implications for debates
over saving remaining rain forest, as well as issues that will be addressed
later, perhaps about intellectual property, things like that.
I think it's very possible in the next ten years that we will have cre-
ated an industrial setting, a line of pigs, that are excellent donors of
humanized kidneys to humans. This year, in the United States, sixteen
thousand people will die waiting for a kidney transplant. And I'm not
suggesting that the science is solved yet. We have lingering concerns
about porcine (pig) retroviruses, and the ability to really trick the human
immune system into believing that it's getting a human kidney, when in
fact it's getting a pig kidney. Imagine what folks like Peter Singer will
have to say about this, and animal welfare people. It's okay to eat them,
but apparently you can't take their kidneys and put them into your bod-
ies. There's now a company called Genetic Savings and Loan that,
frustrated with the lack of successive cloning dogs at Texas A&M, has
decided to do it commercially and make genetically engineered dogs
available for your household. John Sperling has done this work and he's
got infinite resources, since he's the founder of the University of Phoe-
nix, one of the largest degree granting institutions in the United States.
And what if your dog was really smart? I know you all think your
dogs are smart, but what if your dog was really smart? What if, for ex-
ample, you could ask your dog to carry a rose across the restaurant to a
very attractive woman you'd like to meet, and he would do it perfectly? I
suggest to you, read Dean Koontz's book Watchers.2 It's a delightful
meditation upon what happened if you really had a dog that was so smart
you could name it Einstein. Koontz is apparently pretty good as a sci-
ence watcher, especially since the book was published in '88.
But on a more serious note, the challenge for you today is to, as fu-
ture lawyers and policy makers in the United States coming out of a
great school like this, is to think about these three great areas in which it
2. DEAN R. KOONTZ, WATCHERS (1997).
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will be the lawyers, the ethicists, and the elected officials, who take what
the great scientists hand off to them and, hopefully with a dialogue with
those scientists, begin to continue to craft the appropriate rules for the
use of these very powerful technologies.
I wonder, even at an institution like this, how many law students who
have taken criminal law are really aware of the unbelievable impact that
DNA technologies have on the criminal justice system. It is profound,
indeed. I don't have time here to get into it. There are other people in the
room, like David and Richard who are quite expert on it. But it's really
to me very astounding. Not so much the notion of the introduction into
evidence of tissue analysis that confirms the identity of two samples, but
the evolution of large scale DNA databanks. Throughout our society,
with an ever expanding scope for the number of individuals who are
covered by those banks, to the point where I would probably not be sur-
prised if a decade from now it's routine to take DNA evidence--or have
the right to take DNA evidence-from any person in the United States
who's arrested. It's approaching that situation in the United Kingdom
already.
Again, an area that's particularly close to my current work in the
biotech world, there are some amazing regulatory issues that will emerge
as we begin to understand why some drugs work in people and some
drugs don't. As an internist who used to take care of people with diabe-
tes, and heart disease, and hypertension and things like that years ago, I
knew when I gave somebody a drug, as I started to manage their chronic
disease, that there's about a two out of three chance I'd get roughly the
desired response that I wanted. And for one third of the patients, I'd be
trying another drug two or three months down the line. Now why is that?
Well it's because the drug is given to people who each have a different
genetic background. There are other reasons. It could depend on what
other drugs you're taking, how old you are, how well your kidney works,
whatever it might be. But basically your genetic profile changes that. So
one of the things I think we're going to see in the near future-and I ac-
tually don't think it's going to happen in the FDA first, I think it's going
to happen in the United Kingdom first because of their national health
service-is the demand for pharmacogenetic information. The demand
to have that information and incorporate it into decisions about prescrib-
ing and decisions about payment and reimbursement. In my humble
opinion, it will not be the pharmaceutical industry that drives this for-
ward, it will be the payers. And I'm already seeing that. I've been
knocking on the doors of pharmaceutical industry for about five years,
with little success. I started knocking on the doors of the payers, telling
them about this, and the doors were open quite widely and my little
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company now has two research agreements that are not with wonderful
companies like Pfizer or Merck. They're with Kaiser Permanente and
United Health Group, the people who pay the bills. There are huge legal
issues lurking about, and certainly huge regulatory ones.
And a very interesting topic, especially at a great university like this,
is to explore whether there is still even a boundary between academia
and industry. In Boston I'm convinced, there is not. I don't think I can
find a professor in the medical schools I move through that doesn't have
an industrial relationship. And I don't say that because I think it's a bad
thing. I actually think it's a very good thing, but I don't think we as an
academic society have come to terms with it yet, and I'm glad to see you
have a panel that's going to explore some of those issues.
Other topics that might, if you had three days instead of one day, de-
serve equally a panel are some of the ones that I just mentioned, which I
won't repeat because you've heard me say them. I'm going to list some
more here. These are new, and I've deliberately tried to key a couple of
these to legal thinking. Something as basic as the principle of confidenti-
ality, you've probably covered it for thirty minutes in tort law or family
law, may be totally rewritten as a legal concept by genetic information.
Because unlike most medical information, genetic information is famil-
ial. If I have a mutation that I inherited that confers an increased risk of
colon cancer, my brother has a one in two risk of having the same muta-
tion. If I'm the first to discover that, do I have an ethical duty to disclose
this to my brother? Does the physician have an ethical duty to disclose it
if I decide that I don't want it disclosed? Could he override my request to
be honored on the principle of confidentiality? Now if you think that's a
purely theoretical or fanciful hypothetical, let me assure you that that's
wrong. There's already been, some of you may know, two State Supreme
Court cases, one in Florida and one in New Jersey, that have addressed
exactly this issue-lawsuits that grew out of an individual with a disease
who sued a physician because that physician had treated a parent with
the same disease and a warning had not gone out to the next generation.
The two State Supreme Court decisions are antipodal. One says that the
principle of confidentiality should be honored. And the other one says
that the risk inferred from the genetic information, the risk of cancer,
was so great that there was a duty to warn the transcendent principle of
confidentiality. I personally am highly confident that the notion of confi-
dentiality, as it currently exists in state common law, will be rewritten in
the next decade by genetics. The more genetic tests there are, the more
standards of care there are, the more breaches of standard care there are,
and the more lawsuits there are. It's amazing to see how carefully the
plaintiffs bar reads medical journals to see the latest developments in the
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possibility for genetic testing. I get calls from the plaintiffs bar about this
stuff all the time.
A harder one to get our fingers around but something that is actually
bothering me a great deal, you could say for selfish reasons and you'd
probably be right, is the effect of the economic downturn on the very
exciting biotechnology industry. Largely because some of the best minds
in America have moved out of academia into industry, back and forth,
and there's over a thousand biotech companies working to become the
engines of new medicines and new devices to prolong your life and
make you healthier. It has been astounding to see the impact of a down-
turn in the capital markets on those engines. Those engines are
sputtering at best and many of them are failing. It is impossible to quan-
tify the loss to you individually and to your generation and your
children's generation from discoveries that will be delayed and devel-
opments that will not be implemented, or will be implemented a decade
later than they might have been, because of a change in just the way our
capital and our economy flows.
I think another interesting one that would have made a good panel is
how academe will see itself when called upon to get involved in either the
defensive or, let me be so bold as to suggest, the offensive use of bio-
terrorist weapons in coming years. It is, after all, a relatively small
number, a few thousand individuals in the United States that have the
knowledge to do that and most of them are situated in academe or
academic-like settings within pharmaceutical companies.
I think it's wonderful that we have people like David Kaye here, and
others, to think about the impact in the criminal law that I alluded to ear-
lier. DNA can do one thing in the criminal law, it can establish the
identity of two samples and place an individual somewhere in space,
rarely in time. It's possible to determine time only if linked to other
things like the decay of a corpse or something like that. But what about a
day-think about it from a jurisprudential point of view-when by
analysis of the DNA sample you might also be able to infer phenotype.
Phenotype, for a word that some of you might not know, is what you can
see when you look at me or you look at your neighbor. It's the product,
the end of a lifetime of gene and environmental interactions. I'm just
imagining this for a moment, let us assume that, and I believe we will,
that we identify relatively common polymorphisms, gene variance, that
predispose to alcohol abuse. I would not be at all surprised if within the
next decade, it was fairly well established that about ten percent of se-
vere alcoholics in our society have a strong genetic driver. If we have a
really easy test to identify that polymorphism, how would that impact on
sentencing in vehicular manslaughter cases or in parole decisions? It will
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be impossible to sequester that kind of knowledge from those kinds of
decisions. And maybe it shouldn't be. I'm not implying that it should be,
but I think we have to weigh how it would be used.
Imagine a day not so long from now when behavioral geneticists
working with biochemists and psychologists ask to get a DNA sample,
with the appropriate consent from a thousand people that have been con-
victed of drunk driving and a thousand people that have never had a
drink-or have never had a violation. And you look at the distribution of
a certain gene variant in the two, to determine if one variant is much
more common than the others. Is that coincidental or is that a bio-
marker-does that allow us to infer and with what degree of precision
can we map that genetic variation to a phenotype? I'm not saying we're
going to be able to do a good job of it. I am saying it would be irresisti-
ble to investigate the question.
There've been really profound changes in the law already by ad-
vances of genetics, and I could think of no better one than to recall that
twenty years ago there were tens of thousands of cases litigating pater-
nity in the United States, and they've virtually disappeared. They just
don't happen anymore. Why don't they happen? Because the DNA evi-
dence is so powerful in identifying the putative father. Twenty years ago
we could exclude using HLA typing, red cell enzymes, things like that.
We could say he's definitely not the father. But now with the exception
of identical twins, we could say essentially he definitely is the father.
Paternity lawsuits don't happen anymore.
Another area where genetics and law are coming together is in one
of the most problematic areas of malpractice law, the so-called brain-
damaged baby cases where everyone is uncertain of the cause, but eve-
ryone assumes the obstetrician. There are thousands of them in the
United States each year. I've been telling the insurance industry for years
to do a full genetic analysis of every child involved in such a lawsuit.
And based on my experience, I think that it may not sound like much to
you, but we're talking about twenty to fifty million dollar damage
awards. Probably on the order of five to ten percent of the cases the child
actually has a genetic disease that was present at conception, which is
really the cause of the set of problems that has directly led to the lawsuit.
And I'd like you to consider today, either with your panels or sepa-
rately, some of the broad constitutional questions involved in the state's
right to know things about you through your DNA. And I've alluded to a
couple of these earlier. But aren't we heading toward universal sampling
of DNA on entering into the United States? That actually wouldn't sur-
prise me at all, given the recent events. Or what about universal sampling
at birth? You already have compulsory newborn screening, which is in
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fact universal sampling at birth. It's just that the laws weren't created for
that purpose. They were created to ask whether their child had a rare ge-
netic disorder. And the laws don't say you can save the DNA. Actually
it's dried blood, it's not DNA. But now State Departments of Public
Health are starting to save hundreds of thousands of DNA samples. DNA
is not quite as stable as is implied by Jurassic Park, but DNA is a re-
markably stable molecule. You can take a dried blood sample, put it on a
filtered paper disk and let it sit in the basement at room temperature for
twenty years and do a DNA analysis quite easily, actually. Ed McCabe,
from UCLA, has published papers showing you can diagnose single
gene disorders on very old DNA samples that are collected at birth.
And what about the application of routine DNA testing under a pub-
lic safety doctrine? I think I've timed my last few minutes to just give
you one fascinating example. If you flew across the United States in a
commercial airliner in the mid-90s, say from New York to San Diego,
you would, for a period of that flight, have been handled by two air traf-
fic controllers, two brothers, who were at fifty percent risk for a disease
called Huntington's Disease, and their employer didn't know it. Hunting-
ton's Disease is an incurable neurological disorder onset in mid-life-
some of you know it as Woody Guthrie's Disease. One of the first things
you could lose in Huntington's disease is the ability to track an object on
a screen. I actually got called from the physician of the two brothers and
he said, "Wow, what am I supposed to do about this, should I call the
airport where these guys work?" Back to the principal of confidentiality
and privacy. And you can maybe decide what should've been done in
that case.
So there's some of the thinking again, tracking your three panels,
which I think you've put together so nicely. Some of the specific things.
I think the FDA has failed to address the issue of pharmacogenetics as a
true regulatory problem. I think it ought to catch a little grief for that.
The Department of Agriculture has not done enough pre-market safety
evaluation for dispersing genetically engineered products in the field.
We're definitely going to rewrite in the next few years our federal guide-
lines for human subject research. They were written in the early '70s, at
a time when all we thought about was danger of putting a new com-
pound into your body. But now with genetic testing, there's a new set of
concerns about information that are not adequately addressed in the
guidelines. And then you have some of the tragic deaths recently, inevi-
table in a new therapy, that call into question the risk benefit for
subjecting children, particularly, to new therapies.
And one of my favorite ones, and I have yet to see a single article in
any law, science, or medicine, in any journals on this topic (and we'll see
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if I can make the argument to you quickly), is about the role of genetic
information in the workplace. One of two great pillars of regulating the
workplace in America are, of course, the Equal Employment Opportu-
nity Commission, which is charged with implementing the Americans
with Disabilities Act and has certain definitions of disability-the third
one says if I, the employer, regard you as disabled and discriminate
against you, you can claim protections of the act. The EEOC has inter-
preted the third definition in the guideline, written in '95, to say that if I
discriminate against you, my employee, because I learn that you carry a
gene that might predispose you to breast cancer later on, and I'm con-
cerned with the costs associated with that, you can sue me. Of course
that means that under the EEOC interpretation that all 285 million
Americans are disabled, because each one of you carries several muta-
tions that you don't know about. So on the one hand you have this body
of law-a small body of law or regulation-that's saying genetic infor-
mation should not be abused in the workplace. On the other hand, we
have a slowly developing body of knowledge that says some people
aren't really genetically predisposed to occupationally related disease.
Berylosis, contact with the metal in berylium used in aircraft manufac-
turers, is an example. Under the Occupational Safety and Health Act,
people are entitled to the safest possible workplace. If people are entitled
to the safest possible workplace, then should you not be offered a genetic
test if it really could identify people at high-risk for a disease in that
workplace? And how does that fit, or how will that fit, ultimately with
the principles that say you shouldn't be forced to undergo certain testing
and things like that?
So I think there's an interesting law review article. A little bit for-
ward-looking but not impossibly so, because after all we've had our first
lawsuit brought by an Iowa Federal District Court two years ago,
brought by a collection of a group of employees who complained be-
cause the employer coerced them, allegedly, into undergoing genetic
testing because of a spate of disorders that appeared among those small,
collective individuals. It's the Burlington Northern case, if you want to
read about it.3
We certainly are going to have a lot more regulatory challenges in
the insurance industry, I think. I don't really think it's going to be in the
health insurance industry because most of us either get government in-
surance, are uninsured for economic reasons, or get group health. But I
do think that a very interesting issue for the future, which will certainly
generate law review articles, is what would happen if the long-term care
3. Bhd. of Maint. of Way v. Athena Neurosciences, Inc., No. C01-4012 MWB, 2001
WL788738, at *1 (N.D. Iowa Apr. 27, 2001).
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insurance industry, the most rapidly growing sector of insurance in the
United States, designed to appeal to the aging population, ever got its
hands on a test that really did predict risks of Alzheimer's disease, be-
cause that's what destroys the bottom line in these retirement
communities that are sort of promising to take care of you until you die.
Everybody who runs those committees, I think, worries about people
with Alzheimer's disease, because they are so expensive to care for and
they've contracted to pay for it. I was approached a couple of years ago
by a company in Florida that asked if there was a way we could screen
our applicants for Alzheimer's disease. And from the insurance perspec-
tive it makes perfect sense. I mean we exist in an equity-based system.
We don't exist in an insurance system where we all pay in the same
amount and all get the same care. We exist in a different kind of system.
In fact I'm fond of remembering about five years ago Americans were
asked two questions in a poll. The first question asked whether you think
everybody should have access in America to life insurance at a reason-
able premium? Eighty-five percent of the people said yes. But a few
questions later you were asked if you would be willing to pay ten percent
more in your premiums so others could get access to life insurance? And
eighty-five percent said no. So that's the problem. The problem isn't just
the insurance industry. The problem is also the consumer of the insur-
ance product. And you've been looking, while I've been talking, about
some of these other issues.
Back to the last part of my talk. The third panel, I think, is on tech-
nology transfer issues. As somebody who has moved into the biotech
industry, there is nothing I care more about than the care and feeding of
the universities. They're incredibly important to the industry. I always
feel a sense of great pride and accomplishment when I convince a good
investigator in a place like Michigan or anywhere to agree to collaborate
with us, as a sponsor. I think it's important to remember that neither the
universities or government have remotely near the resources needed to
capitalize on their knowledge. This may be one of the most fundamental
issues of all: we generate far more information than we utilize currently,
in the United States. We have got to address that issue. Indeed the
Federal Government twenty years ago or so, said we are going to figure
out a way to move discoveries out of NIH and into the marketplace.
There are websites that list patents available at low costs, if you're will-
ing to develop them. So how are we going to do that? That's a big issue I
think, and even more pressing in an economically stagnate society. There
may be a need to create new sets of relationships.
So in closing, my last slide, what I think are really some of the great
questions that lurk even above and beyond what we're talking about
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formally here today-they're medical questions again. But they're ones
that I hear about when I go around the country and the world. There's
this tremendous sense, which is probably correct, and I'll have to elabo-
rate a little, that we are entering a new kind of eugenic era, and not one
in which its state is driven by government, but it's actually driven by
consumers. If I had more time I would tell you how certain birth defects
that were very common thirty years ago in certain societies have almost
disappeared because the society, however inchoately, decided that it was
an undesirable phenotype. Well that may've been good for the easy cases
but there are harder questions. But it's when consumers are clamoring
for this information that it creates a different set of ethical policy prob-
lems than when it's being proposed from the top down.
Now what is the impact of this knowledge on the whole notion of
how we treat people with disabilities. Because on the one hand we are
introducing and implementing technologies that are unarguably disvalu-
ing certain people, or at least the same phenotype of certain people who
also exist.
As I move to the last two, which are really economic questions, I can
tell you there's very ample evidence in the Third World (China or India,
for instance) that there is deep suspicion about what we're doing with
our technologies. China enacted a law (or rule) recently that said you
can't move DNA samples out of the country for research purposes. You
can go very easily to groups within the umbrella of the United Nations
and find great concern about terms that may be alien to them, like bio-
colonialism. Nevertheless, the fact remains that we do do research, a lot
of research, a lot of genomic research in special populations around the
world, that we do take the knowledge back and largely, not exclusively,
confine it to societies in the West. How would you feel about that if you
were a young physician in Thailand knowing that all the knowledge is
really going to flow back to Europe, Japan, and the United States?
Hopefully what I've done is set the stage for the more important
work of the panels. I look forward to listening in throughout the morning
and hope you have a great day. Thanks very much for listening.
[Applause]
PANEL I
THE LIFE SCIENCES IN COURT
MATT MOCK: I want to thank Dr. Reilly for his remarks. And I do
want to mention that I was just told that all of the royalties from
Dr. Reilly's book that we presented earlier go to charity. So if you have
any interest, please seek it out.
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And now I'd like to introduce the moderator for our first panel of
"The Life Sciences in Court." Professor Richard Friedman is the Ralph
W. Aigler Professor of Law at the University of Michigan. He earned a
B.A. and a J.D. from Harvard. He was the editor of the Harvard Law
Review, and Doctor of Philosophy in Modem History from Oxford
University. And he teaches Evidence here at the University of Michigan,
among other courses. Professor Friedman.
PROFESSOR RICHARD D. FRIEDMAN: Thank you Matt. Well,
this is a wonderful program that you're going to hear. I think the editors
have assembled a terrific dream team of scholars, able to comment on
life science technology, particularly DNA in the courtroom. We're going
to go in alphabetical order. Let me just introduce all the speakers first.
First in the center there is David Kaye, Regents' Professor at Arizona
State University, who is really one of the great scholars of the time on
the scientific use of evidence, among other distinctions. He's been the
editor for a long time of the Jurimetrics Journal.
Then Jay Koehler, who has a couple of long titles, from the Univer-
sity of Texas, where he teaches at both the business school and the law
school. Of course, his advanced degree is in neither business nor in law,
but in behavioral sciences. He teaches particularly Behavioral Decision
Theory, and he's written a series of very illuminating articles on DNA
evidence in the courtroom and the misapplication and misunderstanding
of it.
And finally my colleague Rick Lempert, who bears the wonderful
title of Eric Stein Distinguished University Professor, here at the Univer-
sity of Michigan. He's on loan to the National Science Foundation as a
Division Director and we hope he'll come back soon. Rick is a profound
scholar, not only in evidence, but in sociology-he's former chair of our
Sociology Department. I might mention that Rick was on the 1992 NRC
Panel, considering DNA evidence in the courtroom. And David was on
the 1996 panel. And neither Jay nor I've been on either of the panels.
So I'm going to turn it over to David, who'll first give an overview
of DNA issues, with the history of it, and then give some attention to
emerging issues. David.
DAVID H. KAYE: For the next ten minutes, I propose to give a
broad overview of some of the issues that arise with the use of DNA
evidence in the legal system. There are, as Dr. Reilly indicated, a wide
variety of uses for DNA-based technologies, and Professor Lempert
will be saying more about some of these matters. I am going to focus
on the criminal applications.
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Postconviction Relief
DNA evidence gained prominence in regard to post-conviction re-
lief.4 Case after case, now over 123, of exonerations of convicted
offenders have changed the political landscape for capital punishment
and criminal justice. The possibility of postconviction DNA testing has
raised a plethora of legal issues as well.5 Because these matters have
been highly visible, however, I shall simply leave them for later discus-
sion.
Admissibility of DNA Profiles
Over the past decade and a half, the admissibility of DNA testing for
identity has proved quite contentious.6 This history began with a period
of relatively uncritical acceptance of DNA evidence. Next, the ensuing
mobilization of the criminal defense bar culminated in some successful
challenges to pretrial handling of DNA samples, to the methods used to
analyze the samples, and to population genetics models used in calculat-
ing how rare specific DNA types are.7 This certainly entered the public
consciousness with the O.J. Simpson trial.' This second period was fol-
lowed by renewed acceptance of the calculations in the courts. 9 Today,
still newer analytical techniques are coming into use.' °
4. See, e.g., EDWARD CONNORS ET AL., U.S. DEP'T OF JUSTICE, CONVICTED BY JURIES,
EXONERATED BY SCIENCE: CASE STUDIES IN THE USE OF DNA EVIDENCE TO ESTABLISH IN-
NOCENCE AFTER TRIAL (1996); Paul C. Giannelli, Impact of Post-Conviction DNA Testing on
Forensic Science, 35 NEW ENG. L. REV. 627 (2001).
5. See, e.g., NAT'L COMM'N ON THE FUTURE OF DNA EVIDENCE, U.S. DEP'T OF JUS-
TICE, POSTCONVICTION DNA TESTING: RECOMMENDATIONS FOR HANDLING REQUESTS (1999);
Seth F. Kreimer & David Rudovsky, Double Helix, Double Bind: Factual Innocence and Post-
conviction DNA Testing. 151 U. PA. L. REV. 547 (2002); Karen Christian, Note, "And the DNA
Shall Set You Free": Issues Surrounding Postconviction DNA Evidence and the Pursuit of
Innocence, 62 OHIO ST. L.J. 1195 (2001).
6. See, e.g., I MCCORMICK ON EVIDENCE § 205(b), at 759-62 (John W. Strong ed., 5th
ed. 1999).
7. See David H. Kaye, DNA Evidence: Probability, Population Genetics, and the
Courts, 7 HARV. J.L. & TECH. 101 (1993); Kathryn Roeder, DNA Fingerprinting: A Review
of the Controversy, 9 STAT. SCI. 222 (1994).
8. See, e.g., Nell Henderson & Marc Fisher, Prosecutors Build DNA Case Against
Simpson: Odds are Astronomical that Bloodstains are Someone Else's, Lab Chief Testifies,
WASH. POST, May 12, 1995, at Al (detailing the statistical analysis of DNA evidence in the
O.J. Simpson trial).
9. E.g., 1 MCCORMICK, supra note 6, § 205(b), at 762.
10. See NAT'L COMM'N ON THE FUTURE OF DNA EVIDENCE, THE FUTURE OF Fo-
RENSIC DNA TESTING: PREDICTIONS OF THE RESEARCH AND DEVELOPMENT WORKING
GROUP (2000); David H. Kaye & George F. Sensabaugh, Jr., DNA Typing: Scientific Status,
in 3 MODERN SCIENTIFIC EVIDENCE: THE LAW AND SCIENCE OF EXPERT TESTIMONY § 25-
2.0 (David L. Faigman et al. eds., 2d ed. 2002).
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An example of the early, uncritical acceptance of the evidence comes
from Texas. Brian Kelly was accused of murdering a sixty-three-year-old
woman." He had been dating the woman's daughter, who lived with her
mother. The mother and her truck disappeared one night. Kelly was seen
that night driving the truck. He was seen selling the mother's jewelry.
The body was found in the desert, and there were stains with DNA left in
the mother's bedroom, which linked Kelly to the crime.
The trial court held a hearing on whether the DNA identification
procedure was generally accepted in the scientific community, that being
the standard for the admissibility of evidence in Texas. At this hearing,
the prosecution produced two biology professors, a molecular biologist,
and a "physical scientist with the FBI."'2 One of the witnesses said that
his book, Molecular Cloning, was "the technical 'Bible' of the field."'3
The court observed, with a touch of skepticism, that "[h]e claimed to
have written over 100 research papers, some of which have been pub-
lished in various journals."' 4 In contrast, the defense put on one witness,
John T. Castle, the owner of Castle Forensic Laboratories in Dallas. His
qualifications consisted of "a Bachelor's degree in chemistry and [certi-
fication] to teach life and earth sciences in public schools."'" He testified
that "radioactive technology," which was involved in determining the
size of the DNA fragments, "was too new to be generally accepted in the
scientific community."'
' 6
Needless to say, the court found the evidence admissible, and the
ruling was upheld on appeal. Such outcomes tend to be cited by later
courts, as establishing general acceptance of scientific validity, despite
the one-sided nature of the hearings. In time, however, defendants enlisted
much more impressive experts. In People v. Castro,"' for instance, highly
reputable scientists discerned several difficulties with the DNA testing per-
formed by Lifecodes Corporation. The court agreed, after six weeks of
hearings and what it called "a piercing attack upon each molecule of evi-
dence," that "the testing laboratory failed in its responsibility to perform
the accepted scientific techniques and experiments in several major
respects."' 8 The court may have found it easier to reach this conclusion
11. Kelly v. State, 792 S.W.2d 579 (Tex. Ct. App. 1990).





17. 545 N.Y.S.2d 985 (Sup. Ct. Bronx Cty., 1989).
18. Id. at 996. After the court's pretrial ruling to admit some, but not all of the DNA
evidence in the case, one of Castro's attorneys, Barry Scheck, was quoted as saying that
"[i]t is our view that DNA-based evidence should not be used in court proceedings at all."
Lauren Shay, DNA Evidence Questioned, A.B.A.J., Oct., 1989, at 18.
Fall 2003]
194 Michigan Telecommunications and Technology Law Review [Vol. 10:175
because two of the scientists involved in the case happened to be at a
scientific meeting at Cold Spring Harbor. They arranged for most of the
expert witnesses to meet without any lawyers being present. The result-
ing consensus statement acknowledged that there were problems with
the DNA tests performed in the case.' 9
Around this time, the National Academy of Sciences convened a
panel to report on the status of forensic DNA technology. The committee
issued a comprehensive report in 1992.20 It proved difficult for some ob-
servers to digest. Headlines in the New York limes reported, Labs'
Standards Faulted: Judges are Asked to Bar Genetic 'Fingerprinting'
Until Basis in Science is Stronger.2 ' The same day, the Wall Street Jour-
nal reported Use of DNA Evidence in Court Endorsed." The next day,
the imes printed a story under the secondary headline, Time's Account
in Error: Report Urges Strict Standards, But No Moratorium on DNA
Fingerprinting for Now."
An issue that the report raised but did not resolve was a debate
among population geneticists about calculations concerning the prob-
ability that an unrelated individual would match a DNA type from the
crime scene. Although no statisticians or population geneticists served
on the committee, the report proposed a compromise solution (the "ceil-
ing principle") that infuriated several population geneticists who thought
it was overly conservative or crude.4 The committee did not state that
the standard computations were incorrect, but its pointed recognition of
the fact that there was a scientific controversy made many courts hesitate
to admit the evidence. In response to concerns voiced by the FBI and
others, a second panel was appointed. Before this committee issued its
report, one of the more prominent members of the first panel (and the
originator of the ceiling principle), Dr. Eric Lander, together with
19. See Roger Lewin, DNA Typing on the Witness Stand, 244 Sci. 1033 (1989).
20. COMM. ON DNA TECH. IN FORENSIC Sci., NAT'L RESEARCH COUNCIL, DNA
TECHNOLOGY IN FORENSIC SCIENCE (1992).
21. Gina Kolata, U.S. Panel Seeking Restriction on Use of DNA in Courts, N.Y.
TIMES, Apr. 14, 1992, at Al. This was not the first time that this reporter mischaracterized
the views of experts. See Andre A. Moenssens, DNA Evidence and Its Critics-How Valid
Are the Challenges?, 31 JURIMETRICS J. 87 (1990) (discussing Gina Kolata's claim in Some
Scientists Doubt value of 'Genetic Fingerprinting' Evidence, N.Y. TIMES, Jan. 29, 1990, at
Al, that "[l]eading molecular biologists say a technique promoted by the nation's top law
enforcement agency for identifying suspects in criminal trials through the analysis of ge-
netic material is too unreliable to be used in court").
22. Joe Davidson & Jonathan M. Moss, Use of DNA Evidence in Court Endorsed,
WALL ST. J., Apr. 15, 1992, at B6.
23. Gina Kolata, Chief Says Panel Backs Courts' Use of a Genetic Test, N.Y. TIMES,
Apr. 15, 1992, atAl.
24. Peter Aldhous, Geneticists Attack NRC Report as Scientifically Flawed, 259 ScI.
755 (1993).
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Dr. Bruce Budowle, an FBI chemist, published an article in Nature with
the provocative title, DNA Fingerprinting Dispute Laid to Rest.25 Im-
pressed with Lander's apparent change in stance (he had testified for the
defense in People v. Castro and published several critical articles), the
courts took notice.26
The second panel issued its report in 1996.27 It reaffirmed the useful-
ness of forensic DNA technology and concluded that the ceiling
principle was unnecessary. At the same time, it proposed certain refine-
ments to the standard computation for special situations. Courts were
reassured,28 and debates on DNA evidence shifted to other issues.29
Inferring Phenotypes
Dr. Reilly noted the possibility of inferring phenotypes from DNA
samples. Down the road from me, at the University of Arizona, is a
Dr. Brilliant, who has advertised for research subjects to give DNA sam-
ples to develop a system for predicting hair, eye, and skin color from an
individual's DNA.30 Not long ago, an official at the National Institute of
Health's National Human Genome Research Institute claimed that infer-
ring ancestry from a DNA stain could amount to "racial profiling. 3'
Acquiring DNA from Suspects
Government efforts to acquire samples from suspects have spawned
a variety of legal issues. One is consent. Nearly ten years ago, Ann Arbor
police went about asking black men for blood DNA samples to find a
serial rapist thought to be African-American. And they did not destroy
25. Eric Lander & Bruce Budowle, DNA Fingerprinting Dispute Laid to Rest, 371
NATURE 735 (1994).
26. E.g., Lindsey v. People, 892 P.2d 281 (Colo. 1995); People v. Miller, 670 N.E.2d
721 (I1. 1996).
27. COMM. ON DNA TECH. IN FORENSIC Sc.: AN UPDATE, NAT'L RESEARCH COUN-
CIL, THE EVALUATION OF FORENSIC DNA EVIDENCE (1996).
28. E.g., State v. Morel, 676 A.2d 1347 (R.I. 1996).
29. See, e.g., Jonathan J. Koehler, On Conveying the Probative Value of DNA Evi-
dence: Frequencies, Likelihood Ratios, and Error Rates, 67 COLO. L. REV. 859, 861 (1996);
Richard Lempert, After the DNA Wars: Skirmishing with NRC H, 37 JURIMETRICS J. 439,
453 (1997).
30. http://www.ahsc.arizona.edu/opa/news/feb03/dna.htm.
31. Kathy Hudson, The Human Genome Project, DNA Science and the Law: The
American Legal System's Response to Breakthroughs in Genetic Science: Keynote Address,
51 AM. U. L. REV. 431, 442 (2002). One group of researchers have identified markers that
are said to be extremely accurate in classifying individuals as being of European, African,
and Asian descent. Tony Frudakis et al., A Classifier for the SNP-based Inference of Ances-
try, 48 J. FORENSIC Sci. 771 (2003). The constitutionality of the practice is considered in
Edward J. Imwinkelried & D.H. Kaye, DNA Typing: Emerging or Neglected Issues, 76
WASH. L. REV. 413 (2001).
Fall 2003]
196 Michigan Telecommunications and Technology Law Review [Vol. 10:175
the samples. After the rapist was caught attacking a fourth woman, one
man who had given blood sued for the return of his samples. Today, his
refrigerator contains the two vials pried from the police by a court or-
der.32 Concerns also have voiced about the possibility that police will
obtain samples from health care providers or tissue archives.33
DNA Databases and Databanks
Convicted offender DNA databases have been established in every
state. Several states have laws that require DNA to be provided after ar-
rests or indictments. However, the battle in most state legislatures at the
moment involves expanding the list of offenses. The 1992 National
Academy report suggested that DNA evidence would only be useful in
rape and homicide cases and that states should not include other offend-
ers in their databases. However, it soon was discovered that DNA taken
after convictions for burglary and breaking and entering were leading to
convictions in rape and murder cases. In Florida, hits in rape investiga-
tions doubled after aggravated battery became a collection crime. In the
United Kingdom, by 1999, there was a five percent chance of developing
a DNA profile in property crimes, particularly car theft.' Many car
thieves, it seems, leave a cigarette butt or other such souvenir in the car.
That may change in time as criminals become more familiar with biol-
ogy.
Constitutional challenges to convicted-offender databases generally
have been unsuccessful. Nonetheless, the Supreme Court has had several
opinions in the past two years that have undermined, to some extent, this
36
line of cases.
The ultimate DNA database would embrace the entire population.
Such a database would have many advantages over the current system,
which is resulting in a set of DNA databases drawn largely from racial
minorities. But even with extensive privacy safeguards, having
32. Accounts of the case include Alice Robinson, DNA of Innocent Rape Suspects
Will Not be Kept, MICH. DAILY, Nov. 21, 1997, at 5, and Jack Leonard, Using DNA to Trawl
for Killers, L.A. TIMES, Mar. 10, 2001, at A1.
33. The application of the Fourth Amendment to such practices is discussed in D.H.
Kaye & Michael E. Smith, DNA Identification Databases: Legality, Legitimacy, and the
Case for Population-Wide Coverage, 2003 Wis. L. REV. 413 (2003), and Imwinkelried &
Kaye, supra note 31.
34. See D.H. Kaye, The Constitutionality of DNA Sampling on Arrest, 10 CORNELL
J.L. & PUB. POL'Y 455 (2001).
35. See Kaye & Smith, supra note 33, at 416 n.9.
36. See id., at 442-445; see generally D.H. Kaye, Two Fallacies About DNA Data
Banks for Law Enforcement, 67 BROOK L. REV. 179 (2001).
37. See Kaye & Smith, supra note 33, at 450-459.
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everybody's DNA in a databank is, as one of my colleagues says,
"creepy." This vision, whether appealing or shocking, remains futuristic.
PROFESSOR RICHARD D. FRIEDMAN: Thank you very much,
David. And among other factors, for brevity, staying within the time. So
now Jay Koehler. We're moving down the alphabet and moving down the
technological chain to transparencies.
PROFESSOR JONATHAN J. KOEHLER: I'd say we're moving
down in many other respects as well. It's actually remarkable for me to
be here with this panel. Three of the most famous scholars in advanced
evidence are around me, Rich Friedman, David Kaye, Rich Lempert, and
there's me from the business school with a degree in psychology at
Texas. It's not hard to spot the imposter.
What I want to do is show a couple of overheads. I was shamed into
doing this yesterday when I found out David had a fancy Power Point
presentation. But I just want to start off by offering a couple generalities
about the juror.
The typical juror is a white Protestant with some college, married,
owns their own home, works in manufacturing, retailing, education,
health services. In this sense the typical juror does represent the typical
American. There's a lot of talk about how Americans are able to avoid
jury duty, but actually the typical juror does look like the typical Ameri-
can. And if I can just expand this profile a little bit, based on my own
experience and very little data, I would say that the typical juror can bal-
ance their checkbooks fine but they find algebra confusing; they've never
heard of a standard deviation or a confidence interval; they can follow
elementary logic on familiar matters, but they're prone to thinking anec-
dotally; and they attach too much weight to information that's very vivid,
very graphic, but unreliable, uncertain, or incomplete. As far as their atti-
tude about statistics goes, I think the typical juror is, on the one hand,
impressed with people who have statistical knowledge. On the other
hand, they don't really trust statistics very much. Everybody knows you
can lie with statistics.
Okay, and I want to contrast the juror with the statistical thinker. The
statistical thinker, we all know these guys, they were the ones who made
exhibits for the annual science fair and they excelled in math as kids and
their hobbies include things like puzzles and playing chess in the high
school chess club. They went to college where they majored in biology
and chemistry and math. Some of them went on to become accountants
and medical researchers and engineers. The person who has the statisti-
cal mind frame, who has this sort of background, is somebody who
believes his team will lose to the first place team today. Statistical think-
ers believe that because the team that's in first place is probably better
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than their own team and, as much as they'd like to think that their team
is going to win, they're realistic and they think, "Well, the odds do favor
the first place team." I'd go so far as to say the statistical thinker wonders
whether his will be one of the fifty percent of marriages that ends in di-
vorce. He doesn't want that to be the case but he knows that fifty percent
of the people who get married ultimately get divorced. He knows that
everybody who gets married loves their wife, loves their husband. He
knows that everybody does all that. And so did he. And so he wonders,
"Well, I began by estimating my own chance of divorce at fifty percent,
and now I'll adjust that figure for the individuating features that I know
about myself." Maybe he's super-religious and would therefore be par-
ticularly unlikely to get divorced. Still, he does assume that the fifty
percent base rate probability for divorce applies to himself. In a legal
context, the statistical thinker believes that the defendant is probably
guilty, even before he's heard any testimony. After all, the prosecutor
wouldn't have gone to all this trouble if he didn't have some pretty good
evidence against the defendant. So he comes in to the trial as a juror
thinking, "Sure, I think he's guilty. The odds favor it. Also, I'm aware of
the fact that most defendants are ultimately convicted." So these are the
kinds of things that influence the statistical thinker's mindset.
Now the law may not want jurors operating as statistical thinkers in
every aspect of jury duty. They may not want, for example, jurors to
come into the courtroom thinking that the defendant is guilty. But I
would argue that the law does want jurors to be statistical thinkers in at
least some respects, and specifically, I would say that they do want jurors
to be statistical thinkers when it comes to evaluating the probative value
of evidence. And more specifically still, when it comes to understanding
the probative value of DNA statistics. I think the law prefers to have ju-
rors that are sometimes able to adopt a statistical mindset. The kind of
people who, as the famous statistician Fred Mosteller might say, under-
stand that it's easy to lie with statistics, but it's easier to lie without them.
So statistical thinkers want to have the data so they can see for them-
selves how well the data support the claim.
Okay, so I've obviously over-generalized these stereotypes, but I'm
trying to make the point that I think there's a difference between the
typical juror and the statistical thinker. And it worries me because I think
the typical juror is not well equipped to handle statistical evidence at
trial. And we do know something about how the typical person thinks
about statistics at trial. Now, I'd like to review a couple of those studies
with you.
First of all, how do people in general and jurors in particular assign
weight to statistical evidence? Well, studies in psychology and law
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suggest that people tend to underweight statistical evidence, relative to
its true value. Its true value is described by a likelihood ratio or some
other technical measures that we may talk about if we have a little bit
more time. We know that jurors aren't sensitive to variation in statistics
as much as the normative theory says they ought to be. So, for example,
if a juror is told that a defendant suspect matches DNA evidence that's
found in a crime scene, and the match is such that it occurs for one in a
hundred people, the juror is likely to be somewhat impressed with the
evidence. Now if you tell the juror "Actually the DNA occurs in one in a
thousand people, not one in one hundred people," the juror is unlikely to
be any more impressed by the DNA evidence. The jurors might change
his or her estimate of the chance that the defendant is the source of the
DNA a little bit, but not by as much as the mathematical theory that
underlies probativity requires.
We know from some studies that I've done and that others have done
that jurors and laymen aren't very good at combining probabilities. For
example, suppose you're told that a DNA profile occurs in one in a mil-
lion people. It's a very rare DNA profile. And then let's say that the lab
makes mistakes one time in a thousand. How likely is it that this defen-
dant is not the source of the DNA? In order to figure this out, you've got
two things to think about. First, you've got to think about how rare the
DNA profile is. You've got to consider the possibility that maybe it's just
a coincidental match. This chance is one in a million. And then you've
also got to consider the possibility that the match occurred because the
lab makes mistakes every now and then. This possibility is one in a thou-
sand. It turns out that people aren't very good at combining those two
numbers. What they tend to do when they have a very extreme DNA
match probability like one in a million is to disregard the error rate num-
ber. They think, mistakenly, that the one in one thousand error rate is
swamped by the extremity of the DNA profile statistic (which is one in a
million). That is, they think that if the DNA profile is extremely small,
then we don't have to pay attention to the one in a hundred error rate.
Now, we know that there's a problem with this kind of thinking, because
when you just provide people with the one in a hundred error rate, they
actually are a little nervous about the DNA evidence and they think,
"Well, maybe this isn't the guy after all. One in a hundred is a one per-
cent chance of a mistake and, even though the odds strongly favor that a
mistake wasn't made, I'm not so sure I'm willing to convict beyond a
reasonable doubt." But when people are also provided with a one in a
billion match probability, now they are much more willing to convict
beyond a reasonable doubt. We observe a difference between these two
scenarios even though, from a mathematical standpoint, there's really
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very little difference between them. Strangely enough, there's very little
difference between having a match probability of one in a billion plus an
error rate of one in a hundred, and just having an error rate of one in a
hundred in a situation where you're not even sure what the coincidental
match probability is. The reason they're very similar is that if there's a
mistake, if the suspect is not the source of the DNA evidence, it's not
because of coincidence, it's because of a lab error in both cases. Anyway,
it turns out that's a hard idea for people to grasp intuitively, probably
understandably so.
And other studies have shown that the way the DNA evidence is pre-
sented actually makes a difference to people. Some of these changes don't
make any difference from a math standpoint; they're just different ways of
saying half full, half empty. Yet these different ways of presenting the
DNA statistics can make a big difference, in terms of how probative peo-
ple think your match statistic is.
For example, to this point, I've used a particular format when describ-
ing the DNA profile. I've been saying "Imagine you have a frequency of,
say, one in a thousand." But there are other ways to describe this DNA
match statistic. Before doing so, let me set the scenario. Suppose a person
has been murdered and there's blood under the victim's fingernails that
matches blood from a suspect. And the match is such that the observed
DNA profile occurs in one in every one thousand people. Okay, when you
describe it that way, when you say it occurs in one in every one thousand
people, people will realize pretty quickly that it's not unique, even in a
small city such as Ann Arbor. If it occurs in one in every one thousand
people, there's a bunch of people here in Ann Arbor, including forty or
fifty people here at the University, who would match. So it's not terribly
impressive, relatively speaking, to describe a match probability of one in a
thousand that way.. However, let's say you describe it this way: if the sus-
pect were not the source of the blood evidence found underneath the
fingernail, there's only one chance in a thousand that he would match.
Okay, now that sounds like you got the right guy. If he weren't the source,
the chance he would match is just one in a thousand. By the way, you can
make it sound even better by saying if he weren't the source, the chance
that he would match is .001. People are more impressed with that way of
presenting the statistic. And yet, from a mathematical or probative value
standpoint, each of these statistics is identical.
Jurors are even more impressed with a match statistic when it is de-
scribed as what is known as a likelihood ratio. This term is sneaking into
court more and more. Everybody on this panel, I think, has written about
likelihood ratios and most of us think that it's a terrific way to describe the
probativity of statistical evidence. But what I worry about is how people
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who are not familiar with the term understand likelihood ratios. That is, it
may be a terrific scientific tool, it may be a great way for scientists to
communicate with one another, but, in the end, what is important is what
jurors take away when we give them a likelihood ratio that describes the
probative value of evidence, and whether they understand it the way we
understand it. This is the way to describe a likelihood ratio associated with
that one in a thousand DNA match statistic: it is one thousand times more
likely that the suspect would match if he were the source than if he were
not the source. Or you could say: it is one thousand times more likely he
would match if he were the source, than a randomly selected person. So it
sounds like the likelihood ratio is giving this one thousand to one ratio to
estimate the chance that the suspect is the source which, if true, would
translate into a 99.9% chance the matching suspect is the source. But this
isn't actually what's being said. You can't conclude that there's a 99.9%
chance somebody's the source of a one in a thousand profile. You can't say
that because each of the forty or fifty people in Ann Arbor who matches
would then also have to have a 99.9% chance of being the source. There's
something strange about that translation. It can't be that the suspect has a
99.9% chance to be the source, just because he matches this one in a thou-
sand profile and so too does some administrator at the University of
Michigan. By this logic, the administrator would also have a 99.9%
chance of being the source because he or she is also among those who
match. Likewise, hundreds or thousands of people in Chicago match and,
by this logic, each of them would have a 99.9% chance of being the
source. As should be clear, it can't be that each of hundreds or thousands
of people have a 99.9% chance of being the source. One cannot translate
the one in a thousand match statistic into a probability that the suspect is
the source just by subtracting that from one. And yet we know that people
commonly do that.
I do want to keep my comments brief. Let me mention one other form
of statistics. Well you might say let's just go the frequency route. It's the
most favorable to the defendant. If you say one in a thousand, you know
people are less likely to make that 99.9% error when you tell them one in
every thousand people would match, but lots of other people in the city
would match. If you describe it that way, you don't get as many people
jumping to the 99.9% conclusion. But why is it that we're describing the
statistic as one in a thousand anyway? Why didn't I describe it as say two
in two thousand? What difference would that make? Well it turns out it
does make some difference. When you describe a one in a thousand as two
in two thousand, then people think, "Hey, what about the other guy?"
[Laughter]
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And so people are a little less impressed with one in a thousand de-
scribed as a two in two thousand. So that's a little hint for defense
attorneys out there. On the other hand, the prosecutors have an even lar-
ger advantage, if you're willing to go this route, prosecutors to be. If
you're willing to describe your numerator as a fractional value. So sup-
pose that instead of describing the statistic as one in a thousand, you
describe it as point one out of a hundred. Point one out of every one
hundred people would match. It turns out that that's extremely impres-
sive to people. Why? Because people focus on the numerator and think
wow, not even a person. Point one is so little that they disregard the de-
nominator and say "wow, that's got to be him. Only point one out of
every hundred would match, I'm impressed!" We actually collected data
on that and sure enough, we got that effect . It's a very strong effect for
fractional numerators.
I should also mention that I'm worried, aside from these kinds of
presentation issues, about more fundamental issues related to how peo-
ple understand statistical information. It's not clear to me, for example,
that people understand that a rare DNA match is more impressive than a
less rare DNA match. A law student at Texas, who was in one of my
classes, gained access to four jurors who had just served in a capital
murder trial, in which the jury convicted. That case involved DNA evi-
dence. In that case, blood matching the victim was found on the suspect
and one in twenty people shared that profile. And so the law student gave
each of the four jurors a scenario where he said suppose that you've got
some blood, let's say it's underneath the fingernails of a victim, and that
blood matches the suspect. And the match probability is one in a hun-
dred. So one in every hundred people would share that DNA profile. And
he asked the jurors, "How likely do you think the person is the source?"
One of the four did say ninety-nine percent. So this juror made that kind
of a mistake that I alluded to before where there's a temptation to just
subtract the match profile from one to figure out the probability some-
body's the source of the DNA. And that's obviously not the right
calculation because then one in every hundred people would have a
ninety-nine percent chance of being the source. And that can't be right.
The other three jurors estimated the chance that the suspect was the
source of the DNA was one percent. So what they most likely did was
translate the one in one hundred match probability to a probability that
the suspect is the source. This suggests that if we told them the match
probability was one in a million, they'd say the chance the suspect is the
38. Jonathan J. Koehler & Laura Macchi, Thinking About Low Probability Events: An
Exemplar Cueing Theory, 15 PSYCHOL. SCl. (forthcoming 2004), available at
www.mccombs.utexas.edu/faculty/jonathan.koehler/articles/2004-Psych%2OScience.pdf.
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source is one in a million. And in fact those three people did not convict
in the hypothetical scenario. Their argument was that it just didn't seem
like that was his DNA.
These were four jurors who actually had served on a trial where they
heard DNA testimony. So this is the real deal and I'm really worried
about whether people can understand DNA statistics. I'm not too hopeful
about it. And on that pessimistic note, I'll stop. Thanks.
[Applause]
PROFESSOR RICHARD D. FRIEDMAN: The other pessimistic
note, I'm wondering if I should temper the congratulations I offered Jay
last night on finding out he's engaged to be married.
PROFESSOR JONATHAN J. KOEHLER: Yeah, I'm not a statis-
tical person.
PROFESSOR RICHARD D. FRIEDMAN: You're not a statistical
person, okay. Let me just say before we move to Rick, usually the DNA
evidence isn't presented alone. In other words, in almost every case,
there's other evidence, so that the defendant is going to look more likely
to have committed the crime than are those other people in Chicago with
the same profile. But it's the combination of the DNA evidence with the
other evidence that's part of the problem here. I suppose the only type of
case in which the DNA evidence would be practically alone in proving
identity would be one in which the DNA evidence is quite powerful. But
still it doesn't relieve the problem of the juror misunderstanding.
Okay, so now on to Rick Lempert, who is going to talk about the ef-
fect of DNA evidence on science and on scientific evidence in general,
and some emerging issues.
PROFESSOR RICHARD 0. LEMPERT: Thank you. Those of
you in the audience who are not lawyers probably are not familiar with
the dreaded overtones in the student law journal world of the word "pre-
empt." When a student works for six months on a note for a law review
but before it can be published some other law journal publishes a story
on the same topic, suddenly all that work is for naught. The law review
withdraws the piece because it has been "preempted."
I knew when I came here that my co-panelists were David Kaye and
Jay Koehler. I'm not trying to be polite when I tell you that in my view
David is our nation's preeminent authority on the statistics of DNA evi-
dence, and Jay is the leading student of how DNA statistical evidence is
received by jurors. So I thought that although this is a panel of three
people who had done work on DNA evidence, I would stay largely away
from that topic and talk about other issues. I didn't tell Philip Reilly that
that was what I was going to do, and he gave a presentation which has a
remarkable similarity to what's in my notes. So I'm going to scramble
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and say a bit more about DNA than I thought I would, and probably a bit
less about some of the other areas. Though I will talk about those also,
Philip has in large measure preempted me.
Let me begin with DNA. DNA evidence has had a substantial impact
on our justice system. DNA evidence is absolutely terrific evidence. It's
the best identification evidence that we have today, at least in terms of its
science base. Fingerprint evidence also seems to be extraordinarily good
evidence, but although it has been around much longer, it has not been
studied in the degree to which DNA has. Also there is considerable sub-
jective variation in standards for making claims about fingerprint
evidence, and there has been no official promulgation of fingerprint
identification standards, at least no court-sanctioned regulation that I
know of.
DNA is marvelously probative evidence. As such, it has cast, in re-
cent years, interesting light on our criminal justice system. We have, for
example, learned about the large number of factually innocent people
who have been convicted of homicide or rape. We also know that those
shown to be innocent have to be the tip of an iceberg since only people
alive today, with crimes for which DNA was preserved, can be in this
group. Thus, these "DNA acquittals" say a number of things about our
criminal justice system, which we should take to heart.
The first is that these acquittals emphasize how fallible any human
decision making system is. The second is that they indicate sources of
fallibility. One recurring flaw, that would surprise no one who has stud-
ied criminal identifications, is the fallibility of eyewitnesses. The
confirmation of this fallibility suggests that those courts which resisted
allowing psychological experts to testify before juries about the weak-
nesses of eye witness testimony were in all probability too skeptical
about the value of such experts and may have helped work an injustice
by barring their testimony.
A more surprising aspect of the DNA acquittals is the number of
people who confessed to charged crimes who have been proven inno-
cent. We think we don't have coerced confessions in this country
because we've gotten away from the rubber hose, beatings, and the like,
but we see in these acquittals the reality of psychological coercion.
There have also been acquittals in which the apparent cause of the mis-
take has been perjury by police or others. So again, thanks to DNA, we
have this light on the deficiencies of the system that we should be taking
to heart.
In the past, the system has resisted taking these things seriously. It's
only in the last few years, almost through shame, that a consensus seems
to have emerged in the prosecutorial community that if DNA evidence is
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available and a credible claim of innocence can be made, testing should
be allowed. Some courts have now said this. But in the early days, the
same prosecutorial establishment that was using DNA evidence to con-
vict people and claiming, in good faith, that DNA was terrific evidence,
were arguing, when it came to using DNA evidence to reverse convic-
tions, that we should let things rest and not reopen cases. Perhaps
because there have been so many other scandals in our criminal justice
system, there has been no cry of outrage over this, but there should be. A
prosecutor's task is to do justice, not to secure convictions. Something is
wrong with the system when prosecutors subordinate protecting the in-
nocent to not just securing but maintaining convictions.
Recently in Virginia, an issue has arisen that I find fascinating, for
what it says about official attitudes. A man was executed by Virginia,
although he claimed throughout the process that he was innocent. Ap-
parently, before DNA tests were available seriological samples were
tested and found inculpatory, but with limited probative value. Now the
relatives of the man executed want to test the crime sample DNA to show
that he was innocent of the crime for which he was executed. The state,
including the State Supreme Court, has denied the request to test. One of
their arguments, as reported in the press, was that if the test results were
exonerative, they would discredit our system of capital punishment.
Hello! I mean isn't this exactly what we want to know? Shouldn't we
seek to learn how well we are doing in separating the innocent from the
guilty in order to decide if we wish to maintain a system of capital pun-
ishment and to decide what protections to require if we do. Shouldn't
capital punishment systems be discredited, as the system was in Illinois,
if it leads the state to kill the innocent? As a social scientist and as a law-
yer I deplore a system in which political preferences can override proper
evidentiary value.
I also want to emphasize something implicit in Jay's remarks. Today,
in most cases where we use DNA evidence, we can honestly say that if
the suspect's DNA matches the evidence (crime scene DNA) we are vir-
tually certain that the evidence DNA came from the suspect (or an
identical twin). The probability of a match, if someone else is the source
of the evidence sample is, in most cases, infinitesimally small. Although
to claim that the defendant is certain to be the DNA source is a slight
overstatement, given the findings Jay reports, I think it is a better way of
proceeding than our current presentation of random match probabilities.
If told the match was certain, I think, jurors could take better account of
error in the testing that yielded the match and of the possibility of dis-
honesty in evidence collection or reporting than they are likely to do if
they get random match probabilities like one in ten billion thrown at
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them. The important point, and this has been my hobbyhorse from my
first involvement in DNA as a member of the NRC Committee, is that
the limits of the probative value of DNA evidence are not set by the fre-
quency of random matches. Rather, they are set by the quality of the
technical work and the honesty of the people who are involved in col-
lecting, preserving and analyzing DNA evidence. The probability of a
misidentification from these error sources is, in the typical case, far
higher than the probability that a misidentification occurs because two
people have DNA that is identical at all tested loci.
Let me just give you two examples from a case I'm sure you're fa-
miliar with: the O.J. Simpson case. There were two items of DNA
evidence that seemed compelling because they showed that Nicole
Simpson's blood was on O.J.'s possessions. (I am speaking from mem-
ory here, but I think what I say is accurate.) One item was a bloody sock
found in O.J. Simpson's bedroom, which was reported to have had
Nicole Simpson's blood on it. The evidence was highly incriminatory.
But there was a problem for the prosecution's case. That is that if you
take a sock, which is like a tube in that it has four sides. There was blood
on the inside and outside of one side and on the inside of the other side.
Obviously the blood must have splashed on the outside of the sock,
soaked through to the inside and then been deposited on the inside of the
other side of the sock. But if you're wearing a sock, blood will not go
through your ankle to come to the other side. The prosecution's theory
was that when O.J. took the sock off, it was still damp so when it flat-
tened down on the floor, there was a transfer of blood from the inside of
one side of the sock to the inside of the other, thus accounting for the
blood on the three sides. The defense, to counter this, presented an ex-
pert witness who testified that given the time it would have taken O.J. to
get home, the blood would have clotted sufficiently so that the transfer of
blood would not have occurred-or could not occur to the degree that it
did. The defense theory was that the transfer happened when a police
officer, who contrary to police procedures had retained a vial of Nicole
Simpson's blood, poured blood on one side of the sock when it was lying
flat on the floor and it soaked through to the other side.
Now I don't know which story is true. I tend to believe the state's
theory more than I do the defense theory, despite the expert testimony.
But I certainly believe that the chance that a cop poured blood on the
sock was far higher, even if it was as low as one in a hundred or one in a
thousand, than the chance that that blood did not come from Nicole
Simpson, if it matched her DNA.
Another bit of highly incriminatory evidence in the O.J. case was
that in O.J.'s van, there were very, very small flecks of blood identified
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as coming from Nicole. This evidence too appears to be strong evidence
of O.J.'s guilt. The problem here is that the L.A. police came directly
from the crime scene to the van. At the crime scene, they were involved
in examining Nicole Simpson's body, and it is hard to imagine that they
did not get some blood on them. There was so little blood in the van that
they had to use a technique, called PCR, to amplify what there was for
analysis. It's entirely conceivable that an accidental, unintentional trans-
fer of blood would have left samples of Nicole's blood in the quantity
found. Again, I would not say it is more likely than not that the blood in
the van was due to accidental contamination, but it is far more likely that
there was inadvertent contamination of the van, with Nicole Simpson's
blood, than that the blood came from somebody other than Nicole with
matching DNA. Yet the evidence was presented so that the jury would
think its incriminatory value was defined by the very low random match
probability and not by the far higher probability that there was accidental
contamination. Thus we have to be very careful about DNA evidence,
despite its many virtues.
Another aspect of DNA evidence, which in my mind has been all to
the good, is that because of its tremendous incriminating power, the need
to ensure that DNA testing is reliable has been driving standards for fo-
rensic laboratories in general. The first moves toward accreditation of
forensic laboratories were driven by the critiques of DNA and the aware-
ness of how misleading DNA based errors could be. This does not mean,
however, that laboratories cannot err in DNA analyses. Early proficiency
tests revealed errors. The response of the laboratories to tests that
showed erroneous reports is instructive. They said something like, "Yes,
it's true, we made a mistake, but we've corrected that problem. The mis-
take will never happen again." It may be true that they corrected a
problem, but this doesn't mean there cannot be other problems. Within
the last week, there was a story in The Washington Post reporting that
several hundred DNA identification cases were going to be reopened in
Texas because of sloppy laboratory conditions. If before the story broke
you had asked a DNA scientists whether that degree of malfeasance was
possible, I think most would have replied that it couldn't happen any-
more in the DNA world. In short, DNA is far more reliable than other
forensic identification evidence, but DNA scientists like other forensic
scientists systematically overvalue the virtues of their science by ignor-
ing the inescapable deficiencies of humans.
As interesting as the fact that DNA drove standards for forensic
laboratories, is my sense that DNA analysis is the very rare case where
the law also drove the science. Thus, controversies about DNA statistics
led scientists to empirically examine population genetics and related
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issues sooner and in greater depth than they would have if they were not
interested in presenting the evidence in court. It also led to the rigorous
testing of hypotheses about genetic variation and probabilities of allele
combinations which might not have occurred as soon if the evidence did
not have to be admissible in court. This was in part due to the
involvement in litigation of leading scientists, with quite different
perspectives on the value of DNA evidence as well as to attempts by the
FBI to legitimate DNA evidence by promoting the appointment of two
National Research Council panels on the topic. It is a shame that equally
eminent scientists seldom get as deeply involved in establishing the
validity of other techniques of forensic science. I expect that, as with
hair or handwriting comparisons, this is often because the scientific basis
of the evidence is so weak as to not be scientifically interesting.
Before leaving the topic of DNA, let me also mention the complexi-
ties one gets into when considering felon DNA databases or DNA
databases in general. Despite some disagreements, there seems to be a
consensus that at a minimum, it is appropriate and legal to take DNA
from convicted felons, including felons convicted of crimes other than
rape and murder, and to put the DNA profiles in a database that can be
checked when DNA is recovered from a crime scene. These databases
are becoming much more important tools of criminal identification, as
PCR techniques allow us to develop cold hits in crimes other than rape
and murder. For example, analysis of the DNA left by saliva on a ciga-
rette butt can identify a robber, a burglar, or auto thief.
There is disagreement, however, on whether arrestees should be
vulnerable to having their DNA taken and profiled for inclusion in data-
bases before they are convicted of a crime. Important value questions are
raised. If, as there is good reason to believe, police are more likely to ar-
rest members of some racial groups than other racial groups, then taking
DNA from innocent arrestees means there is a racial bias built into vulner-
ability for future prosecution.
Also a good case can be made that all of us should be equally vul-
nerable. None of us should get a free ride on crime. Perhaps we should
use the blood samples taken from all hospital-born babies at birth and
build a DNA database that includes all of us. But that's not where we are.
Today, I think, most people would not allow this. A universal DNA data-
bank violates our sense of privacy. What we have instead is an "every
dog gets one bite" rule. You've got to commit a crime or at least be sus-
pected of it. I suspect that many people are untroubled by a policy of
taking DNA from arrestees because they believe both that an arrest is
suspicious, and they are not going to be arrested. People, in other words,
are perfectly happy putting the "other's" DNA in a database, particularly
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if their image of the "others" who are arrested is black, Hispanic, or oth-
erwise clearly different from them. But if we allow arrestees to have
their DNA entered into databases in part because we don't think we will
be affected, it raises serious moral issues.
For the moment, however, let us put aside the problem of arrestees
and accept the "one bite" principle: people should not be included in
DNA databases, unless they deserve it because they have committed
felonies and so show they are not law-abiding citizens. Now consider the
following situation. There has been a rape. DNA evidence has been se-
cured and run against a database without yielding a match, so we know
the offender is not in the database. Suppose, however, that of thirteen
places tested, someone in the database matches on ten. We know this
person is not the criminal, but we also know there is a very good chance
that some close relative of the person in the database is the criminal.
What do we do then? Do we ignore the evidence and tell the local police
only that there was no match. To do so might let a rapist rape again or a
murderer kill again. Or do we tell the police to get DNA samples from
the felon's father and brothers. In this case the father and brothers are
effectively in the database even though they have not in the past been
apprehended for a crime. More importantly, if we allow these identifica-
tions not only are some people not protected by the "one bite" rule but
the racial and other biases of felony convictions built into the database
because of the overrepresentation of blacks and Hispanics in the criminal
population are enlarged so that proportionately many more never-
convicted blacks and Hispanics are vulnerable to DNA identification.
This problem is exacerbated if an arrest is sufficient reason to acquire a
DNA sample for database storage.
Because of this, my strong inclination, except for one consideration,
is that we all should have our DNA in the databases. Let's be fair; no one
should get a free ride on crime. I don't care whether you're a first time
offender or you've gotten away with five crimes, or a convicted felon. If
you rape somebody, I want you caught, and I want a world in which
people are deterred knowing that if they commit a serious crime they are
likely to be immediately identified. But here is my problem (which I
admit may just be paranoia about a future world that may never exist).
Recall the movie Casablanca? The movie turns on the presence in Casa-
blanca of a leader of the anti-Nazi resistance named Viktor Lazlo. He
must leave Casablanca to continue his work and the Germans, working
through the apparatus of the Vichy French government, are determined
that he will stay in Casablanca or die. In one scene Lazlo and several
other members of the French underground are at a secret meeting. If they
were found, they would surely be arrested and would probably be shot.
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Somehow the police get wind of the meeting and they stage a raid. At the
last moment the plotters realize their danger. Everybody flees and gets
away. No doubt the police frantically chased them (the movie doesn't
show this, but it is reasonable to suppose) but they didn't catch any. So
the Casablanca underground lived to fight on.
With everyone's DNA on file, however, there would be a different
ending. The police would save their breath. Rather than give chase, they
would take the glasses the people were drinking from and the cigarette
butts in the ashtray, and they would run DNA analyses, arresting or
shooting those whose DNA matched. So in creating a universal database,
we would be creating an ability to follow everyone, for good or for evil,
that we have never had before. It is important to consider even such low
probability scenarios, as we think about how we're going to treat DNA in
the courts.
Now let me briefly address some areas where Phil has in some
measure preempted me. First, it is important to realize that DNA evi-
dence is not confined to criminal cases, and is only going to get more
important in civil and regulatory law. The use of DNA to establish pater-
nity has already been mentioned. DNA analyses today dispose of most
disputes about paternity, so the obligations that arise out of paternity
now turn largely on genetic testing. The number of genetic tests and the
number of adults seeking genetic testing has increased markedly in re-
cent years, and a new profession, genetic counseling, has arisen to help
people with issues related to genetic tests, including coping with unwel-
come results. It turns out that genetic counselors are learning, in a not
insignificant number of cases, that a child being tested is not the child of
the person who thinks he is the father. What should a genetic counselor
do in this situation and what legal liability will arise if the counselor tells
or fails to tell what she has learned? Suppose a father or mother asks.
Must the counselor then reveal what she has learned about paternity?
Another issue that the court has to confront is the genetic coun-
selor's responsibility to persons other than those tested. Suppose, to take
an extreme case, that one identical twin tests positive for the breast can-
cer gene. The test results would alert the other twin to closely monitor
for the development of cancer and might even lead her to decide on a
prophylactic mastectomy. If for some reason the tested twin refuses to
share her results with her genetically identical sister, does the counselor
have an ethical obligation to do so? Will the counselor be vulnerable to a
law suit for breaching confidentiality if she tells the twin sister? Or,
might the sister sue if she is told and preferred not to know? Alterna-
tively, if the genetic counselor does not tell and the twin sister develops
breast cancer, will the counselor be held liable for a failure to warn?
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Genetic tests also have a role to play in adoptions and tracing family
histories. In Argentina, during the "Dirty War," many people were killed
and their children were adopted by others. Mary Claire King, an Ameri-
can geneticist helped trace through DNA testing the relationship of these
adopted children to their grandparents and other blood relatives. Thus,
the children could be returned to their extended birth families, though
there parents were dead. But were the children better off than they would
have been had they been left to grow up with their adoptive families?
That's a question DNA cannot answer.
Genetics may also help decide immigration questions. Relatives of
people living in a country often get immigration preferences. Suppose
there's a dispute, as has happened in England, about whether a claimed
filial relationship is real, with the INS arguing it is phony. DNA can be
used to determine if the claim of relationship is a valid claim.
Consider also the potential relevance of DNA evidence to issues of
responsibility and the issues that a deeper understanding of the genetics
of behavior might raise. One can imagine, for example, that we learn that
some people have uncontrollable impulses to drink alcohol or to act vio-
lently. How do we deal with responsibility for criminal actions that are in
part attributable to genetic propensities? Is this going to be the new
Twinkie defense? Indeed, maybe we'll learn there's something to the
Twinkie defense. Perhaps we will identify a rare mutation which means
that for a small number of people sugar releases inhibitions and stimu-
lates violence. What do we do if a genetic test reveals that a man charged
with assault shortly after he devoured four Twinkies had this mutation?
When we turn from crimes to torts, we find all sorts of implications
for law in the new genetics. Phil gave the example of using genetic evi-
dence to show that a condition like cerebral palsy was not due to harm a
doctor might have caused during the delivery. But genetic evidence cuts
both ways. It may show that some damage is genetic in origin, but it may
also show that it is not. In the latter case, there may be a strong impetus
for a jury to attribute a baby's condition to malpractice when it was
caused by something else, like the womb environment, which is not the
subject of expert DNA testimony.
I have been asked to finish. So I'll just provide a catalog of other is-
sues that I would discuss in further detail if I had the time. One can
imagine a new tort of releasing genetic test results without proper coun-
seling. It can be psychologically devastating to learn one has a disease
like Huntington's. If someone is told she has the gene for Huntington's
but is not properly counseled, does she have a cause of action? Does
someone who does not want to know whether he has the HD gene have a
cause of action against a relative who informs him of her test results,
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when they mean that he has an elevated risk of having inherited the HD
gene? Additional issues are raised by the genetic testing of children. Do
parents have authority to test their children's DNA for diseases like HD
for which there is no known cure? May a genetic tester be sued by a
child for complying with the parents' wishes? Other tort cases are likely
to grow out of pharmacogenetics, allergies to GMO crops, destruction of
native crops by the transposition of DNA genes, and the like.
Another area crying out for legal regulation and fraught with the po-
tential for litigation is insurance. Can a company deny insurance because
a person refuses to allow DNA testing on privacy grounds? If insurance
companies are allowed to collect DNA samples, will there be limits on
what they can test for and with whom they can share results? Will com-
panies face liability if they don't disclose to the applicant health-relevant
genetic information? If insurance companies are not allowed to insist on
genetic tests, how will they deal with the moral hazard problem which
will arise if people use their own genetic test information as a basis for
deciding whether to purchase insurance? Also, will we have different
rules on genetic testing for health and life insurance? States have begun
to tackle some of these issues, particularly denial of coverage and ge-
netic privacy issues, but state laws are a patchwork and much remains to
be done.
Employment is another sector in which genetic tests raise legal is-
sues. Can a company, for example, use DNA tests to determine whether
an employee can work with chemical or biological factors? May it
screen initial hires genetically and exclude those who are most suscepti-
ble to alcohol addiction, if it is worried about shop floor safety, or breast
cancer, if it wants to minimize health care costs? Intellectual property
issues abound; we'll have a whole panel on that later. DNA and biotech-
nology will play an important role in regulatory law. It can, for example,
provide new ways to test the purity of certain products, and recombinant
technology allows genetic markers to be inserted in bacteria that facili-
tate the tracing of non-point sources of pollution. Contracts issues
include the question of who owns DNA samples. If somebody provides a
DNA sample and it turns out that its special properties allow a large
medical payoff, who gets the benefit of the intellectual property? Finally
in almost all areas the law will face the problem of seeking to resolve
complex issues by appeal to the judgment of nonscientist judges and ju-
ries. How can we educate them when DNA is used in court? This list is
by no means exhaustive though I fear I may have exhausted you. Thank
you.
[Applause]
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PROFESSOR RICHARD D. FRIEDMAN: Thank you, Rick. I
want to open it up to the floor for questions in a bit. But let me pose the
first one, which ties into comments by all the panelists.
The question of juror understanding. Jay presented some depressing
data on this and Rick has presented one possible way out, which is basi-
cally for the defendant to concede that the DNA samples come from the
same source. But if the defendant doesn't concede that, is there a way
out? Is it possible that the technology will be sufficiently good, soon
enough, that we can say we can do without all the statistics? That's one
possibility. Or should we at least say that the proponent of the evidence,
most often the prosecutor, doesn't have to present statistics? In other
words, is it plausible to say we can just avoid this whole issue, effec-
tively by brute force because the evidence is so good? Or will that soon
be a possibility? Anybody want to take a crack?
PROFESSOR JONATHAN J. KOEHLER: Well I think most of
us agree that a chance of a coincidence when the numbers are as extreme
as they typically are, is so small that it probably won't even happen in
our lifetime.
PROFESSOR RICHARD D. FRIEDMAN: Right. But yet we still
go through this exercise, right? And I'm wondering how we can avoid
that.
PROFESSOR JONATHAN J. KOEHLER: Well, I mean the law-
yers should probably talk more about it. I have told defense counsel that
I think the best way to focus the jury's attention on the possibility of er-
ror is to simply concede there's no chance of coincidence whatsoever.
PROFESSOR RICHARD D. FRIEDMAN: Yeah, right.
PROFESSOR JONATHAN J. KOEHLER: And then the only sta-
tistic you're talking about is the chance that this could've been an error
and maybe the one percent chance or whatever chance you were able to
introduce for error will be sufficient to make a few jurors think, "I'm not
convinced beyond a reasonable doubt." But lawyers aren't willing to give
that up. They're not willing to concede that there's no chance of a coin-
cidental match because then they lose one issue on appeal. And so
instead we hear lines like this, where an expert will say "there's a ninety-
five percent chance that ninety-nine point three percent of the people in
North America don't have this DNA profile." This is very typical testi-
mony. But I just can't imagine a jury doing anything sensible with a
ninety-five percent chance that ninety-nine point three-so-...
PROFESSOR RICHARD D. FRIEDMAN: Right. So one answer
that now both of you have presented is that the defense lawyer should
just be smarter by conceding the one issue. But if they're not doing it,
I'm wondering what the law can do. Any other thoughts from David or
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Rick on this? Or the technology? As I say, will the technology bail us out
by getting us to the point we can say you know what, we don't want to
hear it, this is the same DNA, assuming there's no lab error?
PROFESSOR DAVID H. KAYE: Two things come to mind. First,
in the cases where courts were concerned about the method of comput-
ing probabilities, many courts wrote that it would not be permissible for
an expert to report a DNA match without an accompanying statistic to
indicate how significant this finding is. One reason that courts gave for
this conclusion is that the 1992 NRC report stated that it is not scientifi-
cally acceptable to report a match without assessing the probability of a
random match. The courts construed this to preclude admissibility of all
purely qualitative testimony about a DNA match. I think that this makes
no sense. Once it is established that DNA typing allows an exquisite de-
gree of differentiation among individuals, it may no longer be necessary
to report that degree of differentiation down to six decimal places.
Rough statements, like "this is a very rare type" should suffice.
Second, in most cases it should be possible for an expert to give an
opinion that the defendant is the source of the DNA in question. The
chance that even a full sibling would match at 16 STR loci, for example,
must be less than one in a million. As early as 1994, Daniel Hartl, a
population geneticist known for challenging the usual computations of
matching probabilities, submitted an affidavit stating that "to a reason-
able degree of scientific certainty," a DNA sample came from a specific
defendant.3 9 Thus, when the probability computed in a given case is
small enough, FBI analysts now report that the defendant is the source of
the DNA .
PROFESSOR RICHARD 0. LEMPERT: I think the FBI policy is
all to the good so long as it is clear that the claim presupposes no fraud
or error. I have a couple of additional comments. One is in defense of the
1992 NRC report. One of the interesting things about being on that panel
was that information about DNA evidence was changing so rapidly in the
course of our writing the report that it was almost overtaken by scientific
advances before the ink on it was dry. One of the problems with courts is
that they're used to looking at authority, and often the older the authority
the better. However, for a science that changes as rapidly as DNA, that's
exactly the wrong policy.
39. State v. Bloom, 516 N.W.2d 159, 160 n.2 (Minn. 1994); see also People v.
Hickey, 687 N.E.2d 910, 917 (Il. 1997) (given the results of nine VNTR probes plus PCR-
based typing, two experts testified that a semen sample originated from the defendant).
40. Bruce Budowle et al., Source Attribution of a Forensic DNA Profile, 2 FORENSIC
Sci. COMM. (July 2000), available at http://www.fbi.gov/hqflab/fsc/backissu/july2000/
source.htm.
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I stand by what we said in that report on the issue David raises as of
the time we wrote it. But relatively soon after the appearance of the re-
port, what we wrote was no longer the best advice that a group of
scientists could give a court, though the random match probability
should be calculated for internal purposes. I think the FBI (and this is
also done in Britain by some scientists) is right to report only that the
defendant is the source of evidence DNA when the probability that the
DNA came from someone else (including close relatives) reaches a cer-
tain low level. We probably need a court judgment about what that
threshold probably should be.
Lawyers, however, like to win, and, unfortunately, sometimes they
like to win more than they like to do justice. Each side has its incentives
to keep using DNA statistics. The prosecution has an incentive to present
random match statistics because if Jay's work is right it may be more
persuasive than simply reporting a unique match and allowing the focus
be switched (as it should) to the error probability. The defense, on the
other hand, clutching at straws may dwell on statistics in the hope of
confusing enough jurors so that the jury can't reach a decision.
Confusion may, however, also hurt the defense. Suppose a match is
found but it is reasonable to think that there is a one in five hundred
chance of laboratory error or police malfeasance. A defense attorney
might think it silly to offer this information, for it seems little is to be
gained from admitting a match with such a small error probability. But
the defense may be misreading the evidentiary strength of this informa-
tion because implications of a probability like this depends tremendously
on the other evidence in the case. If the other evidence is itself incrimi-
natory, as Rich suggested is usually the case, the defendant will lose and
deserves to lose. But if the other defense evidence is strong, for example,
an alibi that seems reasonably solid, an error rate of one in five hundred
might well justify an acquittal. But the jury may not appreciate that DNA
evidence, including error probabilities, must be read in the context of all
the other evidence, and may even think it means that there is only one
chance in 500 that the defendant is innocent.
PROFESSOR RICHARD D. FRIEDMAN: All right, thanks. Let's
open up to the floor. I have enough questions to keep us going if there
aren't any. I'd rather hear from you folks.
PROFESSOR RICHARD 0. LEMPERT: [INAUDIBLE-TOO FAR
AWAY FROM MIC. NUMBER 2:02 ON VIDEO]
PROFESSOR RICHARD 0. LEMPERT: That is a really interest-
ing question. I have several things to say about these issues. First, when
people think of universal population screening, they are usually thinking
about extracting from the blood samples that are taken from newborns
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for state-mandated genetic testing, a profile of the loci used in identifica-
tion databases, and storing these profiles in a searchable database. An
interesting side issue is that for identification purposes all that is needed
are the profiles of these loci, which were chosen in part because they
seem not to code for any known traits. Yet the police often keep the
whole DNA sample on file, from which a wide range of genetic informa-
tion, with no implications for police work, can be extracted. There is a
real question whether we should allow this.
I sit on the advisory committee for the Community Genetics pro-
gram of the Michigan Department of Public Health. Recently we learned
that the blood samples collected from newborns for genetic screening are
kept for something like twenty-one years and then destroyed. The ques-
tion we were asked to discuss was whether researchers should be given
access to these genetic samples. They are tremendous resources for un-
derstanding disease, particularly if we can follow people through their
lives and see what happens to them. In our discussion of the issue there
was general agreement, indeed it went without saying, that if researchers
were to be allowed access to these resources, the access would have to
be anonymous, since the sample donors had not given informed consent
to research uses. People thought that if there was total anonymity, the
informed consent issue was solved. But if we ever establish a universal
DNA database, we will not be able to give anonymous genetic samples
to researchers. There will always be the chance that a person could ana-
lyze the alleles used for identification, and if she had access to the
universal database, determine who is the source of the sample. So all
sorts of problems that one doesn't usually think about arise in this area.
My other quick point is that even though we don't have universal
DNA databases, in some areas, for some crimes, there is tremendous po-
lice coercion on large numbers of people, none of whom would be
conventionally called a suspect, to give DNA samples for identification.
So in a sense, we are creating local DNA databases to investigate crimes.
Indeed the very first DNA identification case in the United Kingdom,
with the marvelous name, Regina vs. Pitchfork, grew out of such a situa-
tion It was a case involving two rape murders near a village in rural
England, which unfortunately for the perpetrator, was near the laboratory
of a pioneer in DNA genetic analysis. The police tactic was to demand
that every male in the village area give a DNA sample. The interesting
thing is that none of the samples matched. But then it turned out that one
person had had a buddy give a sample for him. Sure enough, when that
person's DNA was later tested, it matched the DNA left at the crime
41. Craig Seton, Life of a Sex Killer Who Sent Decoy to Take Genetic Test, TIMES
(London), Jan. 23, 1988, at 1.
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scene. Of course, at this point one hardly needed DNA evidence to iden-
tify the perpetrator.
PROFESSOR RICHARD D. FRIEDMAN: You mentioned blood
samples. My impression is that with newborns you wouldn't take blood
and that when they do the databases, it's usually from a swab.
ANSWER: In newborn testing in Michigan, and I think elsewhere,
they take between three and five dots of blood, which are placed on a
card, and stored. They are used immediately to do a series of tests, in
Massachusetts it's thirty, in Michigan the panel is, maybe, twenty-five,
but the panel is increasing all the time. The cards with blood are kept for
21 years.
QUESTION: [Inaudible].
PROFESSOR RICHARD D. FRIEDMAN: Yeah. Rick said you
know it's a marvelously powerful tool to have the universal database, the
concern being that it could be used for ill. My own personal feeling, I'm
curious what others feel about this, is that's true of all governmental in-
formation. Information the government has is particularly powerful
information but we'd have to develop, as David indicated in the slide,
strong privacy protections. But my goodness, it would mean no first
crack-no opportunity to commit a crime before your DNA has been
collected-which is what a felon database allows. I'm curious whether
others on the panel have comments.
QUESTION: [Inaudible].
PROFESSOR DAVID H. KAYE: If we are going to have a univer-
sal law enforcement database, the only practical way of doing it at
present is something that Dr. Reilly has suggested, which is to use new-
born screening and slowly build the database over time. It could be
structured so that the police do not handle the blood samples, for these
contain information that would be problematic. The identifying loci that
the FBI now uses involves thirteen or more STR markers. These are no
more meaningful than a passport photograph or a Social Security num-
ber. They are essentially random noise in the genome. One could add to
the newborn disease screening done for public health purposes, by force
of law and without informed consent, an additional test for the identifi-
cation markers. That one test result could be transmitted to a single
database without any law enforcement personnel ever handling a sample.
This system would need to be supplemented to include immigrants
and perhaps visitors. The details are by no means worked out, and the
public might well reject the concept at the present time. But twenty years
from now, perceptions and fears may change. Certainly, the technology
for creating identifying profiles at low cost will improve.
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PROFESSOR RICHARD D. FRIEDMAN: Thanks. Other ques-
tions?
PROFESSOR JONATHAN J. KOEHLER: I'd like to see profi-
ciency testing in all areas of forensic science. So I don't know if your
database was concerned, per se. But I'd like to see the experts tested, that
is provide the expert with samples of known matches and see how often
they correctly say match. No non-matches and see how often they cor-
rectly say no match. Then we get a sense of their error rate and then we
introduce that.
PROFESSOR DAVID H. KAYE: Some forensic scientists recog-
nize the need to gather data that would justify claims about
probabilities or frequencies. Researchers in New Zealand have col-
lected fragments of glass from roadways to determine how common or
rare various features of broken glass are.42 In United States v. Nichols,
one of the Oklahoma City bombing cases, an FBI tool mark analyst
referred on cross-examination to a study of the individuality of drill
bits, but the study never was completed. 3 In response to defense chal-
lenges to handwriting and fingerprint identifications, a few experiments
and statistical analyses have been conducted." Thus, there are forensic
scientists who are interested in doing such studies, but far more should
be done.
PROFESSOR RICHARD D. FRIEDMAN: We're over time. I
only have time for one quick question. Gentleman in the back.
PROFESSOR RICHARD D. FRIEDMAN: Can you speak up
please?
AUDIENCE MEMBER: [Inaudible 2:16] How do we ensure that
defendants have counsel? Lawyer training?
PROFESSOR RICHARD D. FRIEDMAN: Yeah, that's a serious
problem. Any comments? I'll just say, if I may, one way of looking at it
is it's one more complexity among many others that defense lawyers
have to deal with and you can view it as just a part of what in many in-
stances is the inadequacy of the assigned counsel, particularly in capital
42. K.A.J. Walsh & J.S. Buckelton, On the Problem of Assessing the Evidential Value
of Glass Fragments Embedded in Footwear, 26 J. FORENSIC ScI. Soc'Y 55 (1986); see also
S.A. Coulson et al., Glass on Clothing and Shoes of Members of the General Population
and People Suspected of Breaking Crimes, 41 ScI. & JUST. 39 (2001); J. McQuillan & K.
Edgar, A Survey of the Distribution of Glass on Clothing, 32 J. FORENSIC SCI. Soc'Y 333
(1992).
43. No. 96-CR-68 (D. Colo. Nov. 10, 1997). Trial transcript available at
www.courttv.com/archive/casefiles/Oklahoma/nichtranscripts/1 II Oam.html (last visited
11/29/03).
44. Susan R. Poulter, Presidential Showcase Program on Expert Witness Law,
EBLAST: THE BULL. OF LAW Sc., & TECH., Oct. 1999 , at http://www.abanet.org/scitech/
eblast/oct99/2oct99.html#expert (describing a talk by FBI laboratory director Donald Kerr).
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cases, and the whole range of problems that they face. But does anybody
else want to offer a quick comment on it?
PROFESSOR JONATHAN J. KOEHLER: My quick comment is
that I think it's the responsibility of your law schools. It shouldn't be the
government's responsibility. I think your law schools should offer some
sort of training in scientific thinking and statistical thinking and prob-
abilities. I know that's not what you're in law school to do. Part of the
reason you went to law school was so that you didn't have to do that
kind of stuff. But I think it should at least play some minimal role in
your training, because science is now playing such an important role in
the courtroom that it's important to understand scientific theory and the
statistical underpinnings of it.
PROFESSOR RICHARD D. FRIEDMAN: I think that's a good
way to end. Okay. Thank you very much to the panelists. Thank you to
the audience.
(Applause)
MATT MOCK: Thank you very much Professor Friedman and
thank you members of Panel I. We're going to break for an hour. We'll
be back around 1:10. Panel II will be "The Regulations of Life
Sciences."
PANEL II
THE REGULATIONS OF LIFE SCIENCES
INTRODUCTION
MATT MOCK: Alright, welcome back everybody. I would now
like to introduce the moderator for our second panel, The Regulations of
Life Sciences. Dr. Joel Howell is the Victor Vaughan Professor of the
History of Medicine at the University of Michigan, where he also holds
appointments in the departments of Internal Medicine, History, and
Health Management and Policy. He received his M.D. at the University
of Chicago, where he stayed for his internship and residency in internal
medicine. At the University of Pennsylvania, he was a Robert Wood
Johnson Clinical Scholar, and received his Ph.D. in the History and
Sociology of Science. Dr. Howell has been a faculty member at the Uni-
versity of Michigan since 1984. He is Co-Director of the University of
Michigan Robert Wood Johnson Clinical Scholars Program and Director
of the University of Michigan Program in Society in Medicine. He has
written widely on the use of medical technology, examining the social
and contextual factors relevant to its clinical application and diffusion,
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analyzing why American medicine has become obsessed with the use of
medical technology. He has also written and spoken widely on the his-
tory of human experimentation, especially the policy implications of that
history.
His current research is an attempt to analyze the implication for
health policy of factors that have both contributed to and slowed the dif-
fusion of medical technology into clinical practice, using both the
sociology of knowledge and a comparative approach. His most recent
book is Technology in the Hospital: Transforming Patient Care in the
Early Twentieth Century, published by Johns Hopkins University Press.45
Dr. Howell's research has been recently supported by the Robert
Wood Johnson Foundation Investigator Award in health policy research,
and by a Burrows Wellcome Fund Award in the History of Medicine. He
was recently named to the University of Michigan's Society of Fellows.
It is my pleasure to present Dr. Joel Howell.
[Applause]
DR. JOEL D. HOWELL: Thank you very much. We're in for an
exciting afternoon. It's a fascinating topic and we've got three wonderful
speakers. And before we get to it, let me just say a couple words about
how things are going to work here. Each of the speakers will talk for
about fifteen minutes, I've been told, and then we will throw the discus-
sion open for questions. I understand the morning session ran over a
little bit. This session will end at two-thirty. Hopefully, that will still
leave us plenty of time for ample questions.
Our first speaker this afternoon is an old friend, Rebecca Eisenberg,
who I've had the privilege of knowing for some time. I once had the ex-
perience of listening to her try to argue me out of a position for about
two hours on a car ride through a dark Virginia countryside. At the end
of the ride I was still sure she was wrong but I couldn't think of a single
way to attack her position.
Rebecca's a graduate of Stanford University and the University of
California, Berkeley, where she was Articles Editor of The California
Law Review. She served as law clerk for Chief Judge Robert Peckham
on the U.S. District Court for the Northern District of California and
subsequently practiced as a litigator. She teaches courses in patent law,
trademark law, and torts, and has taught courses on legal rights and regu-
lation of science and legal issues in the human genome project. In fact,
Rebecca, I think that the NIH Director's office probably has a direct line
to you at all times, when these issues arise. She just recently came back
from the 1999-2000 academic year as a Visiting Professor of Law,
45. JOEL D. HOWELL, TECHNOLOGY IN THE HOSPITAL: TRANSFORMING PATIENT CARE
IN THE EARLY TWENTIETH CENTURY (1995).
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Science, and Technology at Stanford. She's received grants to support
her work from the Ethical, Legal, and Social Implications of the Human
Genome Project, for the United States Department of Energy. She's
played an active role in public policy debates concerning the role of in-
tellectual property and biomedical research. As a member of the
advisory committee to the Director of the National Institutes of Health,
the panel on Science, Technology, and the Law of the National Acad-
emies, and the board of directors of the Stem Cell, Genomics, and
Therapeutics Network in Canada. In short, I can think of no one who is
better qualified to address the issues that we'll be starting off with today.
I present Professor Eisenberg, the Robert and Barbara Luciano Professor
of Law.
PROFESSOR REBECCA S. EISENBERG: Thank you very
much. This is an absolutely huge topic and I was told that I could really
talk about whatever I wanted. So I decided to focus my remarks on the
regulation of research in the life sciences, which is also, of course, a
huge topic. Life sciences research is extensively regulated by the gov-
ernment, which provides multiple entry points for addressing the
concerns that advances in the life sciences provoke about ethics and
health and safety. Advances in life sciences research have been the focus
of recurring public policy debates in different government venues over
ethical issues and the appropriate form and scope of government re-
sponses to the concerns that are raised. This generates lots of public
discussion about emerging areas of research that push ethical buttons-
especially, in recent years, in matters that touch upon the politics of
abortion, such as embryo research and the derivation of embryonic stem
cells. Sometimes we've seen government intervention in research, al-
though rarely do we see outright prohibitions against research in any
particular category. More typically, government regulation of life sci-
ences research has the effect of bureaucratizing certain policy choices
and values choices, and handing them over to the scientific community
for administration. We see this pattern over and over again, in different
particularized settings.
Life sciences research evokes strong feelings among the general
public, both good and bad. On the positive side there is hope for relief
from disease and afflictions, for new scientific breakthroughs that will
prolong and improve our own lives and the lives of our children. On the
negative side are fears about bringing upon ourselves unanticipated con-
sequences, anxiety about human meddling in the natural order of things,
concerns about loss of reverence and respect for human life. Or simply
fear that we will act too quickly upon too little knowledge. Government
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regulation often provides a stage for expressing these hopes and fears,
and a bureaucratic apparatus for addressing and managing them.
One circumstance, more than any other, that inevitably involves gov-
ernment decision makers in oversight and regulation of life sciences
research is the dependence of much of life sciences research upon gov-
ernment research funding. In recent years, private funding has overtaken
public funding for biomedical research in monetary terms. But public
funding remains extremely important, especially for elite scientists doing
fundamental research in academic laboratories. This public funding
comes with numerous regulatory strings attached. Universities and other
recipients of government research funding are accountable for how they
use these funds. Government-funded biomedical research is subject to
regulation on a broad range of topics, including protection of human
subjects, the use and containment of hazardous substances in the labora-
tory, the protection and dissemination of research results, and the
introduction of new products to market. Some of these regulations have
arisen in response to particular notorious episodes in biomedical re-
search that initially provoked widespread public debate, like the
Tuskegee Syphilis Study that led to further regulation of informed con-
sent in human subjects research, the initial experiments with
recombinant DNA technology that led to the formation of the Recombi-
nant DNA Advisory Committee, or birth defects in children born to
mothers who took thalidomide that expanded the scope of FDA regula-
tion. But after the shouting is over, in each of these areas, what has
emerged is bureaucratic institutions that are substantially within the con-
trol of the scientific community itself. This is true of institutional review
boards, to oversee protection of human subjects and informed consent in
research within hospitals. It is true of the Recombinant DNA Advisory
Committee to review research proposals within NIH. It is true of the
delegation to FDA of authority to keep new drug products off of the
market until they have been proven safe and effective. Some of these
institutions are deliberately set up to include lay participation, to provide
a broader range of voices on ethical issues, and to involve some people
who are not co-opted by their own professional stake in seeing the re-
search move forward. But members of these review boards sit alongside
scientific experts, who typically outnumber them and whose expertise,
inevitably, skews the discussion towards the concerns of the scientists.
And so, although the mandate of an institutional review board or the Re-
combinant DNA Advisory Committee may include attention to ethical
issues, the mechanism itself, over time, starts to look more and more like
another layer of professional peer review.
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Non-experts have a larger voice in regulation of science at the legisla-
tive level. They have a larger voice before Congress. Congress makes
broad choices about legislative appropriations for publicly-funded re-
search and exercises some control over the terms of grants, although the
more fine-grained choices about priorities and how to allocate funds
among competing proposals are generally left to funding agencies, like
NIH, that are substantially within the control of the scientific community.
On the whole, public funding of research has been a very welcome form
of regulation within the scientific community, despite the strings that are
attached to it. Biomedical research, in particular, has benefited greatly
from the high hopes of the public for future medical breakthroughs ex-
pressed in the political process through lobbying by disease advocacy
groups for more funding of research on particular problems. This may
not be a perfect system for deciding how to spend federal research dol-
lars, but it is a system that has generated substantial increases year after
year, for many years now. Sometimes the research community bristles at
a particular legislative allocation for something that they think is a po-
litical distortion of scientific priorities, such as the formation of a
National Institute of Alternative Medicine, to cite a recent example. Or
sometimes they grouse about overallocation of funds to the study of par-
ticular diseases relative to spending on fundamental research that is not
disease specific.
Perhaps in their dreams, researchers would prefer to enjoy the same
growing levels of public funding without any legislative guidance as to
how they should spend the money. But the two go hand in hand. The ex-
traordinary legislative largesse that biomedical research has enjoyed,
relative to other worthy fields of scientific inquiry, like physics and
math, is a direct result of the political effectiveness of the disease group
advocates, who have pleaded successfully for more funding for their par-
ticular causes. And the research community doesn't complain too much
because for the most part, they have been quite successful at exercising
control over how funding agencies spend their appropriations through
mechanisms that are within the professional control of scientists, such as
peer review of grants. To return to the example I mentioned earlier, when
Congress decided to create and fund a National Institute for Alternative
Medicine, within the NIH, the inevitable upshot has been that these funds
are used for peer reviewed empirical tests of remedies like Echinacea and
St. John's Wort, and glucosamine-chondroitin. Peer review goes far to en-
sure that public research funds are ultimately deployed in accordance with
the priorities and methodological commitments of the scientific commu-
nity, within broad constraints set by Congress.
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Sometimes, however, legislative control does not stop at writing out
checks with broad directives about how to spend the money. Sometimes
Congress, or even the Executive Branch, sets limits on how the money
can be spent that are a little harder to work around. Sometimes they seek
to prohibit the use of federal funds for particular types of research, like
Congress's ban on human embryo research a number of years ago, or
President Bush's more recent ban on the use of human embryonic stem
cells derived after August 2001, in federally-funded research. This sort
of move-an outright prohibition on what you can do rather than an af-
firmative provision of funds for a particular purpose-is far more
frustrating for scientists, particularly when it cuts off government-funded
academic scientists from use of an emerging technological platform like
human embryonic stem cells that is likely to have implications for a
broad range of problems. And it has been much harder for the commu-
nity to figure out ways to work around. This type of prohibition is
actually pretty rare, and so far has arisen primarily in areas touching
upon abortion or the values implicated by abortion and the status of
human embryos.
But the scientific community is bristling at it and sometimes ques-
tions not only its wisdom, but also its legitimacy. Scientists argue that a
restrictive approach to federal funding of embryo research, for example,
has set back fertility research considerably, by effectively excluding fun-
damental research on fertility of the sort that the government might pay
for, but the private sector generally will not. Some research is done, of
course, in private fertility clinics, but it is not the sort of rigorous, peer-
reviewed, fundamental research that is most respected in the scientific
community and that has been so productive of advances in other fields.
This is a fair criticism of the choice to withhold federal funding for re-
search in a particular area: it chokes off university research, with the
effect of slowing the kind of applied research that private investors are
willing to pay for. In other words, withholding federal funding not only
limits the total amount spent on research in a particular field, such as
fertility research, but also limits the character of research that is likely to
be done, by limiting the involvement of academic scientists who rely on
public funding and relegating these fields to the private sector. The pri-
vate sector is very effective at carrying out certain kinds of research
projects that are within site of profitable endpoints, like drug develop-
ment. But it is less effective at funding and performing "upstream"
research of the sort that has flourished in academic institutions with pub-
lic funds. Even though the private sector has been extraordinarily
forward-looking in biomedical research, funding upstream research that
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is far removed from product development, there is still a significant loss
to upstream research from withholding federal funds in an area.
The historical importance of government-funded academic research
to biomedical advances is a powerful argument for maintaining federal
funding in areas of biomedical research that we want to promote. This
argument often wins, but it doesn't always win. The academic biomedi-
cal research community is very well represented in Washington. It has
the backing of organized disease group constituencies, and together they
lobby hard for federal funding of things like stem cell research that
promise to advance fundamental knowledge of human health and dis-
ease, and they are often successful. They win so often that it seems
illegitimate to them when they lose.
Indignant scientists are arguing that it is irrational to withhold fed-
eral funding from ethically controversial areas of research, such as stem
cell research, that Congress has not chosen to prohibit entirely. If stem
cell research is ethically repugnant, why not prohibit it entirely? If it is
not so repugnant as to justify an across-the-board prohibition, then why
not fund academic scientists to perform the research in the public sector?
They note that the paradoxical consequence of withholding federal fund-
ing from research that is not prohibited entirely, such as embryonic stem
cell research, is that controversial research still goes on in private labs,
behind closed doors, under conditions of trade secrecy. It is pursued for
profit, outside of public oversight, rather than in the public and academic
sector, where the ethical issues that it raises could get more fully vetted
and explored by researchers and institutions that are publicly account-
able and motivated to advance knowledge rather than to make a profit.
A wiser government might well be investing more public research
dollars in embryonic stem cell research right now. However, it is not irra-
tional or illegitimate or inconsistent to withhold federal research dollars
from an ethically controversial field just because the federal government
has not taken the stronger step of prohibiting the research entirely. We
need to make collective political decisions about whether and how far to
regulate controversial fields of scientific research, and we don't always
agree about the underlying ethical constraints or the force of competing
ethical imperatives. At one end of the spectrum, many of us might agree
that certain areas of research are completely ethically unacceptable. We
might choose to prohibit entirely, for example, research that poses unto-
ward risks to human subjects or that uses human subjects without their
consent. But prohibiting research entirely is a very heavy-handed step
that we do not want to take unless there is widespread consensus that
there is something really wrong with allowing it to proceed. We also
value free inquiry and we particularly value progress in biomedical
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research. We therefore want our government to think long and hard be-
fore issuing an outright prohibition against research that could prove
fruitful, at least in advancing human understanding and perhaps also in
advancing human health.
At the other end of the spectrum is research that seems so good and
so valuable to so many of us that we're actually willing to tax ourselves
so that we can subsidize it in the public sector. Much, but not all, bio-
medical research falls under this heading. There is nothing that we value
more than our lives and our health, and if publicly-funded research offers
real promise of prolonging our lives and improving our health, we want
to encourage it. We're even willing to pay for it, even in times of fiscal
belt tightening.
But it stands to reason that some kinds of research are going to fall
in the middle of this spectrum. They are not so unambiguously unethical
as to call for the extraordinary move of an outright prohibition against
research by anybody (or perhaps those who find the research unethical to
enact a prohibition), do not command enough of a political consensus,
but still ethically controversial enough that we cannot reach political
agreement to subsidize the research. For the moment, that seems to be
where we are with human embryonic stem cell research in the U.S.: we
neither forbid it entirely nor subsidize it without restrictions. And the
result is to drive much of this research to private funding sources.
I wish that the political forces in favor of the research were more
persuasive to the government. But I don't think the current stalemate is
inherently irrational or improper. It is a pragmatic compromise. But if
the terms of a pragmatic political compromise are to have democratic
legitimacy, then it's important to have the competing arguments fully
vetted in public, in the political process. And for that reason, I find it a
little troubling that the current compromise position on the use of human
embryonic stem cells in federally funded research was not worked out in
Congress, but rather imposed by executive fiat, in the form of President
Bush's decision that it is okay to use preexisting embryonic stem cell
lines, but not to create new ones. That's not a call that the President
ought to be making. It belongs to Congress, as a more broadly represen-
tative body that is more accessible to lobbying on all sides of the issue
and can conduct public hearings that give it a full airing. So when we
disagree sharply about competing ethical imperatives, I think the issue
calls for broad public discussion, not a resolution that's imposed by the
Chief Executive.
I may have gone over my allotted time, so I'm going to stop here.
DR. JOEL D. HOWELL: Thank you very much. [Applause]
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We will now move on to hear from Rosemary Quigley. Rosemary
Quigley is Assistant Professor of Medical Ethics and Health Policy at
Baylor College of Medicine in Houston. She serves on the National In-
stitute of Health Directors Council of Public Representatives, sitting on
the Council's Working Group for the Protection of Human Subjects in
Research. She served on the Advisory Committee to the Director Work-
ing Group on Oversight of Clinical Gene Transfer Research, so she's had
a quite a bit of experience in this area.
At Baylor she teaches in the first-year medical student and residency
programs, as well as in the Ph.D. program, and Philosophy. She serves
on the Ethics Committee and Case Council Service at the Methodist
Hospital, working specially on implementation of medical decision-
making policy. Her research interests include the protection of human
research subjects and adverse event reporting in clinical research, the
impact of genetic information, and the prospect of gene transfer research
in patient care, as well as regulatory and constitutional issues involving
intellectual property, professional standards and disability.
Professor Quigley received her A.B. in English Literature from
Harvard College and her Law and Public Health Degrees right here at
the University of Michigan, where she was also the Book Review Editor
of the Michigan Law Review. She clerked for Judge Carmen Lopez of
the U.S. Court of Appeals for the First Circuit. Professor Rosemary
Quigley, Assistant Professor of Medical Ethics and Health Policy at
Baylor.
PROFESSOR ROSEMARY QUIGLEY: Thank you very much.
What I'm going to be focusing on today is adverse event information
and how intellectual property issues come into play, in terms of the
safety of clinical research. It seems that in these debates about who owns
clinical trial data and human body parts that the public interest in medi-
cal research has been considered, the industry's interest in this research
has been considered, but rarely have the interests of the research partici-
pants been considered in these debates about intellectual property. And I
would assert that they might actually have interest in this as well, given
that they're the ones who are giving their bodies, often experiencing the
adverse events, and they might want their fellow research participants or
potential research participants to have the information about their ad-
verse events and about other goings on in clinical trials before they make
decisions about enrolling in these trials.
From the literature standpoint, there's been a growing discussion
about the commodification of biological materials, specifically human
tissues and their cells, genetic sequences, fragments of genetic se-
quences, as well as the potential for sale of organs. This has become a
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hot topic ever since the Moore Case when we took cells from someone
without telling them we were going to use them for commercial devel-
opment. In that case, the patient did not win for various reasons, but
since then we've wondered--do people who contribute to the advance of
medical research have any stake in what they contribute?
Private interests have increasingly been assigned ownership of body
parts or biological material once it has been removed from the body.
Once that happens, the participants rarely have any claim to their data or
their fluids anymore. Even the case law has essentially supported the
commercial stake in that kind of information. It hasn't really advocated
for even the public interest, let alone the research participant interest.
And there are people who think, especially in medical research where
there is a history of exploitation of research participants, that this has the
potential for subordination of people who are giving of their bodies, who
might not have full information about an investigation of a new thera-
peutic research substance. And this has been discussed actually veryS• 46
thoroughly in a book by Peggy Radin, Contested Commodities. She
talks more about body parts than she does about research, but I think a
lot of her concerns are about the potential that there will be an under-
class of people who need the benefits of medical research and thus sign
up for these trials, which is applicable to the research context.
Professor Eisenberg has talked a good bit about the new emphasis on
oversight of some areas of clinical research. One of these areas is finan-
cial conflicts of interest. This primarily concerns industry's influence on
setting research priorities. It's not clear whether participants in research
want to know about how much control industry has over research, how
much their investigators, often their own personal physicians, are also
influenced by what industry has them do in the conduct of clinical trials.
But there is a kind of emerging consensus that we need better regulation
of this.
In terms of informed consent, there is a debate, particularly about
adverse events and whether these participants who are in research should
get real-time information about the experience of adverse events in clini-
cal trials, given that they might need that information to appreciate
whether they're having an adverse event or whether they will suffer in-
jury in the trial. Some people think that this action might skew the
performance of the trial, if you give them too much information about
the risks or the history of adverse events in the trial, that more people
will notice adverse events or report adverse events. And that that this
might ultimately have the effect of undermining research or even that
compliance with more research regulation will force industry to pull out
46. MARGARET JANE RADIN, CONTESTED COMMODITIES (1996).
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of pursuing certain research products. There have been demands for pub-
lic and participant disclosure for adverse event information, but the
industry has actually made a claim that this sort of information is pro-
prietary and that is mainly what I'm going to focus on.
Just to give you an idea of what a serious adverse event is, this is the
definition from the National Institutes of Health: "[A]ny event occurring
at any dose that results in any of the following outcomes: death, a life-
threatening event, in-patient hospitalization or prolongation of existing
hospitalization, a persistent or significant disability/incapacity, or a con-
genital anomaly/birth defect. I'm focusing on serious adverse events
because that's what some of the proposed regulation focuses on. There
are lower grade adverse events that happen in research and it's possible
that some of this movement toward public disclosure of this information
could ultimately cover a broader range of adverse events.
Issues with adverse events are very complex. Often investigators
don't know how to report them exactly. They're supposed to say whether
they're related or unrelated to the research product, whether it was an
anticipated or an unanticipated adverse event. And also the occurrence of
adverse events, many times, is a result of the underlying disease that the
research participants have. It may not be related to the therapeutic agent
or potentially therapeutic agent that's being tested. So it's very hard to
parse out what events are actually relevant to the research protocol.
Dr. Reilly made a reference to this case this morning, and I'm going
to talk about it mainly because it raised the issue of gaps in serious ad-
verse event reporting. It involves Jesse Gelsinger in a gene therapy trial
at University of Pennsylvania. Many of you have probably heard about
this case. Gene therapy, in general, has not gone especially well. Even
the success that it has seen, particularly in the trials of SCID in infants,
has recently had a setback. Some children with that trial were cured of
the Severe Combined Immune Deficiency Syndrome, but at the same
time, two or three years down the line two of the people who got the
gene therapy have now developed a form of cancer, a form of leukemia
actually. So those trials are on clinical hold now. And essentially that was
the only shining light in the history of gene therapy research and that
now seems to be slipping away a little bit as well. That said, this trial
was going forward and it was a trial for OTC deficiency. Jessie Gelsinger
was eighteen; he was receiving an adenoviral vector product by hepatic
artery infusion. There were many problems with this trial, as it turned
out in the end. The consent was a little bit misleading. It didn't disclose
the serious history of catastrophic events in the animal studies and
47. Department of Health and Human Services, 66 Fed. Reg. 57970, 57975 (Nov. 19,
2001).
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information about adverse events earlier in the trial. The trial had, at one
point, been put on clinical hold by the FDA, that means the Food and
Drug Administration stopped the trial because of safety concerns. And
then it got started up again. And there is some evidence that Gelsinger
and his family were misled about early evidence of the efficacy of this
gene transfer protocol. There were adverse event reporting violations in
this case. Earlier in the trial, there had been significant toxicities, result-
ing in elevated liver enzymes and inflammation, hospitalization of some
of the research trial participants. In reports to the Food and Drug Ad-
ministration, the investigators stopped flagging these serious adverse
events, these toxicities. They had been doing that and they stopped doing
that, apparently because they didn't want to be put on clinical hold again.
And then Jesse was the eighteenth person enrolled in this trial and he
died of respiratory distress and massive organ failure. They're still inves-
tigating why that was, but you know even if he did die from some
previously unknown condition that this gene transfer product caused be-
cause of his own susceptibility, there still were major ethical gaps in the
administration of the trial.
I'm going to talk mainly about gene therapy. What's the deal with
these oversight mechanisms? Professor Eisenberg talked about some of
them. The NIH, National Institutes of Health, oversees federally funded
research. Their Recombinant DNA Advisory Committee, the RAC, re-
views all these research protocols. They review novel gene therapy
protocols publicly. A lot of industry people who do the gene transfer re-
search actually do submit their protocols to the RAC for public review
because it's part of what they think will endear them, I think, to the
overall funding community. And it does get thorough scientific review.
So for federally funded research in this area, public disclosure of re-
search information is routine. There are some studies, though, that do not
receive federal funding. All these trials are reviewed by the FDA, but the
FDA has, to this point, viewed that kind of information as proprietary
and thus not publicly disclosable. And again the FDA is the entity, gen-
erally, that has the power to impose the clinical hold and stop a trial as it
proceeds.
At the time of the Gelsinger case, up to seventy percent of adverse
event reports were not being made to the National Institutes of Health
per the requirements. As a result, a working group was established to
reevaluate what exactly was going on with adverse event reporting over-
sight in these trials. I was actually on this working group. We did revise.
Trials had been able to go forward without final review from the RAC.
At one point, we kind of rearranged so that they would have to get final
sign-off from the NIH RAC in order for the trials to go ahead. Also, the
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FDA and NIH had, until now, different definitions for what was a serious
adverse event and for what was a related adverse event. The definitions
were slightly different, which of course drove scientists nuts in terms of
having to report those adverse events. And the working group, in gen-
eral, emphasized that there should be public discussion of adverse
events, that this sort of information should not be termed trade secrets or
proprietary, and in fact that the data, especially in terms of gene therapy,
should be disseminated in an analyzed, interpretive form.
And what kind of data were they talking about? Well, complete de-
scriptions of the events; the actual incident that caused the adverse event;
other clinical observations relevant to the protocol; the gene delivery
method used; the vector type; the dosing schedule for the trial; how it's
being administered: is it being administered through an aerosol or
through an artery; and then the names of where the trial's being done and
the investigators.
So the NIH went ahead with this, which they had the ability to do
because some cohort of the protocols that they review are publicly
funded and so the public maybe should have access to that data. The
FDA had this idea that all that information was proprietary for the industry
protocols that weren't subject to the public review. The FDA changed its
mind and decided at least for gene therapy and for xenotransplantation
that, in fact those protocols were under such scrutiny in the public that
there should be public disclosure of adverse events and of those complete
protocols. In terms of the xenotransplantation-I was hoping that I would
be the first person today to say porcine retroviruses, but Dr. Reilly beat me
this morning. There have been big setbacks in xenotransplantation re-
search as well. But it's worth noting that xenotransplantation also probably
covers a cohort of stem cell research because some of those cells in the
stem cell research are cultured in animal products. And so this research
might be constituted as xenotransplantation regulation as well. So the
FDA said, we're going to write a rule that we're going to publicly dis-
close the protocol, the amendments to the protocol, annual reports about
the protocol and all the serious adverse events. Then in terms of the ad-
verse events, they essentially wanted the industry to begin to say these
are our consent forms, these are the kinds of setbacks we've had. Indus-
try got furious about this. They said that if we had this kind of
information disclosed, where the clinical studies were, what the biologi-
cal products are that are being used, what the regulatory status of the
research is, that other competitive biotech companies would be able to
streamline their protocols, size up the competition as to where they were
compared to where a competitor was, and essentially skip ahead and
avoid the costs of some of the initial investigation of research materials,
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and also make decisions about abandoning and or pursuing a research
agent based on others' costly finance. The FDA justifies this rule, essen-
tially by saying that these are serious ethical and scientific issues. The
decision-making process on these trials should be transparent. These
types of information should not be considered confidential and proprie-
tary.
This is a big change from the FDA's position. In this case, it only
applies to gene transfer and xenotransplant research. At the same time
they might extend it to other types of protocols. There's no reason why it
should be limited to those types of research necessarily. There are other
types of research that are under just as much of a public eye, that are just
as risky, including chemotherapy research and vaccine research, so
maybe they're just starting here to make the process more transparent.
But ultimately, I believe that the rule should probably be applied to a
broad range of research trials that the FDA has control of for reviewing.
Industry objects to these rules also on very precise legal grounds.
Essentially they think this action is "arbitrary and capricious" under the
federal law, under the Freedom of Information Act, and as well a viola-
tion of the Federal Trade Secrets Act. Essentially, if a public official
discloses information that they get in the process of regulation that could
be considered confidential, it would be a potential violation of the
Federal Trade Secrets Act. They also say the FDA lacks authority under
the Food, Drug and Cosmetics Act to regulate in this area. The FDA
thinks, broadly defined, we are supposed to act in the public interest and
in the safe development of drugs and so public disclosure of this sort of
information comes within those auspices. And then industry's big power
argument is that the disclosures would violate the Takings Clause of the
Constitution.
So my question: is this a trade secret? Are adverse event reports
trade secrets or confidential information? The Freedom of Information
Act argument is not the strongest argument. The Freedom of Information
Act (FOIA) might not even apply because it addresses requests from the
public for disclosure by an agency and here, the agency essentially wants
to disclose. But that body of case laws is actually pretty helpful in find-
ing out where we might go in terms of deciding what the status of
adverse event information is. Is an adverse event a trade secret? Actually,
Public Citizen has filed most of the suits in this line of cases, trying to
get clinical trial data publicly disclosed. The definition that the D.C. Cir-
cuit came to, in this case, was "a secret commercially valuable plan,
formula, process, or device that is used for making, preparing, com-
pounding, or processing of trade commodities.' '8 Nobody thinks that an
48. Pub. Citizen Health Research Group v. FDA, 704 F.2d 1280, 1288 (D.C. Cir. 1983).
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adverse event or an adverse event report is something that's involved in
the processing or in the development of a product for marketing. It's a
different species of information altogether. So under the current case law,
an adverse event report is probably not a trade secret. Under FOIA, there
is a question, and this is number two of the definition, if it's a comrer-
cial product or commercial information, which it probably is, it's
probably information the industry needs to progress through the research
approval process. But the courts need to decide, under the D.C. Circuit
test, if disclosure causes substantial harm to the competitive position of
the person from whom the information is obtained. In most cases, indus-
try has made kind of conclusory assertions about whether there is
substantial harm. There's not a lot of proof out there about whether pub-
lic disclosure would cause a competitive harm, and so there are times
when the courts have said they don't find this argument compelling. We
actually think that the clinical trial data should be publicly disclosed. At
the same time, there are times when they have seen evidence of one
company trying to get a jump on another company, based on the public
release of data. But that's sort of where the test has been.
The most recent case in this line of cases is Public Citizen v. FDA
from 1999. 49 And I just want to raise this because in some of the case
law, there has been a balance described between the public interest in
having this information disclosed and the private interest in protecting
industry's competitive edge. In that case, they actually decided that some
of the information was not publicly disclosable.5 ° But at the same time,
the majority of that court said they don't even think that the public has
an interest in having this information disclosed, which was against exist-
ing precedent.5' Judge Garland of the D.C. Circuit concurred in this
result, but he also said that denying a necessary balance means that even
if disclosure were the only way to prevent the loss of human life, that
would count for nothing as against a showing by a company that disclo-
sure would cause substantial harm to its competitive position. 2 And in
his opinion, he sort of revived the idea that there is a substantial public
stake in this kind of information that ensures the safety of clinical trials,
as they go forward.53 So I think this is an unsettled issue and that recent
decisions of the D.C. Circuit have reinvigorated the question.
I'm just going to tell you what the current status is, as I close. The
NIH guidelines were amended to promote the reporting of adverse event
information in gene transfer trials. The FDA rule that I referred to was
49. Pub. Citizen Health Research Group v. FDA, 185 E3d 898 (D.C. Cir. 1999).
50. Id. at 907.
51. Id. at 903-05.
52. Id. at 907.
53. Id. at 907-08.
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open for comment-it was closed for comment just over two years
ago-and the FDA has taken no final action on the rule. Notably, this
rule for openness and transparency was proposed during the Clinton
Administration. It was inherited by the Bush Administration. The FDA
did not have a director for a while, so it is in limbo and I would not be
surprised if it doesn't come out of limbo for some time. But I think there
are outstanding issues on serious adverse event data, and whether pa-
tients might benefit from having this kind of information when they're
enrolling in trials. We don't know if they'll be deterred from enrolling in
trials, based on receipt of this information. But I think there is potential
for future litigation in this area, certainly if these rules go forward at
some point industry will sue.
I encourage all of you to not necessarily go to work for the law firms
that are going to represent the industry, although they might have a good
argument in some cases. But you might consider representing the par-
ticipants in these research trials, as they might also have an interest in
their own human experience. And I think the more the investigators in
industry detach the experience of the adverse event from the actual par-
ticipants, who give of themselves to advance research, I think we're
losing something in terms of what kind of benefit we're trying to derive
from clinical research for society broadly. Thank you very much.
[Applause]
DR. JOEL D. HOWELL: Thank you very much. That was a fasci-
nating presentation. We're going to move on to a third presenter, for a
third perspective from a third institution. Reverend Clayton Thomason is
Assistant Professor in the College of Human Medicine at Michigan
State. His position in Spirituality and Ethics in Medicine is a very inter-
esting appointment. It's a joint appointment between the Department of
Family Practice and the Center for Ethics and Humanities in the Life
Sciences. Reverend Thomason's responsibilities include directing
courses in spirituality of medicine, directing a mentoring program of
professional development for medical students, as well as teaching bio-
ethics. He's also an Adjunct Professor in the Michigan State University
Detroit College of Law, where he teaches Bioethics and the Law. He
serves on the Human Subjects Committee, the IRB, and the Michigan
Department of Community Care in the Michigan Public Health Institute,
and was appointed by our then Governor, John Engler, in 2000 to serve
as the bioethicist on the Michigan Commission for the End of Life Care,
and served as Chair of that commission which released its report to the
governor and the legislature in 2001 and eventually resulted in legisla-
tion being enacted in January of 2002.
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Professor Thomason has studied bioethics at the Kennedy Institute
for Ethics at Georgetown University and the Hastings Center in New
York. He's published and taught in the fields of biochemistry, bioethics,
law and spirituality, including works on issues of law and aging, spiritu-
alness and ethics of AIDS care and the use of advance directives in
health care. His current work focuses on spiritual assessment in medi-
cine, the role of virtue in professional development, public policy in end
of life care, and the role of spiritual values in bioethical decisions. Rev-
erend Clayton Thomason.
PROFESSOR CLAYTON L. THOMASON: Thanks very much. I
want to thank you and the student organizers of this conference for doing
important work here and say how privileged I am to be part of this very
august panel. Going last allows me the opportunity of knowing where
the other panelists have been and being able to incorporate by reference
some of the details of the material that both Professors Quigley and
Eisenberg have already discussed.
What I would like to do this afternoon, as briefly as I can (and I will
endeavor mightily to stick to my fifteen minutes and give us time for
some discussion), is to step back a little from the sort of specific exam-
ples that we've been looking at today and think analytically about why
this is so hard. Why in these public policy discussions is it so difficult to
adequately capture and address the regulatory environment of biotech-
nology, particularly with regard to the human genome? I want to suggest
three conceptual models-three ethical categories of ways in which law
responds to these challenges in the human genome. They are ownership,
stewardship, and privacy. These are arguments by analogy, we'll notice,
in which we're frequently trying to figure out how old law that used to
work just great for other things that we know about well can apply to
something new, in the form of a new technology.
I want to think first about a model that we might think of as the
model of ownership: can life be patented? This is a central question that
Professor Eisenberg has written very importantly and helpfully about,
from my perspective. But it is nonetheless an ownership model, a model
that applies to property. So we have to ask whether and how well it
applies to genetic material, to the moral and legal status of DNA and
RNA, to animal models, to human models. Without much review here,
you probably already know the general outlines of the purpose of
patents. The United States Patent Office issues them in order to confer a
right to exclude others from competing with you in the invention,
distribution, or production of your widget--of a thing, a product. And
the goal is to encourage the time and money invested in research and
development. The three criteria of novelty, non-obviousness, and human
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invention are particularly significant with regard to human genomic
material because of how difficult it is to get these criteria to fit exactly.
We know pretty well how to apply these criteria to manufactured
products-the kind of products that you can hold in your hand and look
at and sell in boxes at the hardware store. But it requires some argument
by analogy to make them fit genetic material. So for example, in the
realm of genetic patenting, novelty is most clearly seen (from the
viewpoint of those who rely on genetic patents) when considering
something like transgenic organisms, which we've heard about already
today.
In transgenic modification, you may know, a gene or a segment of
genetic material is transferred between species. So a gene typically
found in a species of bacteria that codes for the production of a toxin-a
kind of pesticide, for example-could be spliced into the DNA of a corn
crop. You can get corn plants that have a built-in pesticide. There's no
naturally occurring species of corn that has that ability, so that looks
new. That's a new product, that's novel. And the same can be said for
animal models as well. The distinction is harder to make with specific
genes. If the gene is simply sequenced and then isolated from the natural
environment, the question becomes whether it represents something new,
or is an isolated form of the gene simply a found object? Is it an inven-
tion or a discovery? There is a long history of allowing patents to be
granted for products of nature that have been isolated or purified. Since
the purified state is not seen in nature, it tends to be conceived of as a
new entity.
The non-obviousness criterion is again a challenge in that it requires
that we have new advances, not just technical tinkering or modifications
of existing products. Thus, some would argue that the insertion of a gene
into an organism to improve the overall health or the productivity of the
whole organism, for example, is now obvious to specialists in the field.
Since the technology has already been developed that allows it to happen
in the first place, by this view, only the first event of gene splicing would
become patentable and it's up to the Patent and Trademark Office to de-
termine the level at which that distinction is going to be made.
The most interesting and difficult challenge has to do with whether
something is a discovery or an invention. Products of nature themselves
can't be invented by humans. They can only be discovered. So the heart
of the issue revolves around this distinction. You wouldn't expect some-
body to be granted a patent on crude oil, for example. Or on minerals,
because they preexist-they're products of nature that are found. But an
individual who creates a product from something-a plastic developed
from crude oil, for example-deserves a patent for being an invention. It
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is important to distinguish this from the novelty criterion. Mother
Nature, if you will, can be thought of as the original inventor by that cri-
terion, while the human invention criterion requires a human
intervention that is given credit for the invention. For example, in the
case of the Harvard Onco-Mouse, the genetic manipulation that was per-
formed on the whole mouse was sufficient for the Patent and Trademark
Office to classify an entire animal-and its offspring-as an invention
for the first time. This is a frame shift. This requires a new way of apply-
ing an old and well-established form of law to a new technology. Or in
another example, Dr. Anand Chakrabarty's petroleum-eating bacterium
that he had genetically modified to be sprinkled out on oil slicks and
gobble them up, metabolize them, was finally recognized as an invention
after some eight years of struggling his way through the court system.
If we think, then, about some of the effects of this ownership model
of genetic patents on three categories of work, the first would be how
does issuing patents on genetic material affect research? Well we've al-
ready heard this afternoon that scientific and medical research requires
this kind of free flow of information. There is this expectation that there
is a kind of collegiality and openness and objectivity among researchers.
The concern about trade secrecy is that openness and collegiality be-
comes perceived as a risk to the proprietary trade rights of patent
holders.
Secondly, there is concern among clinicians that in clinical medi-
cine, patents on naturally occurring mutations, for example, might
prevent physicians from having ready access to the therapeutic informa-
tion they need in order to treat a disease that's caused by that naturally
occurring organism. Or again, that patents on fragments of genes might
impede the progress of research. Or again, those patents may actually
increase the research and development costs of important therapeutic
modalities that would otherwise be marketed.
Finally, Professor Quigley described for us some of the commodifi-
cation arguments and concerns. Whether or not patenting genetic
material, patenting human gene sequences, represents somehow a com-
modification of life. Does it take into account some kind of argument
about the intrinsic worth or value of human life, or does it assign a
merely instrumental or a merely commercial value to life? And again
you can see that the models hold just fine for widgets. We feel relatively
sure about commodifying crop plants, for example. We feel relatively
comfortable about owning livestock and animals and animal products.
We start to get a little bit fuzzier about what it means to own their ge-
netic material. And then as we move into the realm of human genetic
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materials, we come up against some limitations about our perceptions of
what property is and what is appropriate to own or not to own.
So I want to suggest that that takes us to a second category of ways
in which we can think about genetic materials. And that's a stewardship
model. Let me just think briefly with you about this ethical category that
I want to impose on a number of ways the law responds to these tech-
nologies, by thinking about duties and obligations. What kinds of duties
and obligations come with these new technologies? With new knowl-
edge? And duties and obligations to whom? Again, I want to use this
ethical category of stewardship to encompass things like the obligations
and duties that are owed to others through tort law, for example, that lead
to actions in wrongful death or negligence or medical malpractice.
We've already heard now twice today about Jessie Gelsinger's case,
which is a terrific example of the application of that kind of legal cause
of action to a novel situation in which someone dies in the course of ge-
netic research. And yet the law works pretty well to take account of the
kinds of special relationships that had been developed in the Gelsinger
case. Between, for example, doctor and patient, or between researcher
and subject. We might also think about the ways in which special rela-
tionships engender special obligations. Those might include parent and
child relationships and the whole realm-that we haven't quite touched
on yet-of reproductive technologies and the ways in which those chal-
lenge the parent/child relationships that we're used to using to structure
family and personal life.
Then we might think of statutory or regulatory obligations that have
been imposed on, for example, human cloning and stem cell research.
We have highlighted some of those for you today, such as the regulation
of research involving human subjects through the "Common Rule" that
Professor Quigley has guided us through a little bit today. 4
A third kind of stewardship obligation to others has to do not simply
with obligations to individual, identifiable others, but obligations we
recognize to whole populations and to generations yet to come, to puta-
tive persons who aren't yet here. And so we have a whole scheme of
environmental regulatory mechanisms that seeks to think about those
kinds of stewardship obligations we might be said to have to the human
genome itself or to the biosphere at large. This is another way in which
we have to try to expand our thinking about the kinds of obligations that
count when we're regulating genetic technologies.
I don't think I need to talk much more than Professor Quigley al-
ready has about protection of human subjects through federal regulation.
It might be worth just noting for a moment, though, the status of human
54. See 45 C.F.R. § 46 (2002).
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cloning bans. Currently, both reproductive and therapeutic cloning have
been banned by statute in both in Michigan and Iowa. There is a repro-
ductive cloning ban currently in California, Louisiana, Virginia, and
Rhode Island. There is a federal bill that passed the House once and
stalled in the Senate in 2001 and just passed the House again last Thurs-
day, that would impose criminal fines and imprisonment as well as civil
penalties for attempts at human cloning, as well as the kinds of research
banned by executive order that Professor Eisenberg reminded us of this
afternoon. This is all an example of the kind of vigorous debate address-
ing a range of issues that I would categorize as stewardship arguments.
Finally, and very quickly, I will just mention the third category
having to do with privacy. Privacy concerns are not so much other-
referential but self-referential. If patents have to do with exclusionary
rights of ownership against others, and stewardship has to do with our
obligations to others, privacy has to do with protecting one's own
autonomy. In moral terms, privacy concerns the protection of my
autonomy interest in myself, in my own body, extending to my own
information. So for our purposes, it concerns who owns genetic infor-
mation and who has rights to know information resulting from genetic
tests. How about the police, the military, employers, insurance compa-
nies? It gets scarier and scarier the farther along that kind of list you get,
right? How about law schools or universities? Do they have a right to
know about the results of your genetic tests? Or should pharmaceutical
companies own your health or genetic information? How about the pos-
sibility of economic benefit to either you or your family? I must quickly
suggest that this is another category that we have to take into considera-
tion, whether or not you would allow your DNA be used for research
purposes.
Then how shall we protect genetic privacy? What would happen if
you lost control of how your DNA is used? We have some existing kinds
of laws that attempt to accomplish this, including potentially, at least,
some provisions of the Americans with Disabilities Act that might offer
some protections against genetic discrimination in the workplace, for
example (though they haven't been tested very well in the courts).
HIPAA, of course, the Health Information Portability and Accountability
Act, is going into final effect next month and it will be interesting to see
exactly how that plays out. There's the ELSI (Ethical, Legal, and Social
Implications) program within the Human Genome Project at NIH that's
addressed this at the federal level. Thirty-seven states, including Michi-
gan, have state laws against genetic discrimination in health insurance.
Twenty-four have state laws about genetic discrimination in employ-
ment, including Michigan.
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In closing, I might suggest opening the discussion by considering
some questions about what kind of protection we should afford genetic
information, who should own it, who should have access to it, and how it
should be used. How will we balance the public and private interests in
genetic privacy, stewardship, and ownership? Thank you very much.
[Applause]
DR. JOEL D. HOWELL: Okay, the floor is open for questions. I'm
going to take executive privilege here and say we'll extend this session
by a few minutes, since we did get started a little bit late, but not by too
long because we want to give adequate time to the session to follow.
Would anybody like to take a stab at answering one of these questions or
asking another question of your choosing?
AUDIENCE MEMBER: Hi. I work for a biotech spinout, called
HandiLab, and have to work with the Federal Government on many lev-
els, with NIH, SPIR grants, FDA, the Center for Medicare & Medicaid
Services (CMS). And I'd like to hear from the panel a little bit more on
some of your thoughts about the FDA-how it has new leadership and
its role. My question is: do you think the FDA and the CMS have over-
lapping and in some ways duplicative mandates when trying to decide
safety and efficacy?
PROFESSOR REBECCA S. EISENBERG: I'm not sure exactly
what kind of a product your company produces. I think there are inter-
esting overlaps in the roles of FDA and other agencies. And I think that
we traditionally understand the role of FDA as being about protecting the
patients, protecting the health and safety of patients. I think the role of
FDA intertwines with NIH and with the patent office, for that matter, in
more complex ways than that, surrounding generating information, mo-
tivating firms to invest in certain forms of R&D that generate socially
valuable information. So yes, of course, these are not distinct. We think
of the core mission of FDA as about health and safety, the core mission
of NIH as about promoting investments in research and development.
But these are overlapping missions and it's not surprising to see that
there are some overlap in the kinds of oversight that these two agencies
engage in. Maybe Rosemary can respond to your question....
PROFESSOR ROSEMARY QUIGLEY: Well I was actually go-
ing to add that I think the FDA and people generally are concerned about
research protection. The FDA hasn't had enough of a mandate to review
the ethical content of research. I think to the extent that there is overlap,
there are some other entities within the government that are starting to
assume responsibility for that particular oversight, the Office of Human
Research Protections in the Secretary of HHS's office is probably the
best example. But whether it's the FDA or whether it's the OHRP office,
Life Sciences, Technology, and the Law
they don't have enough resources to find out-I mean from my perspec-
tive and from many people's perspective-if research is being essentially
conducted up to code. And there's also not really high quality informa-
tion exchange between researchers broadly and the FDA, about why, for
example, the FDA might need more information in one case but not in
another case. If there could be more discussion, I think, with the agency
and with the research community about that, there might be a way to
streamline the FDA responsibilities. And when you have to report to
more than one entity, as you do adverse events for some instances, you
have to report to both NIH and FDA, or at least you have to for certain
kinds of research. You know, that creates use of resources that could be
better utilized, in terms of promoting safety.
DR. JOEL D. HOWELL: Other questions?
AUDIENCE MEMBER: You've mentioned various kinds of infor-
mation that could be released, adverse effects but also protocols. And
then there's the "who" question of who receives the information. Cer-
tainly the potential participants need as much information as they can
get, but I'm not sure about the competing company. So what I'm driving
at is, is it reasonable to ask whether there can be different levels or shells
of disclosure?
PROFESSOR ROSEMARY QUIGLEY: Well I do think it would
be possible to have a mechanism by which potential enrollees in research
get information that isn't otherwise publicly disclosed. But I think the
way the environment is right now, industry doesn't necessarily want to
give information to the potential enrollees, who they really need to get
enrolled in this research so that it can be done and so they can move
through the approval process, and they don't really want to tell some of
the investigators either. Investigators often only have the research data
for their own site, they don't have the data for research being conducted
in other sites. So there might be limits on how much a physician who's
enrolling their patient in a trial knows about the safety of that informa-
tion. That seems so egregious, given the fiduciary responsibility there.
So I think they've kind of jumped at public disclosure because they're
not getting anywhere in the interim level of just getting better informed
consent.
PROFESSOR CLAYTON L. THOMASON: There is a real con-
flict between a theory of informed consent for human research subjects
and the protection of confidential or proprietary information. Putting a
gag order on subjects in a research study that would prevent them from
disclosing information that had been disclosed to them runs counter to
the whole thrust of the last half-century of development of informed
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consent doctrines that are about full and open disclosure. So I think that
that hasn't been adequately explored or resolved in any sense yet.
DR. JOEL D. HOWELL: I've always wondered about one type of
disclosure, but I haven't been able to convince anybody to do this study.
It would be very interesting to see what would happen if patients being
enrolled for clinical research studies asked to see the proposal, if they
said at the end of the consent process: "That's very nice, now may I
please see the grant that you've written for this protocol." Once the grant
is funded it's probably FOIA-able, it's publicly available, so would the
investigators be willing to share it with the patient?
PROFESSOR REBECCA S. EISENBERG: Yeah, I don't know.
PROFESSOR ROSEMARY QUIGLEY: After the new drug ap-
plication is approved it would be.
DR. JOEL D. HOWELL: It would just be interesting to see what
would happen to researchers when subjects said I'd like to see the re-
search protocol please. I would guess that most researchers would say
no, and we might then wonder what that means about full disclosure and
openness. The gentleman here, I believe, had a question and once again
I'm going to keep talking until you get the microphone.
AUDIENCE MEMBER: It was kind of on the same topic, actually.
And since I work for a large pharmaceutical sponsor in the area, I
guess-
PROFESSOR ROSEMARY QUIGLEY: Do you want to meet
outside afterward? [Laughter]
AUDIENCE MEMBER: I'd be happy to touch base about anything
afterwards. I have some of the same concerns about-I can at least speak
about personal experience-if I had access to the data of my competi-
tors, I know it would be most helpful. You know it might not be helpful
to them. And I think it's a very important process to work on, the in-
formed consent process that has some inherent intentions built in. I think
that a lot of the information that is mandated to be disclosed to the inves-
tigators brochure through all the past studies, all the information that
does go to the regulatory agency. So I guess just the comment that I had
not heard that, specifically for gene therapy, not all concepts are needed
for public disclosure. I definitely have some real concerns about it. I just
want to add my comments there.
PROFESSOR ROSEMARY QUIGLEY: I think there really are
commercial concerns. I didn't mean to say that those weren't valid. But
there are people who also think that if there was public disclosure and
people heard what's going on with other research that research might
become more efficient and the research might be expedited and that
people might not make the same safety mistakes in other trials that
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they're making now. And whether that will ultimately deter investment in
biotech and have some downstream adverse effect on progress, there's
no answer to that question.
PROFESSOR CLAYTON L. THOMASON: One of the principles
behind the openness and sharing of research protocols in the first place is
to prevent duplication of efforts, so that you do not have to reinvent the
wheel, over and over again, as well as allowing scientific validation of
the research by others.
PROFESSOR REBECCA S. EISENBERG: Yes, I think that the
interest of the companies and the interest of patients are at odds here.
The patients stand to benefit from the information that you're presenting
to the FDA being fully vetted by competitors. That's good for patients,
right? The competitor might reanalyze the data in a way that would draw
different conclusions and that would allow their doctors to make better
choices for them. Now you don't want that, from your own perspective
as a pharmaceutical firm, you'd rather be in control of the information
that goes out to doctors about the effects of your products. And so shar-
ing the information is going to make those products less profitable for
you, which is going to make you less motivated to invest in developing
those products and generating information about them. So I think I come
out at the same place that Professor Quigley does. We have a bottom
line, unanswerable question: do we place more value on having a greater
incentive to invest in drug development by making it more profitable, or
do we have a greater public interest in making sure that such knowledge
as we have about drugs is widely disseminated to permit people to make
the best choices about what drug products to use? And that information
may be adverse to the interest of the sponsor.
DR. JOEL D. HOWELL: We have time for one more question, in
the far back.
AUDIENCE MEMBER: I just wanted to say that it seems to me
that, to some extent, the whole FDA system is inconsistent with the no-
tions that you're talking about. If we were actually talking about trying
to facilitate this kind of sharing of information, and I agree, that compa-
nies like Pfizer and HandiLab could benefit from information that's
come out of studies from other companies, but in fact the FDA doesn't
facilitate, it regulates. And that's a very different thing. So if we created
a system and went back and stopped worrying about looking at compli-
ance and looking at confidentiality of data and rather looked at a way in
which that data could be shared efficiently, we would eliminate some of
the cost of the big drug companies to putting these products on the mar-
ket. And it's that cost that causes them to be competitive. So by reducing
the cost to market, they would be less inclined to be so proprietary about
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the data in the first place. So if the FDA, in fact, became a funding
agency and not a regulatory agency, that might actually help.
PROFESSOR REBECCA S. EISENBERG: At the end you said a
funding agency. Generating the data is costly. If we want the data, that's
costly.
AUDIENCE MEMBER: Yes, but it's the FDA that requires that the
data be generated in the first place. So they've created this very cumber-
some and very expensive system and then they criticize the companies
who are forced to use the system. When in fact, if we put all of that en-
ergy, and time, and money into a system that allowed sharing of data-
so some sort of central review and funding of trials-and allowed the
patent system, in fact, to protect the proprietary positions of the com-
pany, that might be more efficient.
PROFESSOR REBECCA S. EISENBERG: I'm not sure if I get
exactly what you have in mind, but if you want the data, then you've got
to get companies to incur the cost or else the data doesn't get generated.
I guess you're saying have the FDA fund the data collection.
AUDIENCE MEMBER: Exactly.
PROFESSOR REBECCA S. EISENBERG: But that doesn't make
the cost go away. That just means the cost has to be borne by taxpayers
instead of by drug companies. It doesn't make it any cheaper.
AUDIENCE MEMBER: The drug is cheaper in the long run.
DR. JOEL D. HOWELL: And it may have the potential of encour-
aging the funding of studies of drugs that are not new. As a clinician, one
of my greatest frustrations is fighting with trainees who want to use the
latest, greatest drugs. Why? Because the new drugs are well advertised
and well pushed. One rationale that is often given is based on studies
about relatively new concepts, such as diastolic dysfunction. Older, less-
expensive, quite effective drugs like hydrochlorothiazide might or might
not work for diastolic dysfunction. We don't know, because nobody's
studying them. And nobody's studying them because there's no money
to be made running that study. And so, perhaps, if the funding of drug
studies had more to do with the funding of those studies that would be
the most beneficial to patients, rather than the most benefit to the bottom
line of the companies, we would have a different pattern of drug studies.
I want to thank very much the three presenters in this session for giv-
ing us a wonderful session. Lots of food for thought and I think the fact
that we haven't answered all the questions is a very good sign rather than
a bad sign. Thank you.
[Applause]
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MATT MOCK: I just want to echo those sentiments. As long as
we're this close to being on schedule, we're going to stay on schedule, so
at a quarter till.
PANEL III
THE EVOLVING ROLE OF TECHNOLOGY TRANSFER
INTRODUCTION
MATT MOCK: Our third panel is "The Evolving Role of Technol-
ogy Transfer." I'm sure this will be an interesting panel. I would like to
introduce once again Professor Rebecca Eisenberg, who is the Modera-
tor for the panel and we'll leave it at that. She is the Robert and Barbara
Luciano Professor of Law, here at the University of Michigan Law
School. Professor Eisenberg.
PROFESSOR REBECCA S. EISENBERG: Thank you very
much, Matt. This panel focuses on a topic that has been a great profes-
sional fascination of mine for many years, and that's technology transfer,
or the movement of research discoveries from public and academic labo-
ratories out to the private sector for commercial development. And one
of the reasons I'm particularly pleased to be moderating this panel is that
the people who do this stuff have had really interesting career paths. It's
inspiring to look at what they've done, particularly for people who are
beginning your careers. You see people who start off doing one thing,
change their mind completely, do something else, and then it turns out
that they have a combination of backgrounds that uniquely suits them for
doing yet another really cool and interesting thing. So they're sort of fun
to introduce, just to go over their biographies with you a little bit.
Our first speaker is Carl Gulbrandsen, who is the Managing Director
of the Wisconsin Alumni Research Foundation, which is I think, the
great granddaddy of the university tech transfer offices. Wisconsin was
one of the first universities to get into the business of patenting technol-
ogy and licensing it for commercial development. Dr. Gulbrandsen
received both his Ph.D. in Physiology and his Law Degree from the
University of Wisconsin at Madison. He has practiced law in the areas of
patent prosecution and patent litigation. Prior to becoming Managing
Director of WARF, he was the general counsel of Lunar Corporation and
Bone Care International. He went from there to be the Director of Pat-
ents and Licensing at WARF, where he is now the managing director.
Dr. Gulbrandsen.
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DR. CARL GULBRANDSEN: This is kind of an unusual position
to be hidden behind a projector here and try to talk. I'm usually walking
around when I'm talking, but I'll try to do this.
So I'm going to talk a little bit about technology transfer because
that's one of the things that WARF does. One of the issues that we deal
with is what do we mean when we say technology transfer? My chancel-
lor tells me what WARF does is a very insignificant part of technology
transfer at the University of Wisconsin. And he's serious about that. The
biggest technology transfer that any university is engaged in is graduat-
ing students and moving them into the market place. University staff also
engage in publications, presentations, conferences, all these things trans-
fer technology that's occurring at universities. Industry sponsors research
on campus. They send their scientists to work with our scientists. That
results in technology transfer. Our faculty love to consult with industry
and that also results in technology transfer. There's transfer among scien-
tists from universities of biologic material and ideas, and among
scientists at universities and scientists in industry, both ways, of materi-
als and ideas. And this is informal technology transfer. That's what's
been going on for as long as academia has been around.
Then there's the licensing of IP that I'm going to talk about. Ken
will talk about startups. And as I said, I understand where my position is
in life, when my chancellor tells me that what I do is a very insignificant
part of technology transfer at the University of Wisconsin, Madison.
As a manager of a technology transfer office, we have a number of
constituents and a number of expectations, and we're always sensitive
about that. I just throw these out as things to consider; I'm not going to
address all of these issues, at least specifically. I will address some of
them indirectly. But you know the first constituency that we have, since
we are a public university, is the taxpayer, the public. And there is a gen-
eralized expectation of the public, that the research should be done to
benefit the public. The Federal Government is probably our largest inves-
tor, at the University of Wisconsin, Madison, and probably here, at
Michigan. And as the largest investor, they have expectations of us. When
they give us money for research, there is an Act in place, that I'm really
not going to talk much about. It's the Bayh-Dole Act. That Act lays out a
uniform patent policy for federally funded inventions and an expectation,
if we decide that we're going to handle these inventions, as to how we're
going to handle them and what we're going to do with it. There are expec-
tations built into the Bayh-Dole Act, and to other federal laws governing
funding, that the technology ultimately is commercialized, used to benefit
the public and will advance research. I think the Bayh-Dole Act probably,
to a good measure in response to Dr. Eisenberg's work, was just recently
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amended in the prelude to indicate that this act would not be used to
frustrate research. Something like that?
PROFESSOR REBECCA S. EISENBERG: I had nothing to do
with it, but thank you.
[Laughter]
DR. CARL GULBRANDSEN: And the university, as an institution,
has expectations regarding its technology transfer offices. More and
more today the expectations of the universities are that they're going to
get money in return for the transfer of technology. And it's particularly a
dear expectation now when all of our states are in deficit and everyone is
scrambling as to how they're going to replace the state dollars that aren't
going to be coming to the university.
Technology transfer today, more and more, is being used for faculty
retention or recruitment. It's become a relatively recent phenomena that
on the way to recruitment interviews, faculty stop off at the technology
office to find out how you handle their intellectual property, if they gen-
erate any.
Faculty and staff, once they get hired and start to work, they have
their expectations and they're constituents of ours. We treat them as cus-
tomers, just like we treat industry as customers. Faculty expect us to
commercialize their invention, so if they disclose something to us and
we take it, there's an obligation on our part. And, of course, they want to
make money from it. Money both for their research, but money to sup-
plement their salaries. They love to have consulting arrangements with
industries and they look at the technology transfer offices to help facili-
tate that through their licensing agreements.
State government, more and more, is looking at the universities as
sources of economic development and I'm sure Ken will talk more about
that. And then industry, what does industry want? Industry wants access
to new technology. They don't want to pay double for it. They don't
want to be unduly hampered with red tape when they come in. They
want things to be facilitated. And they certainly want a competitive ad-
vantage.
A little bit about WARF WARF is the exclusive patent management
agency of the University of Wisconsin, Madison. We're an old organiza-
tion. Actually we're seventy-eight years old now. We were established in
1925 by Professor Harry Steenbock, a professor of agricultural biochem-
istry. And we are a tax-exempt, not-for-profit corporation. Why was
WARF founded? There was another professor that preceded Steenbock
by the name of Babcock. Babcock, who was a famous Wisconsin gradu-
ate, discovered a technique for measuring butter fat, which at that time
Babcock felt should be dedicated to the public. He did not believe in
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patents, particularly patents on academic discoveries. And so he pub-
lished his butter fat process. He did not bother to try to protect it. And
the invention was actually misused. There were a number of companies
that advertised that they were using the Babcock technique for butter fat
measurement, when in fact they weren't. It ended up giving his technol-
ogy a bad name. He always regretted the fact that he didn't do something
affirmative to try to control the use of that technology.
Well when Steenbock came on the scene, he remembered that story.
Of course Babcock was his dean and made everybody aware of the fact
that he was upset about what had happened to his discovery. So in 1924,
Harry Steenbock discovered that if you irradiated animal tissue with ul-
traviolet light, you increased the Vitamin D content of that tissue. Now
take note that this is 1924. At that time, Quaker Oats came along and
offered Steenbock nine hundred thousand dollars for that invention-in
1924! And Steenbock, being a lot smarter than I'll ever claim to be,
turned them down. He went to the university and he said I have a par-
ticularly valuable invention that I want to protect. I don't want the same
thing to happen to my invention that happened to Babcock's invention. I
also think that we can use my invention to fund my research. So I'd like
you patent it and license it and bring the money back to fund research in
my laboratory. And the university-unfortunately for the university or
fortunately for the university, however you want to view it-turned to
Harry and said, "Harry, we're an academic institution, we don't get in-
volved in commerce. And we have no vehicle, no authority to do this. If
you want to sell your invention to Quaker Oats, sell it. But frankly,
you're hired here to work in your laboratory and get back to work."
So Steenbock being a stubborn Dane, a very persistent Dane, got to-
gether with eight of his friends, all alumni at the University of
Wisconsin, Madison, and each threw in a hundred bucks. We carry nine
hundred bucks on our books today, still, as the dues paid in for WARF.
They founded Wisconsin Alumni Research Foundation. Steenbock as-
signed his technology to WARF and over the next ten years they made
fourteen million dollars off that invention. That was in the twenties and
the thirties. He also controlled how that invention was being used. The
beer industry came to him and said they'd like to use that invention and
he said no. The cigarette industry came to Steenbock and said-we'd
like to use that invention; we'd like to make healthy cigarettes.
[Laughter]
And he didn't license to them. So he recognized there was a way to
control the technology. And if you look at the early records of what they
did, they actually did control the technology and they persisted very hard
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in making the technology widely available and in fact eradicated rickets,
which at that time was a significant problem.
WARF has a very simple mission. Our mission is to support research
at the University of Wisconsin, Madison. And we do it in two ways, we
do it by transferring inventions from the lab bench to the marketplace
and, hopefully, when we do that we can bring some consideration back
that is used to fund further research. We also have an endowment that
has been built up over the seventy-eight years of our existence, starting
with the seed that Steenbock gave us. And at the end of each year, we
take what income we receive off of patenting and what income we re-
ceive off of investments and we give the university a non-restricted gift,
which in recent years has been in the range of thirty-five to forty-five
million dollars.
I thought what I would do is give you a more current example today
of the types of things that a technology transfer office can get faced with.
And so since Dr. Eisenberg talked about human embryonic stem cells,
it'd be appropriate if I talk a little bit about human embryonic stem cells.
People don't like the term "breakthrough technology" but I'll call it that.
In 1997 Dr. James Thompson, at the University of Wisconsin, Madison,
came to WARF and disclosed that he had been successful in culturing
what he called human embryonic stem cells. This was not a serendipi-
tous discovery. He'd been working on it for some seventeen years. He
started first in the field of mouse embryology, and then he moved over to
the Oregon primate center and started working with monkeys. Then he
came to the Wisconsin primate center at the University of Wisconsin,
Madison, and continued his work, succeeding in about 1994 with cultur-
ing primate embryonic stem cells in Rhesus monkeys. He then
duplicated that work with Marmoset monkeys-these two species of
monkeys are farther apart in lineage than is the Rhesus from the human.
So he figured since he was successful with both of these species of
monkeys, he would be successful if he had the opportunity to do it in
humans. Unfortunately, at that time the Federal Government prohibited
the use of any federal funding for work with human embryos, which he
needed to derive these cells. So at that point, he was in a fix as to what to
do and WARF wasn't smart enough to fund the research. So a company
by the name of Geron came along and said-in fact three days after he
published his article on the monkeys-they've had a pool of money and
would like to fund the research to do this in humans. And Geron has
some rights, as a consequence of that.
WARF now has two U.S. patents. One covering primate embryonic
stem cells generally and one covering human embryonic stem cells. And
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Jamie Thompson got his face on the cover of Time Magazine and had a
private dinner with Dustin Hoffman. How great is that?
[Laughter]
So what is the use and promise of embryonic stem cells? Well, it'll
probably surprise many people to learn that ninety percent of what we
know about early human development is inferred from studies done with
mice. You can't work with human embryos, so work in the mouse em-
bryo is a good platform that is well understood and well used and a lot of
work has been done on that. There's a lot of research that has been in-
ferred from mouse research to what early human development is. But
this is a cross section of a mouse embryo and a human embryo about the
same day, same time, same stage in development. The colors on this
slide represent various tissues and you can see that they have relatively
similar tissues but the shape is quite different at this stage. I will tell you
from a physiological standpoint, the physiology at this early stage at the
seven-day stage is also quite different. At this stage, the human embryo
releases a hormone to set up the uterus for implantation in the embryo.
The mouse doesn't have this hormone at all, and it uses a completely
different scheme to get itself implanted. So you can see that that's just
one example. There's probably a number of examples that makes it risky
to infer too much from the mouse embryo to the human. Well with hu-
man embryonic stem cells, for the first time, we have a window of
opportunity to look at one stage of development and see what factors
cause an undifferentiated cell to become a more specialized tissue cell.
Research, of course, is just a basic understanding; it is a great prom-
ise. But there's also promise for drug development, drug discovery.
Molecular switches that turn genes on and off. I'll give you just one ex-
ample. Now that's a picture of human heart cells that have been derived
from the human embryonic stem cell. That meeting of those cells occurs
in the petri dish. And there's a coordinated contraction, which is quite
remarkable. Electrophysiology done on those heart cells shows that
they're very, very consistent with an absolutely normal human heart tis-
sue. As far as we know, there are no human heart stem cells. But the
human embryonic stem cell gives us an almost infinite supply of human
heart cells that we can apply drugs to and do drug screening or toxicity
studies, something that's not available today. Today you do your early
screening on animals, which may or may not be similar to humans. You
hope that at some point you'll get into a clinical study with a human be-
ing, but you aren't going to do the early studies on human hearts. I can
speak from personal experience, I used to do heart research. Once in a
while I could do research on a human heart, but it was always a diseased
human heart. You didn't take a normal human heart and do research on
Life Sciences, Technology, and the Law
it. So that's just one application of the technology that hopefully will be
quite useful.
The most hyped indications for it, of course, are disease treatment,
self-therapy. And we could go on forever on that. But there is legitimate
promise with some of it. It's quite a ways away. But truly the most prac-
tical near applications of this is with the research. There's a patent
controversy about this. You know Wisconsin Alumni Research Founda-
tion owns these basic patents covering human embryonic stem cells and
people question-do these patents obstruct research? Do they frustrate
development? I had to appear in the Senate, in front of Senator Harkin
and he asked me if there was any reason why he shouldn't move to re-
scind these patents. Now I don't know that a U.S. Senator can do that,
but I wasn't going to argue with him at that point.
[Laughter]
I tried to convince him that that wasn't smart to do. You know as a
technology transfer office and as a patent lawyer, we have some basic
assumptions that we work from. I have a basic assumption that univer-
sity patents encourage innovation. They provide some incentive to our
inventors. They facilitate publication. Patents themselves are a publica-
tion. We never try to hold up publication at Wisconsin. We use the
provisional patent system very readily to make sure that our academics
can publish as much as they want to publish and can talk as much as they
want to talk. And this helps supplement salaries of inventors. University
patents help support research. They protect academic freedom. I strongly
believe that. If we allowed industry simply to own the patents, industry
would be setting the agenda. If universities own the patents, then univer-
sities set the agendas, it's as simple as that. And then university patents
can serve the public good by guarding against abuse or irresponsible li-
censing. I think Steenbock realized that. Those examples demonstrate
that. And I think some of what we've been doing with human embryonic
stem cells demonstrate that. How am I doing?
PROFESSOR REBECCA S. EISENBERG: Well you know I'm
really interested in this, so I have a conflict of interest here, but probably
we are just about at your time. If you want to take another couple of
minutes to finish up.
DR. CARL GULBRANDSEN: Okay, we do have an institute that
has been established. We did that because we had biological concerns
that needed to be guarded against and you couldn't use federal dollars
when we started with this research. So we took it off campus. We still
have the institute operating. We also had a high demand for the cells and
we didn't want Jamie Thompson just to be expanding lines and distribut-
ing stem cells, so the institute does that.
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Rebecca's talked about the President's compromise. There's argu-
ments on both sides of the fence about whether that's good or bad. My
simple-minded view of it is it threw the ball back in the laps of the scien-
tists and at some point if the research is successful, these restrictions will
be relaxed.
We have an active licensing program. If you talk about obstructing
research, I will tell you that we have inter-institutional agreements with
over a hundred institutions around the world, most of them in the United
States. And we have distributed these cells to over a hundred and thirty
research groups throughout the world, again most of them in the United
States. We provide support to these research groups. And we do have
ongoing, a national research project in human embryonic stem cells. We
have also facilitated licensing with the PHS, the Public Health Service,
so that other groups that have stem cell lines can freely make these lines
available to other researchers without fear from Wisconsin Alumni Re-
search Foundation. And yet we also protect WARF's rights to license the
cells for future commercial benefit.
I just will show you this for your legal class, today's lesson on shar-
ing has been canceled and will be replaced by a lesson on protecting
intellectual property. [Laughter]
And I think that I've said enough, so I'll move on.
PROFESSOR REBECCA S. EISENBERG: Thank you very
much, very interesting.
[Applause]
Such an interesting story. Our next speaker is Ken Nisbet, who is the
Executive Director of the Office of Technology Transfer here in Ann Ar-
bor, at the University of Michigan. He's had a very different career path
that has also led him into the field of technology transfer. He was previ-
ously director of new business development within the Office of
Technology Transfer, where he was responsible for creating new busi-
ness startups with University of Michigan technology. So it's a
somewhat different emphasis in his role within the technology transfer
profession.
Mr. Nisbet has over twenty years of experience in the commercial
sector within engineering, finance, marketing, and management roles at
Ford Motor Company, Digital Equipment Corporation, and Nortel. He
was a co-founder and president of Memory Bank Incorporated, which is
a storage systems provider, and was a director responsible for business
startups at Trinovas Corporate Technology Laboratory. He holds a
Bachelors Degree in Mechanical Engineering and an MBA, both from
the University of Michigan, and is active in a number of community ac-
tivities, including leadership positions within the Ann Arbor IT zone,
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New Enterprise Forum, Great Lakes Entrepreneurs Quest and the Wash-
tenaw Development Corporation. Ken Nisbet.
KEN NISBET: Thank you.
I'd like to continue from Carl's presentation on the issues in running
a tech transfer office to focus on the impact from and on tech transfer
related to new business development and economic development. In or-
der to do that, I thought I should define economic development. Most
people would say it's growth in industry, resources and talent in a fo-
cused geographic area, and its purpose is to generate industry or jobs and
improve the quality of life. Economic development can happen naturally.
In fact I would argue that in most cases economic development that one
can see in the Bay Area, Boston, is impacted more by natural rather than
artificial stimulation programs. But there are things that you can do to
stimulate economic development and we're seeing these results. So in
areas that are perhaps lacking in resources, different organizations, uni-
versities, state governments, et cetera, are looking to invest resources and
induce behaviors to stimulate economic development.
So today I'll talk a little bit about how tech transfer offices at univer-
sities are influenced by the linkage to economic development, and what
we're doing that both help and are affected by economic development.
First, a quick little background on tech transfer, going back a bit to
what Carl said. Nineteen-Eighty was a watershed date, because at that
point some legislation was created that induced universities to invest in
technology transfer. And in 1980 there were fewer than two hundred and
fifty patents awarded to universities in the United States. In the year
2000, there were sixty-three hundred patent applications and over thirty-
seven hundred patents awarded. So you can see there was a tremendous
increase in that activity, a lot of investment, and some very positive re-
sults. And as Carl mentioned, with this legislation, the Federal
Government not only gave universities rights to the inventions funded,
they expected certain performance outcomes, and part of this patenting
activity is just that. A couple of other dry statistics: in the year 2000,
there was thirty billion dollars of sponsored research going on within the
universities; there were thirteen thousand disclosures of inventions dur-
ing that year; four thousand licenses and options, which you can equate
to products and services on the market. Looking at startups, meaning
new businesses that were created with university technology, there were
454 new companies founded in 2000, all with university technology. And
in that twenty-year period, almost twenty-five hundred startups were
created. Interestingly, many of the startups stay local to the university.
They don't always stay local companies for long, depending on re-
sources. But 80 percent are still located close to the licensor university.
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And tech transfer does generate licensing revenue, which everyone likes
to focus on: about $1.26 billion dollars. That money is plowed back into
the university system to stimulate more research, more fellowships, edu-
cation, basically to try to prime the pump and get more research and
more results in research stimulated.
So why do we do this? There are a lot of benefits. And these benefits
are just more than in fact the results of research. There are rewards of
attracting faculty, getting a reputation for talent, attracting students, gen-
erating income, promoting economic growth. And I'll focus on that last
element, economic growth.
There have been some real success stories across the country that
have built over time and a lot of people have said, we should do that too.
So states as Michigan have taken a look and said we would like the
benefits of economic development and we'd like to utilize the resources
we have within universities for that purpose. Wisconsin's a great story,
because of how long they've been at it, how good they are at it, and also
how actively they work together with state government. There was a
study in 2002 that looked at, not just the return on investment of a col-
lege education to the people within a university system, but also the
enhanced quality of life, the reputation and expertise in the area. They
took a look at the spending and the income of people involved with uni-
versities, directly and indirectly, and technology transfer. They figured
out that about ten billion dollars was added to the state economy, which
is about 5.5 percent of the state's gross product. They figured it produced
150 thousand jobs, which is about 5.5 percent again, of the state's em-
ployment. So not an insignificant contribution to the state's economy.
Not to be outdone, our state government, the Michigan Economic
Development Corporation, did a similar study and they found out that
Michigan universities contributed thirty-three billion dollars. Now com-
pare that to the ten billion dollars in Wisconsin, and I think that's
because we have a bigger football stadium.
[Laughter]
No actually what they did is they took one more dimension and said
let's take a look at the earnings of someone who would go through the
university system and compare that to the earnings they would have if
they didn't go through the university system. And that's obviously a very
large number. So this is a very popular argument now with tight budgets,
because they're arguing that for every dollar going into a university sys-
tem is going to produce twenty-six dollars of benefits. Now I'll be
honest, I don't believe all of this.
[Laughter]
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But the bottom line is that there are obviously some benefits. So
people now have very increased expectations of the benefits that univer-
sities can contribute to economic development. We definitely are seeing
this influence in tech transfer offices. The university itself wants in fact
to have economic development and they're looking to again attract tal-
ent, build their reputation and attract research. Local communities like
Ann Arbor are quite interested in seeing what we can do to leverage the
presence of the University of Michigan and its research and reputation,
to help our town to build industry. Many more of our students coming to
the university want to see benefits associated with economic activity and
tech transfer, both for their own educational reasons, being able to par-
ticipate in research, and thinking about their own vocational
opportunities after they leave. And then obviously there's also financial
implications. I'll point out that the financial returns of tech transfer pale
in comparison to all these other economic measurements. So the direct
result of tech transfer is not going to be a significant amount of revenue,
but obviously the actual activity itself leverages a lot of other economic
activity.
But a little bit of caution here. I think a good tale here is looking at
Stanford, again one of the most successful universities in terms of tech
transfer. In 2001, they reflected back on thirty years of operation and
said that they had produced over forty-three hundred disclosures, but
only 30 percent of them were successful and 70 percent were not. So
when an inventor comes to you, you just have to realize that probably
he's not going to be successful, yet you still have that service element of
trying to help technology reach the marketplace. Of that 30 percent that
were licensed and successful, only 50 percent produced more than ten
thousand dollars in income. You probably understand there's a huge in-
vestment, not only in people but in patenting. So with ten thousand
dollars, you are not making any money. But again, that's not the main
purpose. And they also found out that only 10 percent produced more
than a hundred thousand. So if the goal of your technology transfer ac-
tivities is for the money, you're in for a big disappointment because
you're probably not going to make money and the licenses that do make
a significant return are going to be a very small minority. Nationwide,
only 125 out of over twenty thousand licenses produced more than a mil-
lion dollars. So there's a perception about universities and tech transfer,
you're making lots of money for lots of people, but the reality is it's
about a half percent of what is licensed that makes a lot of money.
Meanwhile, who cares? There's a lot of great technology, helping peo-
ple, stimulating and building up and increasing the resources to do some
really terrific things.
Fall 2003]
256 Michigan Telecommunications and Technology Law Review [Vol. 10:175
New business creation, creating startups, is a focus area within many
university tech transfer offices. Startups are a great channel for moving
technology because often academic research is really too early to be in-
teresting to established companies, and they would like to take more of
the risk out of it. And sometimes the small, hungry, focused group of
individuals, even though it looks like they're a risky bet, can actually be
a safer bet. Sometimes a larger company, if it doesn't have the right
champions, is not, in fact, the right channel for technology. Startups lead
to jobs and local economic development. People like that. It fosters the
growth of entrepreneurial faculty, it leads to opportunities for students,
and it enhances the reputation of the university in the region. So most
tech transfer offices now look at new business creations as being a good
addition to the toolkit of trying to have technology reach the market-
place.
But this activity is not without cost and risk. It definitely leads to
more complex conflict of interest situations, very long lead times for
success, and it is very expensive to try to do this activity. It's very hard to
find good talent and to keep them within the university environment.
And I think it's very highly dependent on the resources that are inherent
in a region. So if you're in the Boston or Virginia area, for instance, it's
actually very easy to do startups. If you're in an area-you know I don't
want to pick on anybody-in some city in some midwestern state, it is
actually fairly difficult because the resources just aren't around you.
So very quickly I'll close on what's happened here at U of M. We've
made a focused effort at trying to use startups and resources to stimulate
economic development. The good news about all of these influences and
some of the efforts is that they have produced a consensus of the U of M
leadership that technology transfer is not just only important but worth
investing in. And that, I think, is one of the prime ingredients for suc-
cess. It's required a broadening of our skill sets within the office, where
before we focused nearly entirely on just the licensing and protections.
Now we really have a much broader focus. We have to look at business,
we have to look at marketing, and we have to look at entrepreneurial
skill sets. So it's a much broader skill set than we had before.
We have built a very small team of people that I call Business For-
mation Consultants, and they act as counselors. They screen, and they try
to bring resources to our inventors. The state here has injected a lot of
resources. I'm sure many of you have heard about the Life Science
Corridor. They've taken the tobacco settlement monies and spread them
out over time to try to stimulate new research and commercialization
efforts. They've also taken some gambling money and put that into a
kind of a complimentary fund to induce some gap spending. I'd like to
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say that we're trying to get all the sins covered here and we'll get eco-
nomic development really rolling.
[Laughter]
There's also been, I think, a real change in collaboration out of this
effort-a change in attitudes. There's been a lot more collaboration
among the universities and state, and also within the Midwest. There's
been a lot more collaboration within the city. I think it's broken down a
lot of the town problems we had before. And I think it's actually led to a
lot more engagements for the alumni. Our development office likes to
use me in their alumni meetings. And I love it because I'm gaining con-
tacts and resources from people all across the country that help me do
my job better.
So the bottom line is that although we have a long way to go here in
Ann Arbor, we're doing pretty well. A lot of this stimulation, a lot of this
investment and interest has led to some really good things. A lot more
disclosures, we had 30 percent more disclosures to our office in the last
year. We've done really well with startups. Talking to Carl, Ann Arbor
actually is blessed with some resources which have really helped us. We
had twelve startups in 2001, including HandiLab back there. We had
some terrific opportunities that are going to lead toward great products
and some great job opportunities. And overall I'll say that the momen-
tum is very, very positive. We have some terrific financial rewards that
may be coming, that will allow us to do the work we do and that this
enthusiasm in our staff and faculty and in the community is very refresh-
ing. Thank you.
[Applause]
PROFESSOR REBECCA S. EISENBERG: Thank you very
much, Ken. It's a very interesting counterpoint-somewhat different fo-
cus or maybe a shifting focus of technology transfer in universities in the
years since passage of the Bayh-Dole Act.
Our next speaker is from the other side of tech transfer. He's from
the private sector. He's also had an incredibly interesting career path in a
lot of different institutions. He received his Ph.D. in physics from
Stanford University and was a post-doc following that at the University
of California, in biophysics. He has held scientific and technical
management positions at NIH, at QuantaRay, at Applied Biosystems, at
Hewlett-Packard, and since Agilent Technology spun off from Hewlett-
Packard, he's been with Agilent Technologies where he recently became
chief scientist for the BioResearch Solutions Unit. In all of these
positions he has worked extensively on systems for sensitive
biochemical measurements. At Applied Biosystems he was responsible
for groups that were developing novel genotyping and comparative DNA
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sequencing technologies. For the past three years he's been R&D
manager for the division of Agilent that develops DNA microarray
solutions for gene expression measurements in bioscience research
markets. Dr. Kronick.
MEL KRONICK: Thank you. For my remarks today, what I'd like
to do is to give you a personal perspective on technology transfer. It's
interesting that Ken mentioned Stanford; in the early seventies when I
was a graduate student there the work I did for my Ph.D. thesis was pat-
ented and licensed by Stanford. I remember visiting Neils Reimers in the
little trailer that he had out in the parking lot at Stanford when the licens-
ing operation there had really just begun. And since then, in my career,
I've managed to be at a few different companies, and a lot of the activi-
ties that I've personally been involved with have been the result of, in
one way or another, university research which was licensed to commer-
cial organizations.
What I'd like to do this afternoon is to focus primarily on life sci-
ence applications and technology transfer, because that's the real topic
we're talking about today. And my remarks will be slanted more toward
comments considered most relevant to some of the issues that come up
in genomics and molecular biology kinds of applications. And it proba-
bly goes without saying that these are my personal remarks, not the
remarks of the company I work for.
There are three fundamental premises I want to put forward. The
first and most fundamental premise is that the nature of the life science
research and technology that's going on in universities today is so inher-
ently state of the art, novel and cutting edge, that it causes a whole bunch
of problems and issues to arise with licensing. I think that the newness
and novelty implies, for example, that it's a long way from the time that
something develops in the university to when it can become a commer-
cializable product. That means a lot of time, a lot of investment.
My second premise is that when the invention in the university in
these life science areas I'm talking about actually gets patented, the pat-
ent can actually often create a lot of confusion in the scientific and
commercial areas, i.e., in the commercial marketplaces, because of the
patent office's inability to really fully anticipate the implications of
granting unreasonably broad patents. That's a theme I'll keep coming
back to. It is something that a lot of us involved in these areas get very
upset about and are very concerned about.
My third premise follows from my first two. Because of the fact that
there is a long gestation time with a lot of these inventions and because
of the danger of the patent office granting overly broad patents, I think
the university, in doing technology transfer, must use utmost care to
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make sure that the intellectual property they're responsible for gets into
the private sector in a manner which really maximizes the benefit to so-
ciety and, at the same time, maximizes the long-term and not the short-
term benefits to the university. What we all do not want is a situation
such as the one described by Dr. Stan Williams last September before the
Senate Commerce Science and Transportation Subcommittee on
Science, Technology, and Space. Williams was a faculty member at the
University of Illinois and is now a Principal Scientist at Hewlett-Packard
in Palo Alto. Williams claimed that relations between universities and
corporations have rarely been worse. He commented that it was easier
for Hewlett-Packard to start up a research collaboration with a university
in Russia or France than one a few miles down the road in the Palo Alto.
And Williams felt the Bayh-Dole Act encourages universities, when
granting intellectual property licenses, to favor small companies, often
started by faculty members, over larger companies that have supported
much of the research. He noted that a lot of companies feel that they
have been burned a lot of times in licensing deals with universities. So I
think that's an attitude that we all have to work to try to change; some-
how we must think through the processes so that we do not have that
kind of attitude existing within the commercial side.
I want to go back to the first of my three premises about big invest-
ments being made. I want to remind everybody about all the things that a
company has to do from the time it starts looking at a technology until
that technology becomes a commercial product. I have often observed
that the people in a university who invented something feel if they have
run an experiment four times and it worked, then they think its develop-
ment is done and it's ready for commercialization at a company that
ought to be making it in six months and charging a very small amount of
money to sell it broadly. But I think most of the companies I have
worked for probably spend a maximum of maybe 20 to 40 percent of
their investment in a product when they are done developing it as a tech-
nical entity. The rest of that investment-the majority-all goes into
things like scaling-up manufacturing, investing in facilities, investing in
quality methods, figuring out how to package the product and how to
market it, creating learning tools for customers, training the sales and
support people, setting up that infrastructure, doing advertising, promo-
tion-lots of things like that. All that kind of investment is really
necessary. And even just the feasibility phase of a project needs to ad-
dress considerations which university researchers do not consider. We
constantly amaze ourselves with the details that can slow us down, even
with stuff invented internally, ideas that we are not in-licensing. You
have to take an invention and see how it works in the real world where it
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will be used. If you're talking about a research tool, it might be used by
different people who will handle it in different ways. If you're talking
about a drug, it's obvious that a company needs to understand how it
works on different people or, for a plant improvement, how the plants
will incorporate the invention in different environmental conditions. A
company must also determine how the product works when it is made
from different lots of the same raw materials, things like that. There's
just a lot of nitty-gritty, difficult scientific and technical hurdles that you
have to go through following the initial invention or licensing of some-
thing.
This large investment of time and money needs to be considered in
the context of my second premise: that so much of this life science tech-
nology is so new that the patent office doesn't know quite what to do
with it. A most bothersome thing is when you license one patent to try to
get a product going and then you realize, either soon afterwards or,
worse yet, later on, that you have to license three or four other things as
well. The area of DNA arrays that I work in is a prime example of that.
To use a DNA array, you run into intellectual property issues having to
do with the enzymes and dyes that are used to label the DNA. You run
into intellectual property issues with respect to how you actually make
the DNA arrays. You run into intellectual property issues associated with
many, if not all, of the particular DNA sequences with which you want to
be interrogating on the array and the sequences could be owned by fifty
different organizations. And you might then have additional IP issues
associated with the ways in which you choose to actually scan the mi-
croarray and analyze the data coming off of the array. I mean it's just a
lot of different organizations to work with. It's really very complicated.
You have a situation which, I think, is a prime example of a principle
described a few years ago in an article written by Professor Eisenberg
and a former Michigan faculty member, Michael Heller.55 They called
this principle the "tragedy of the anticommons." So many people have a
stake in the action that it's very, very difficult for a company to commer-
cialize something and do it at a profit without an inordinate amount of
investment and a lot of wasted time.
I think a lot of these problems have to do with, as I said earlier, the
fact that technology is really very, very new. There is a wonderful article
by John Barton, a professor of law at Stanford University, that appeared
-56a few years ago in the journal Science. Barton talked about reforming
the patent system. He points out here that changes should be enacted to
55. Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation? The
Anticommons in Biomedical Research, 280 Sci. 698 (1998).
56. John H. Barton, Reforming the Patent System, 287 Sci. 1933 (2000).
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shield our society from the problems which can result from broad, overly
basic patents on fundamental research processes that may deter and
complicate follow-on research. Barton said in dealing with this issue it's
crucial to balance incentives to initial innovators against incentives to
follow-on innovators. And although the point deserves further study, ex-
perience suggests that this balance is currently weighted too much in
favor of the initial innovator. The problem is likely to be increasingly
serious in the areas of biotechnology and computer software. Barton's
article goes on to quote a Supreme Court case, Brenner vs. Manson,57
which discusses the risks to the public interest that would arise if patents
block off entire areas of scientific inquiry and development.
A recent example in my field of DNA arrays provides a great exam-
ple. There's a patent out there now on databases of gene expression
profiles. In my mind, compiling a database is a pretty obvious thing to
do when you're starting to collect a lot of data. It's a little bit like the one
click patent that Amazon was dealing with a few years ago.
Fortunately, I think the tide may be turning a little bit. And in fact
there was a significant court ruling this week, I think on Wednesday, in a
lawsuit that the University of Rochester brought against Pfizer on COX-
2 inhibitors, molecules used as anti-inflammatory drugs.58 The Rochester
patent was held to be invalid, or at least not enforceable against the mak-
ers of COX-2 inhibitor drugs like Celebrex (the target of the suit in
question) because of the fact that the patent really was too broad and
wasn't really enabling the particular invention that Celebrex was and
represented to the drug company."
There are other kinds of complications which arise from bad patents.
We all know that you can get a very legitimate patent which reads on
somebody else's patent, because the new patent can represent a very
innovative improvement of a previous invention. So you have this
wonderful thing but you can't, in a strict legal sense, commercialize it
unless you figure out ways of getting rights to the broader patent that
dominates. At this point, interesting negotiations sometimes occur,
because if your innovation really changes the rules of the game, the
company that holds the dominating rights may be willing to engage with
you-trade, barter, things like that. That process is reasonable. But a
related issue I think goes back to the way the patent office works again.
One of the things that just drives us in industry crazy is when a patent
that we know about has issued with very narrow claims. Then, perhaps
years later, what's called a submarine patent 'surfaces' wherein the
57. Brenner v. Manson, 383 U.S. 519 (1966).
58. Univ. of Rochester v. G.D. Searle & Co., 249 F. Supp. 2d (W.D.N.Y. 2003).
59. Id. at 235.
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inventors have managed, through aggressive legal representation, to wear
down the patent office to the point at which claims in a continuation are
broadened so they cover almost everything. Frequently, in doing this, the
attorneys take advantage of the insights developed during the continuing
evolution of the science and the technology. In doing so, they distort
what the original inventor had in mind five or ten years ago and make it
seem like the inventor was far more prescient in his thinking than he
probably really was. And then you're all of a sudden faced with the fact
that you've invested a few years in developing something, thinking that
Company X had a relatively narrow patent. Suddenly Company X owns
the whole field because they were able to convince the patent examiner
that the broad interpretation of the specification was really what the
inventor had in mind. It is as if I had invented the wheel but now I were
claiming I also had invented the automobile. So you know it's very
frustrating sometimes to deal with that lack of sophistication within the
patent office, which could result in such a distortion of the patent
continuation process.
So I think really all of us have to work to try to improve the quality
and the nature of the decisions that are made out of the patent office.
And frankly, it's a very, very difficult thing to do. I think that the really
good legal minds, like are present here, and scientific minds usually
don't want to go to work in Washington at a low salary, looking at one
patent every twenty minutes and trying to pass judgment on it. Barton
made similar comments in his article, noting that the PTO service ideally
should become a career rather than a stepping stone to private practice.
And yet the current employees of the patent office are the individuals
that really end up establishing whether a patent exists or not. I think it's
a fundamental difficulty in the way the system works today. And I know
that some creative ideas have come forward with regard to privatizing
the system here or making it a little bit more similar to the system that
works in Western Europe, where there's a comment period during the
initial pursuing of the patent and where a pending patent is opened up
for external comment. In Europe, a lot of people get a chance to com-
ment during the prosecution-anybody that might have an interest in that
patent can ask the patent office to look at a particular previous publica-
tion that could affect the patentability.
Taking into consideration the amount of investment required to
commercialize most university inventions and the overly-broad issuance
of claims on certain patents, the situation we are all in just requires a lot
of sensitivity on the part of universities that are involved in technology
transfer. I would say that when you, the university, are dealing with a
patent for which you're lucky enough to get very broad claims-perhaps
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like the Wisconsin stem cell patents that were just discussed before my
talk-I think non-exclusive licensing is extremely important. The way
Wisconsin's been doing it has not really upset the way in which the mar-
ketplace can work and does not really stand in the way of future
developments.
I recently read an article from a nanotech trade magazine that I get
called Small Times. The nanotechnology industry is now struggling with
a lot of the issues that biotechnology has been facing over the last several
years. And, in fact, the scientist Stan Williams that I mentioned before
works in the nanotechnology area. In this particular article in Small
Times, Harold Wegner, who's a partner at Foley & Lardner, a law firm in
Washington D.C., made a statement that I know from my personal con-
nections in Stanford is true. Wegner said that the initial success of
licensing the Cohen-Boyer patent, one of the most fundamental gene
cloning patents, was based on the very modest demands made by
Stanford. 6 Stanford asked only a ten thousand dollar fee per year to have
blanket research use of Cohen-Boyer patent. The patent was widely sug-
gested to be of questionable validity but a standard form agreement was
offered to everyone at this modest rate, far less than the cost of even a
modest legal opinion on validity. The licensing policy resulted in the
patent being broadly licensed and was definitely the biggest money mak-
ing patent that Stanford has had. The second biggest one that Stanford
has had, something I personally ended up being involved with when I
went to Applied Biosystems, had to do with a protein labeling technol-
ogy. And again it was broadly, non-exclusively licensed.
I would suggest on most of these broadly applicable technologies
that the policy of the university ought to be to make them easily avail-
able. Follow more the Southwest Airlines or JetBlue model in making
the transactions simple, not a big complicated negotiation. Just a few
weeks ago I had a call in about something I was interested in to one of
the University of California licensing offices. And I asked the person
there if the university wanted to license it exclusively or non-exclusively.
He said, "It's just a lot easier for us if we do it exclusively." I just think
that's the wrong attitude. You have to look at the idiosyncrasies of the
particular patents and issues that you're dealing with. And attitudes like
that just upset a lot of people in industry who are trying to respect the
value of legitimate intellectual property but also are trying to run a busi-
ness.
I think the second point about exclusivity is that the university
should be careful about locking up the rights too soon with any one
60. Stephen B. Maebius & Harold C. Wegner, America's Technology Leadership at
Stake if Patent Owners Control University Research, SMALL TIMES, Jan.-Feb. 2003, at 23, 61.
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party. That sort of goes along with making broad patents widely avail-
able. I talked to a few people I know in the technology transfer on the
university end and on the industry end before coming here. And I think
that it makes the job of people in the technology licensing office a lot
easier to have the inventor be a real advocate for the patent. Tech transfer
offices are motivated if somebody comes to the tech transfer office and
says, "This is great, you 'gotta' get it out there." Such encouragement is
clearly going to really be a very motivating thing. On the other hand,
there's certain conflict of interest that exists there, especially as long as
the inventor is an employee of the university. I think the technology
transfer office has to look out for the university and society in a bigger
sense and listen to what the inventor has to say but not be overly influ-
enced by that. I think there's lots of room for continued creativity on the
part of all to come up with licensing conditions that either do things like
limit the license to a certain area of exclusivity or licensing at a very
minimal cost to a company up-front and then, as the company has that
license for more and more time, charging them more and more. That
would encourage a company to try something, and if they like it, then
they have to pay more and more. A company does not want to get into
the big up-front negotiations to just try something, because then it's just
not going to be worth it to go down that path.
Finally, I would just like to go back to that comment I made on ex-
clusivity, and combine that with some of Ken's remarks. It's difficult to
know when you get a very preliminary invention if it's really going to
make a lot of money or not. And I think the quicker inventions are pro-
duced and get tested and tried in the marketplace, the sooner the true
value of those inventions is going to really come out. It's just hard to
pick winners. I think the easier everybody can make the process the
better-for both the tech transfer offices and the universities so that you
create situations like Carl talked about where a hundred institutions get
licensed to use something in a relatively short period of time. I think
that's the goal that we really ought to be moving toward. I think it'll end
up maximizing the income for the universities over the long term and
it'll maximize the effectiveness with which inventions get transferred to
commercial licensees.
So in summary, I think that what we want to do is to recognize in
some of these really dramatic new areas of biology that the patents are
imprecise and broad when they're granted and that the most important
thing is to figure out a way to let innovators who can build on some of
this new technology have access to the exciting stuff that's coming out of
universities. We do not want to set up a situation I earlier referred to as a
tragedy of the anticommons. If we do, I think that we'll just end up
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putting a lot of time and energy into efforts in which companies are
fighting each other and universities, rather than really trying to produce
more products for the common good. Thank you.
PROFESSOR REBECCA S. EISENBERG: Thank you very
much. That was a very interesting set of presentations that each offer
interestingly different perspectives on the issue of technology transfer. I
think while I wait for some of you to frame your own questions, I'm go-
ing to invite the first two panelists to see if they want to respond to Mel
Kronick's presentation, because he was offering a peek at the industry
perspective on the dark side of technology transfer, the ways that things
can go wrong that would have the opposite effect of the underlying goal
of achieving more widespread development and dissemination of tech-
nologies coming out of universities by patenting them and licensing
them to the private sector. You can have too much of a good thing, obvi-
ously. You could have patents that are covering fundamental technology
that are too broad, where the underlying technology would be better util-
ized if broadly disseminated, or you could have technologies of the type
that I think Ken Nisbet has in mind, that form the kernel of some of
these new enterprises where you probably do want to have an exclusive
license in order to get some new business off the ground. So how do you
try to manage some of the tensions involved between the good side of
technology transfer as a way of promoting investments and economic
developments on one hand, and the bad side of technology transfer, that
can get in the way of effective utilization and dissemination of new tech-
nologies to the scientific community?
DR. CARL GULBRANDSEN: Well, I agree with Mel. I don't
think that it's strictly a university problem. I think that industry also, if
they can get a broad patent, will get a broad patent. It takes people that
are sophisticated and educated and understand that your market is
probably better if you license it broadly. We're much better off if we get
a cheap license than if we hold out for an expensive license and we never
get it licensed. So our goal is to get things licensed. That's what our goal
is, to get it into the marketplace and get it commercialized. The issue of
stacking patents is something that all of us worry about, particularly in-
dustry worries about it. But it's not anything that's really new. I came out
of the medical device industry and every time we wanted to build a new
product, we had to do our literature searches and our patent screening to
find out whether or not we could even make the product. And generally
it involved acquiring rights from other companies or universities, it
wasn't strictly universities. So this is kind of an age old problem that has
been worked out in the marketplace and I can just say that in our own
experience, at WARF for instance, we used to ask for reach through
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rights, which means that when you license somebody with a research
product and they get a great discovery on it, you want some part of that
end discovery. We very rarely do that anymore because it's a waste of
time. It's difficult to monitor administratively for one thing, and we'd
rather just get paid. And so we license it for a low price, and as long as
they continue to use it, hope that they pay us a moderate price, but then
license it broadly. And at the end of the day, we'll probably do much bet-
ter than trying to license it to a company and try to extract anything that
they might gain from it down the road. So you know there are creative
ways to approach these things. But I do think it takes people that are rea-
sonable and don't have too high of expectations of commercial property
when they start.
KEN NISBET: You know, I think the same thing. I think we agree,
we have to make sure that the interests are aligned. We train our people
that industry is our client. And we also have inventors on the inside who
are also clients. The bottom line is that we know that there is a substan-
tial investment required to have our technology reach the marketplace.
Ten times what we put into it. And we need to have those incentives to
make sure that the outside companies are willing to do it. This is not sell-
ing. They do not come in and say I'll take one of these and one of these.
I mean it is really hard to match up our technology with industry. It's
even more than, I think, the exclusivity issue. It's also about time. We
have so many things we're trying to get out and we're servicing so many
masters. If we can get more of our technologies out and leave a few
nickels on the table, that's the attitude.
PROFESSOR REBECCA S. EISENBERG: We welcome any
questions from you. Meanwhile I'm just going to keep asking questions.
Oh yes, Jason Owen-Smith from the Sociology Department.
AUDIENCE MEMBER: Question for the panel. I'm not quite sure
who to address it to, and I have a sense that you might have differing
thoughts. I'm interested in how academic scientists decide to patent
things. But one of the issues that runs through that is that scientists at
work in academia, especially life scientists at the bench, typically aren't
terribly concerned with the overlapping patent rights, the background
rights that are necessary to enable someone downstream to practice their
invention. So I was wondering if the technology licensing directors
could speak to the role that their offices play in trying to figure out what
background rights exist and if the representative of Agilent could speak
to the ways in which licensing from universities may be more difficult
because they're typically not directly concerned with such rights.
DR. CARL GULBRANDSEN: Well we have a professor bring a
disclosure to us. There are several things we consider before we decide if
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we're going to take them. First of all we look at whether or not we can
protect the invention-that's not true in all cases. We handle also a lot of
biological materials we don't bother to patent, or software we don't
bother to patent, so that's less of a concern. But if you're talking about
an invention that is of the type that you would like to patent, you want to
figure out first can we protect this. Secondly, is there a market or can
there be a market built for it. And then thirdly, what's the importance of
this from the standpoint of the public good or use. Is it something we
should invest in? Stem cells, for instance, I can tell you we've never
made any money on stem cells. Whether we ever make any money on
stem cells is a big fat question mark and likely we won't. But it is an in-
credibly important research tool, and we've decided to invest in it. So
that's what we are doing. As far as looking at what background rights
exist, I don't know if we necessarily do that except to determine whether
this is something that we can protect.
KEN NISBET: Yeah, I just have a comment. That is very difficult.
But one of my colleagues here, Elaine Brock, works in sponsored re-
search. The time they think they have something valuable is not the best
time to help commercialize it. We have to go way back and look at who
were their relationships, what materials did they use, what other people
were involved in helping you discover this? And at times we find that
unless we give them counsel early on, there really isn't much that we can
do with it afterwards. I have to admit, I don't think most of the inventors
have a good grounding on all of these elements because when they first
are starting their research, they are not always thinking about the end
goal of commercialization. We have to help them with those options.
DR. CARL GULBRANDSEN: I would add onto what Ken said,
that one of the other considerations that is on our checklist of things to
look at is complications. And complications arise when they've been
consulting with somebody in Warsaw or they've been working with
somebody at another university and we need to deal with that university,
or graduate students have come and gone and we can't find who the in-
ventors are, those types of things. There are too many complications.
PROFESSOR REBECCA S. EISENBERG: Maybe the decision
in the University of Rochester case, that was alluded to earlier, will dis-
courage some of these broader claiming strategies or make them less
effective. I want to recognize Elaine Brock, who's been negotiating
sponsored research agreements for the University of Michigan for many
years and has also had a lot of experience in the other direction of tech
transfer, which is bringing stuff into universities from the private sector.
AUDIENCE MEMBER: Right, taking it out too. But I think one of
the key differences between university technology offices and industry is
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universities do not defensively patent. We don't defensively patent, so
we won't take a technology and patent it just to be able to shelve it to
promote a product that's closely related. So that is a key difference.
PROFESSOR REBECCA S. EISENBERG: Actually that's a nice
segue into another question that I had here in my notes. Recently, the
Court of Appeals for the Federal Circuit decided a case called Madey v.
Duke University, which is a patent infringement suit against a university
brought by a disgruntled faculty member who held a patent on a technol-
ogy that the university had built a special lab around.6' After a falling out,
he sued the university for patent infringement. The university defended on
the grounds of a research exemption, that this is noncommercial academic
research. And the Court of Appeals for the Federal Circuit said basically,
what research exemption? You are using this technology in accordance
with your ordinary business purposes, that being noncommerical aca-
demic research, and therefore you are an ordinary infringer, and don't
think you have any special exemption.6' Is this maybe part of the other
side of the coin for technology transfer: that as universities become more
assertive about their own patent rights over their own technologies, they
start to look like ordinary players in the patent system and they lose their
special status as nonprofit users of technologies developed elsewhere?
And if so, is that something that's likely to change what Elaine has just
suggested to us? Will universities be able to afford not to patent defen-
sively, if they feel more vulnerable as infringement defendants?
AUDIENCE MEMBER: I don't know if anybody in the room is
looking at the Madey case, but it's a great example of what not to have
done procedurally. And potentially calling the question might be a bad
thing to have done, not only for universities, but for industry who also
believe, to some extent, in the research use exemption. But I don't neces-
sarily think it'll promote defensive patenting. But it definitely will make
us treat research tools differently, particularly when we're actually using
them in non-industry sponsored projects, because to the extent that the
Federal Government puts millions of dollars into research, on which
we're basing the potential research result on a tool that's available only
commercially from somebody else and that we've been relying on the
research use exemption to promote, we may end up having a lot of fed-
eral investment of money in a potential product that we can't move out
because of a background right. But I'm not so sure that that problem
doesn't already exist, for the reasons that Carl said; we have those prob-
lems already. If it's too complicated, if there are too many blocking
patents, if we can't find the inventors, then we're not likely to try to
61. Madey v. Duke Univ., 307 F.3d 1351 (Fed. Cir. 2002).
62. Id. at 1361-63.
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move forward with it anyway, just because we don't have the resources
to be able to do that the way industry does. But like I said, the Madey
case is not going to make great law.
DR. CARL GULBRANDSEN: I guess I've talked to Ken about this
and I know Michigan-there was an amicus brief that was filed by the
Association of American Universities and by the Association of Ameri-
can Medical Schools. Wisconsin didn't join that and I know Michigan
did not join that. I don't think that the decision in the Duke case is too
much of a surprise. It was a surprise for them to say that if you're using
it for the business of the university, which is education, it is infringe-
ment. I think that's going a little bit far. But I think as everything
happens in the law, you'll see shadings of this and probably contractions
of it. It came out of a disgruntled employee suing the university. It
wasn't a company suing the university. And frankly, there is kind of an
unwritten rule among companies particularly in the biotech area that
they aren't going to sue universities. And I don't think that this case will
precipitate a lot of lawsuits. Saying that, at Wisconsin we certainly don't
encourage our professors to infringe, if they knowingly are using some-
body's technology. And we will negotiate for licensing position, even
though the courts have said you can't sue a state university for damages
on infringing intellectual property, we don't encourage infringement in
Wisconsin.
PROFESSOR REBECCA S. EISENBERG: Jason?
AUDIENCE MEMBER: A follow on to the discussion of Madey v.
Duke, does either WARF or Michigan explicitly reserve rights to use
technologies they license exclusively in research, as part of contractual
arrangements?
DR. CARL GULBRANDSEN: Absolutely. It's the holy cloth. We
do not take that out of our license agreements.
KEN NISBET: Same here.
MEL KRONICK: Even the stuff that gets licensed out that was fed-
erally funded, the government always holds onto a license, too.
That doesn't make any difference.
AUDIENCE MEMBER: Well sometimes it can if it wants to use
the technology. I've run into situations where it actually worked to a
company's benefit.
QUESTION: Looking forward to the continual evolution of the
technology transfer office, is that considered to be the vehicle for creat-
ing synergies for research between universities and companies? I know
from a company standpoint, as I work for a company in the R&D side
for over ten years, we used to look at universities a lot for these collabo-
rations but at some point, things changed and now we go overseas, for
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the most part, and look. Not just because of maybe some of the terms are
better-I mean we have more control over what's generated, as far as
from a property standpoint-but also costs and how much it costs to do
research in the U.S. versus somewhere else. It's almost like an extension
of the manufacturing issue of do you make it here or do you make it
elsewhere. Now the thing is do you invent it here or do you invent it
elsewhere. And how are the tech transfer offices going to react to that, to
keep the pipeline open for these synergies between universities and
companies to continue?
KEN NISBET: I think you have to break that question into two
parts. Tech transfer offices are really interested in having technology re-
sults, our research results, being used by industry. If you really want to
know about the relationships of how to engage the universities to do
some work collaboratively, it's really the sponsored research group,
which is separate from tech transfer typically, or corporate relations, or
obviously just personal interactions that occur. And I really can't com-
ment too much about whether we are becoming more or less
competitive, but it certainly does seem, when you look at the dramati-
cally increasing levels of research going on at universities, the chronic
shortage of space, the talent drain in both directions, that it's becoming
more difficult, but obviously there is a lot of good research going on.
Most of that is federally funded and not as much corporate-funded. It
depends on the strategic direction and intent of the university, and again
the economic development aspects of that as well.
DR. CARL GULBRANDSEN: I think that there is some truth to
what you say, that technology transfer offices are getting more and more
involved. The university technology is at a very early stage. It always
needs a tremendous amount of development before it can become com-
mercialized. These early stages of development often are efficiently done
at the university and we encourage the companies to use our talent in the
laboratory. In fact we have a program in Wisconsin, that the first seventy
thousand dollars of any license agreement goes right back into that labo-
ratory, to help fund additional research in that area. So the company that
pays gets that research without having to pay overhead. So there are pro-
fessors like that and companies like that. But it is a recognition that
university research can be cost efficient. And licenses can help drive
sponsored research at universities.
PROFESSOR REBECCA S. EISENBERG: We have time for one
or two more questions.
This is Larry LaVanway, a law student who's also had some experi-
ence in tech transfer.
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AUDIENCE MEMBER: A couple of times during this panel a few
people have mentioned that because a lot of this technology is done from
the universities, it's more basic and fundamental in nature, and therefore
it creates a lot more effort and investment to get it into the marketplace.
And I'm wondering if newer, kind of younger, generations of researchers
and people affiliated with the academia are more aware of the technol-
ogy transfer option and possibly looking at more applied research in
their labs, because they're aware of this option now, as opposed to just
simply publishing in academic journals and going to academic symposi-
ums. Instead of just simply publish or perish, it's maybe publish and/or
patent or perish. And, therefore, the inordinate or very large amount of
investment that's necessary to get this into the marketplace is maybe de-
creasing because new, younger generations of researchers are more
aware that this is an option. Do you see a trend in more applied research
because of the options for technology transfer, or is it still basic re-
search?
KEN NISBET: I actually don't think there's a trend towards more
applied research. Obviously I think people are more conscious of the
work that's required to make their research attractive and are more aware
of the technology transfer option. But it really stems down to what's ex-
citing and stimulating. That's why they're at the university. Typically it is
very early, very exciting research and that's what they want to do, and
they'd be bored at finishing the job. I mean I saw that in industry as well.
There's different kinds of engineers, different kinds of scientists. In the
end, I think the answer is probably to continue to work with people and
find additional resources, things like gap funding, things like finding a
particular development or marketing specialist. You know, Larry, by the
way, participated in an internship program we have here at the university.
And in applying resources like interns towards projects to help reduce
the risks and make it more attractive is a very good strategy. So in the
end I don't think you can dramatically change the way research is done,
but we're trying to add resources to make it more attractive and less risky
for outside partners.
MEL KRONICK: I do have a sense, and I read some similar things
in preparation for coming here, that the issue of tech transfer is creating
a bit of a schism between different camps within universities. Some peo-
ple just want to not have anything to do with the technology transfer
process or any of the limitations that people place upon themselves when
they have to think about the patenting system. This is in spite of the
downsides such as Carl talked about in the particular example of the
Vitamin D therapy. I recently read that Professor Steven Austin, who's at
Princeton, says that when the subject comes up, he just doesn't want to
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collaborate with people that are going to try to patent what they're doing
because it just distorts what he perceives to be a fundamental value of
the university system. So I think it's still an issue which universities
themselves, I think, are struggling with. It's an interesting issue as well
with everything going on now with regard to publications. There's a big
movement now to trying to set up web-based journals that go around
copyrights associated with the for-profit journals that exist out there. It's
creating another interesting intellectual property controversy within the
university of whether to publish freely or privately.
DR. CARL GULBRANDSEN: I think I agree with Ken. Wisconsin
is very active in this area, but I don't know that there are many research-
ers that I have contact with, that have really changed the style of their
research and are going more toward applied research. There's certainly
much more interest in startups, which is a little bit different issue. It's
very sporadic across the university, whether anybody's given credit for a
patent or not. Most departments don't give you credit for the number of
patents that you have on your resume. If you're Hector DeLuca, at the
University of Wisconsin, and you've brought in a hundred million dol-
lars, they give you credit for it. You become Chairman of the
Department. But that's an unusual situation. So I don't think it's a whole
lot different, other than there's more awareness today.
PROFESSOR REBECCA S. EISENBERG: Well thank you very
much for a very provocative and interesting discussion.
INTRODUCTION
MATT MOCK: Thank you Professor Eisenberg and thank you very
much to members of Panel III. It's a great discussion. And before I in-
troduce our closing speaker, I want to encourage everyone to take a
moment to fill out the evaluation forms that you got in your packets. Or
if you need a form, please raise your hand and we'll hand you one and a
pencil. You can place the forms in the metal basket that are on the table
outside this room. Or if you'd like you can mail the form to the address
that is on it.
And now to give some closing remarks, summing up what we've
learned here today, I'd like to present Professor Lempert.
PROFESSOR RICHARD 0. LEMPERT: I looked at the program
and it says closing remarks four-fifteen, next event six-thirty. This gives
me a lot of time to fill. But don't panic. You are going to be partly in
control of the time. We certainly will not go past five, and I'm not going
to speak nearly that long.
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The staff of the Michigan Telecommunication and Technology Law
Review have thanked everybody but themselves. So on behalf of the
speakers and those in the audience, I want to thank you all for mounting
this terrific conference, taking the initiative, having the idea, and pro-
ceeding. The three students that I think have done the lead work are
Matthew Mock, Larry LaVanway and David Abramowitz. So I thank you
very much for this intellectual feast for the law school and people in the
community and around the university. Also, as a panelist who came from
out of town, I want to thank Maureen Bishop who has been responsible
for our care and feeding and transportation and everything else. She has
done a great job. I also want to say a word with my hat on as Director of
the University's Life Science Values and Society Program. LSVSP is
pleased to be one of the cosponsors of this event and to have played a
role from the start in talking with the staff and journal about the paths
this conference might take. Many of you know about the LSVSP. Those
of you who don't know us can be kept abreast of future activities of this
sort by going to the University of Michigan website, following the Life
Sciences link to our web site and signing on to our mailing list. If your
interests change and you no longer wish to hear from us, it is just as easy
to get off.
I have some remarks to make, but you all have sat through this day
and I think you've heard a lot and learned a lot and we've had a lot of
questions. So by way of summary, I'd like to invite people in the audi-
ence to give statements, not to ask questions. If you have any
observations that you want to make, based on what you've heard today
or on other concerns, here is a chance to share your observations.
AUDIENCE MEMBER: Thanks for the opportunity. I first want to
say that I'm from the business school, I'm an MBA student. And I came
back to school after thirteen years in industry, again in the R&D side,
engineering, because I realized that most of the times technology was
interrupted or innovation was interrupted, not so much because of the
technology issues but because of legal or business issues. So I came back
to school to understand a bit more about that. Since then I've come to
understand or think of innovation more of like a parallel to a supply
chain. At one time companies were highly integrated and they manufac-
tured everything their products needed from nuts and bolts, but today
they mostly buy a lot of that stuff when making it is not value added.
They focus on manufacturing just the part that they're best at. I think
innovation is going the same way. Products are more and more complex
and no matter how big a company is it cannot invest the trillions of dol-
lars it would take to invent everything it needs. There's just too many
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bright people out there. So that's what my interest is in and how I came
to this panel, because of the tech transfer side.
I think there is an evolutionary path that needs to continue or accel-
erate so that we get to some synergy level between universities and
companies that doesn't exist right now. I think that if we add up the
parts, we only get the sum of the parts and nothing greater than the sum.
I think universities could be great suppliers of innovation to companies,
but as was pointed out, companies need to be true to their strategies and
to their stakeholders. Thus, we must continue the dialogue to figure out
where are the opportunities to keep the truth and the ethics side in sight.
You are a university, and you are doing research to improve the common
good and to get innovation in the hands of all innovators, but you must
figure out how your innovations fit the incentives of a business scheme
so that companies can multiply their value and spread it through the
globe.
So my statement is that I think universities among themselves are
still very isolated in how they collectively market their innovations and
offer them to companies that are seeking not to reinvent the wheel every
time, and not to reverse engineer, and not to work around patents, but to
just figure out how they can legitimately utilize innovations for their
products. On the other hand, companies need to understand that in uni-
versities, in particular, the biggest value is the creativity and not try so
much to push investigators or professors to deliver a product that's al-
most ready to market. Those are the observations that I want to bring to
the table. And again, I thought the panel was fantastic. Thank you.
PROFESSOR REBECCA S. EISENBERG: I'm going to hold you
all to two minutes, I should note.
AUDIENCE MEMBER: I applaud the organizers for this confer-
ence and also all the attendees because I think Ann Arbor needs more, as
a community, and we all have to participate in the theme of talking about
life sciences. But being an MBA student and also working for a biotech
company, the role of law is so apparent to me, whether it be the deal
structure between the company and university or the company and ven-
ture capitalists. When you're trying to commercialize a product and you
have to go through the USPTO, and have to work to gather data for
clinical trials, and have to set up manufacturing policies, and try to sub-
mit data to the Senate for Medicare/Medicaid Services, you realize the
power of law. I think that it is a tribute to the organizers that we're talk-
ing. Hopefully we'll have more discussions about law and how when
you're trying to commercialize a product you need to work with the uni-
versity, the government, all the different players, and other companies.
So I think it's good that we addressed-I mean we also talked about life
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sciences and biology-that bringing that out is very important, just to
realize that you can't escape law when you're trying to commercialize
life sciences.
PROFESSOR RICHARD 0. LEMPERT: Other comments? Well
if there aren't any I'll share some closing observations with you. I didn't
prepare anything in advance but just noted issues that arose during dif-
ferent presentations. So I will be taking you back through points that
struck me in the talks and share some reactions with you.
Listening to Alan Saltiel and his opening remarks and hearing him
talk about complexity (which is an important buzzword and problem
area in modern biological life science research) I was reminded of
what's become a mantra of mine. As some of you know, I'm now at the
National Science Foundation, on leave, temporarily, to direct the Divi-
sion of Socioeconomic Sciences. This is a relatively small program. I
think our Directorate, which includes the Behavioral and Cognitive Sci-
ences as well, has a budget of about a hundred and ninety million dollars
when the next smallest program has half a billion dollars to spend. As
you know the other sciences are often referred to as the hard sciences.
That might be true, but the social sciences are the difficult sciences. That
is, the problems that the social science deal with are in many ways less
tractable than the problems with which many so-called hard scientists
must contend. I have no doubt that given enough time and investment
we're going to uncover the causes of many diseases, that we will under-
stand the genetic structure of germs and advance pharmacogenomics
among other things. I have much more doubt that we'll ever resolve sat-
isfactorily and, without considerable clashes, debates about human
embryo stem cell research or therapeutic cloning. The issues that we're
trying to grasp in a forum like this are truly difficult. This is, in part, be-
cause their answers cannot be found through hard science. There is no
one best patenting system for biological products, or if there is, nobody
knows or can prove what that best system is in the way scientific hy-
potheses can be tested and proved.
At the same time, I think we've learned from these panels something
else I deeply believe is true. Scientific progress and, particularly the hard
science progress, has become inextricably linked with developing effec-
tive ways to deal with value and other social issues. Several forces put up
roadblocks to scientific progress, such as the potential roadblock to
therapeutic cloning if Congress passes certain bills now before it, and the
President signs them as he says he will. We have also seen progress
slowed by disputes over embryonic stem cell research, suspicion of
GMOs and similar bones of contention. In short, the advance of science
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depends, in part, on our resolving the kinds of issues that we have been
discussing today, at least to some point of general satisfaction.
Listening to Philip Reilly, there was much I found intriguing. I was
particularly struck by his interesting statistic that more bills were intro-
duced in state legislatures across the country on the topic of regulating
genetic information for insurance purposes, than any other topic. When
you think of the concern with crime, with welfare and with the economy,
it seems extraordinary that somehow genetic information should be at
the top of the attention list of state legislatures. There are lots of reasons
for this. One is that there are real problems here, though, ironically, at
the time these bills were being introduced, we were far from having to
confront most of them because we didn't have that much genetic infor-
mation which was of use to insurers. Hence, while I think the spate of
bills on genetics and insurance are aimed at real problems, they also re-
flect something else, fears of change and of the unknown. For a while
with respect to biotechnology and now in nanotechnology, there is sub-
stantial fear of what the future holds. Some of that fear exists for good
reason and sometimes one wishes the scientists advancing these tech-
nologies were a bit more fearful. Some of it is of the "person's read too
much science fiction" variety. People think that dangers they can imag-
ine are imminent or certain to happen at some time. These fears are also
fed by publicity seekers, like the people who claimed to have cloned
humans. But whether fears are justified or not they are real and need to
be taken seriously and responded to. This is in part for the sake of those
who needlessly fear and in part because even baseless fears can derail
scientific progress. It is also in part because fears that are not baseless
may be underappreciated by scientists or commercial exploiters of sci-
ence, each of whom has incentives to ignore the dangers of low
probability, high cost outcomes. We have seen possible examples of this
in several gene therapy trials including, most famously, the research at
the University of Pennsylvania that led to the death of Jesse Gelsinger.
Because popular fears tend to focus on outcomes that are unambigu-
ously bad, usually extreme and easy to characterize or visualize, I think
popular fears often lead us to focus on the wrong issues or the wrong
aspects of issues. GMOs (genetically modified organisms and crops) are
a good example. As Phil Reilly has pointed out, both here and last night
at the conclusion of Ann Arbor Reads, GMOs may not be accepted in
Western Europe, but everyday in China farmers are planting more and
more GMOs, and they're doing it for a good reason. They have a large
population to feed, and they're finding they have a much better yield per
hectare from GMOs, than from customary crops. GMOs allow them to
feed China's population, prevent starvation and save lives. Clearly
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GMOs have tremendous potential for good. The problems, which has
stalled the acceptance of GMOs in Europe and which gives many people
pause is the fear that if we eat these so-called "frankenfoods," we will be
seriously harmed. I don't think these fears are completely fanciful; in
particular the danger that we may be obscuring or creating allergens
which may harm a small percentage (but still a large number) of people
strikes me as real. However, only limited gene transfer work has been
done in food crops to date, and no widespread harm has been reported.
I'm not, however, sure that immediate adverse health consequences is
the danger that demands most attention, especially as those producing
GMOs are acutely aware of this potential for harm and of what GMO-
induced deaths would do to their markets.
Let me illustrate my point about misplaced concerns by switching the
example. Some years ago, Monsanto got in big trouble through its inclu-
sion in certain seeds of a "terminator" gene. This gene meant that crops
grown from Monsanto seeds would be sterile, so those planting these
GMOs would always have to come back to Monsanto for more seed. They
couldn't save seed from their crops for planting. Monsanto took a lot of
flack about how this would destroy subsistence farming; they were named
exemplars of corporate greed, etc. Eventually Monsanto terminated the
terminator gene.
I don't want to denigrate the concern about the culture and liveli-
hood of subsistence farmers, nor do I want to claim that Monsanto is less
concerned with maximizing profits than the next company, but I do want
to point to another concern about GMOs, which may have considerable
substance. This is the escape of GMO varieties and genes into the envi-
ronment. I don't know enough about the biotechnology, but it seems to
me that we might want to incorporate a terminator gene in genetically
modified crops not to maximize profits but to prevent the uncontrolled
spread of GMOs in the environment and cross-pollenization with native
species that can then reproduce. Another example is the concern over BT
corn; that is corn that has been genetically modified to produce BT, a
natural pesticide. People oppose its planting by appealing to the yuck
factor. Here is the yuck: do you want to eat insecticide? Behind this
yuck, there is a serious issue, for the concern is not so silly that it may be
dismissed out of hand. But willingly or unwillingly virtually everyone in
this country who eats corn or soy beans or products made from them has
been ingesting these BT products, and no clear evidence of harm has to
date emerged.
My fear is that this concern for health draws our attention away from
more likely harms. It is almost certain, indeed it seems to be happening
already, that over the not very long run insects that feed on BT corn and
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soy beans, will evolve, so that the pesticide is no longer an effective way
of controlling them. If this happens what we will have done is taken an
organic, natural pesticide, (one of the few that organic farms have avail-
able) which if used selectively and on a limited basis, might be useful for
the next fifty or a hundred years, and shortened its effective life to per-
haps ten years, before insects evolve so that they are not affected by BT,
whether it comes in corn or it comes in the application of a pesticide.
Again, what grabs the popular imagination and what creates the fear is
not always a likely harm, and it can distract our attention from problems
that should be of more immediate concern to us.
Now let me turn to regulation of life science research, and share with
you several concerns. One concern is widespread within the social sci-
ences. Because the potential dangers faced by subjects in clinical trials
involving new biotechnologies and celebrated lapses in research ethics
with tragic consequences (the study that recruited Jessie Gelsinger
comes to mind), universities, spurred on by the federal government, are
erecting higher barriers to research involving human subjects in the form
of more careful Internal Review Board (IRB) examinations of research
protocols. In the abstract, it is hard not to applaud this. But many social
scientists complain that IRB's are applying standards designed for situa-
tions in which there may be lives at risk, to surveys and other research
with very low harm potential. Standards of informed consent well suited
for subjects in clinical trials where lives might be lost can make low risk
social science research, like some survey research, difficult if not impos-
sible. For example, if a survey researcher must explain why a question is
being asked, answers may be so likely to be distorted that they are use-
less. In short, clinical models of research do not always apply in other
settings and we must be wary of taking this one model and applying it
across the board. More generally, this issue serves to remind us of the
subtle ways in which life science research has widespread ripple effects.
Ripples of life science research that are of low visibility in universities or
social systems occasionally become far more salient because of the is-
sues they raise.
It's also worth reflecting on the instinct to withdraw funds for politi-
cally controversial life science research. As Becky said, this is a
questionable strategy, even from the point of view of regulation, because
funding gives leverage for regulation. Funders can impose rules for how
money will be spent, and the possible withdrawal of funds is a powerful
incentive to meet standards. If our government is not funding human
embryonic stem cell research (HESCR) or is funding too limited a set of
cell lines to allow rapid progress, the research is likely to find a home in
other countries or in private industry. This research will almost certainly
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proceed with much less regulation, oversight and transparency than
would occur if our government were funding it with a set of reasonable
regulations and reasonable requirements for transparency. The problem
is that official support for human embryonic stem cell research has a
symbolic importance for some politically powerful groups such that they
prefer the official affirmation of their values to policies that may make
their concerns less likely to be realized.
This reflects a more fundamental problem which has helped shape
the debate on both therapeutic cloning (i.e. cloning not designed to pro-
duce human babies but rather to produce stem cells that might be used to
fight disease in the cell donor) as well as human embryonic stem cell
research. I'll use the latter as my example, and simply state my position
in the debates about this research. Becky referred to HESCR as morally
controversial, or morally problematic. I see nothing morally problematic
about the HESCR that's being proposed. I see nothing morally problem-
atic because although it's true that this research uses and destroys human
or pre-human life (depending on when one thinks human life begins) the
proposed sources are embryos that were created for in vitro assisted re-
production, that were not needed for this purpose and that after a period
of time in storage will be destroyed. (It is estimated that more than
200,000 such embryos are in storage today.) No human life, assuming
barely visible embryos are human life, that would endure is destroyed
nor, from everything we know, will any life experience pain. Created cell
lines will, however, endure and will be used to find ways to preserve the
lives of babies and other people and prevent their suffering and pain. The
hardly differentiated embryo-no larger than the period at the end of this
sentence-suffers no different fate than it would have eventually suf-
fered, and some people's lives may be saved or wonderfully transformed.
So I personally don't see any moral problem raised by HESCR unless
it's the moral problem of preventing research that could save human
lives.
But there are large numbers of people who feel differently. To them,
the moral question is as clear as it is to me. For them, human life begins
at conception, and it doesn't matter if the embryonic sources of stem
cells are doomed anyway. We should not intentionally be taking their life
whatever their likely eventual fate. Life in this view must be respected,
and no matter how noble the aim in taking it, it cannot be treated as a
means to an end, even the end of saving other lives that are not necessar-
ily doomed.
How does one reconcile these competing views? I do not see any
way. I also think we should recognize that these are both legitimate
moral positions. Decent, thoughtful, moral people can hold different
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positions in the HESCR debate, but by and large, they can only talk
around the problem. If one side objects to the claim that the embryos
used will be destroyed anyway by saying they might be adopted, the
other side says it is willing to make adoption a priority and use only em-
bryos that will be discarded, but the response seldom persuades. If
responses like these don't persuade, I don't think we can persuade, and
we certainly shouldn't coerce opinion change.
So what can we do to resolve these issues? I think we actually have a
very good way of resolving the issues, and it's called democracy. When
we have value conflicts, we can vote on how we want to resolve them.
Democratic resolution works as well or better than other methods of re-
solving value disputes so long as it combines two things: majority rule
with respect for opposing positions. Even while imposing a resolution-
which is what even democracies do in the end-each side should recog-
nize that differing positions in the HESCR debate are not silly but reflect
deeply held positions by thoughtful moral people. The winning majority
should not run roughshod over the minority but should require only the
minimum that must happen to implement its views while maintaining
maximum respect for the other's position.
Problems with the democratic solution arise when a minority has po-
litical leverage, meaning that through political pressure, its views can
prevail over the majority's. It doesn't matter if the minority is the biotech
industry or a "right to life" or "right to choose" lobby. Minority control
tends to delegitimize resolutions and creates tensions that are difficult to
resolve as well as resentment on both sides.
The Conference has raised a number of other fascinating issues.
Consider the question whether people should retain ownership of body
parts removed in surgery and in cell lines drawn from their tissues. One
might argue that giving individuals ownership rights will not help them
at all because surgeons, researchers and hospitals can always make waiv-
ing ownership interests a condition of operating, and what patient will
refuse a possible life-saving operation because he wants to retain an
ownership interest in an organ to be removed. Contracts for surgery will
invariably be contracts of adhesion. It is, of course, not clear that we
should want to give patients ownership rights in their tissues, for no mat-
ter how unique their biological material, it is the researcher's work that
gives it its value. But if we do see a moral or ethical problem here-after
all what is more completely one's property than one's body-traditional
notions of ownership are likely to be of little help in resolving it. Rather,
we must consider unbundling the concepts of ownership and the idea of
property rights. We might, for example want to give people inalienable
right to a percentage of profits that can be traced to research using
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unique features of their tissues while not letting them exercise other pre-
rogatives of ownership, such as blocking the use of one's property by
others regardless of reasons. We must, I would argue, deconstruct tradi-
tional notions of property and reconstruct them if we are to deal
effectively with the numerous issues that advances in the life sciences
are likely to raise. Creative lawyering may be as important as good sci-
ence in realizing the benefits of what science allows. Lawyers should do
a lot more thinking about those issues.
Gene patents provide another example of policy issues that require
legal and social science attention. Maybe we want to allow genetic in-
formation to be patented for some purposes and not for others, or
perhaps we should allow wide open patenting with compulsory licens-
ing. There are many points midway between total ownership with the
full bundle of property rights and denying property interests altogether.
Indeed as we heard today that universities and other actors are asserting
or enforcing property interests that are compromises between competing
values. We also have groups, like the SNP consortium, that is rushing to
put information in the public domain so that it cannot be patented. The
federal human genome project had similar policies and provided for the
release of genetic information almost as soon as it could be ascertained.
One problem which the issue of property rights in the genome has in
common with other issues raised by advances in the life sciences is that
there is little consensus about the basic principles we should draw on to
resolve it. Yet we need to draw on core principles if we are to get beyond
self-interest and the political lobbying that goes with it. The problem is
we don't have a basic consensually agreed-upon set of principles. Moral
philosophy, where one might look for such principles, seems of little
help because moral philosophers themselves have no agreed-on perspec-
tive. Different bioethicists draw differentially on the virtue school,
utilitarianism, deontological philosophy and other perspectives. It's go-
ing to be hard, if it's possible at all, to come up with a core set of moral
principles that most people, or even most philosophers, will accept.
Some questions are to be sure, easy. Today, for example, the permis-
sibility of human reproductive cloning presents an easy question. I don't
know of any responsible life scientist, social scientist, lawyer or ethicist
who believes we should be creating a human "Dolly." But this is an easy
question because the science itself suggests that there are tremendous
risks involved. Suppose, however, these risks diminish, and experiments
with primates convince us that cloned babies will encounter no more
difficulty than babies that result from in vitro fertilization. What then?
Surely, opposition to human reproductive cloning will not melt away
entirely. Indeed it may hardly melt away at all, but it is likely that the
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consensus that now exists on the issue will be shattered. Moreover, even
among those who reach similar conclusions, principles that justify the
conclusions are likely to differ.
The final point I wish to comment on was raised during the last
panel's discussion of the challenges of managing tech transfer and the
issues that arise in considering tech transfer. It is fair to say that this
panel was composed of three cheerleaders for university involvement in
tech transfer, and I will confess my own bias, which is that I am some-
what of a cheerleader as well. I believe it is on balance a good thing for
universities to be involved in tech transfer to try to facilitate the applica-
tion of university based inventions to the resolution of human problems
while returning a profit to the university. But as some of the questions
indicated, there are many people, particularly within universities, who
are deeply concerned about the implications of tech transfer. Their con-
cerns are not frivolous. A major concern is that research directions will
be distorted and the openness associated with university-based research
will diminish. There is evidence this is already occurring. At the Univer-
sity of California, Berkley, for example, one department in return for
substantial financial support purportedly established a research agenda to
please a commercial supporter and agreed to give the company an early
look at all research results produced by department researchers regard-
less of whether the company's funds had supported their work. But even
without such overt institutional commitments, commercial interests will
almost inevitably effect individual research. Imagine a scientist who has
a choice of working on two problems that are intellectually fascinating
and practically important. One of them is perhaps a little more interest-
ing, but the other one, if it succeeds, will make the scientist wealthy.
Which topic will the scientist study? I don't know about you, but I would
shamelessly choose the one that might make me rich. I don't think this
choice is a sin, but in the long run and in the aggregate, such choices risk
the distortion of priorities and ignoring of basic research in favor of work
with more immediate financial pay off.
There's also the issue of whether universities are subsidizing private
gain. Few university professors entered the academy to become rich and
few have done so. But, although only a small proportion of professors
have grown wealthy from their research, stories of such people circulate
as do stories of professors who have subordinated teaching and scholarly
duties to financial interests. Regardless of the representation of such sto-
ries or even their veracity, their circulation can do harm. Universities can
lose good will and invite regulation and people less committed to aca-
demic values may be attracted to faculty ranks.
Life Sciences, Technology, and the Law
Of more immediate consequence are the effects of commercial sup-
port and interests on publication and sharing research materials. We are,
I think, in the last decade or so, seeing delays in publication, pending
legally protective disclosures and maintaining secrets to see if there is a
commercially valuable further step that could be taken before work is
publicized. There is particular concern about the effects that commercial
considerations have had on the transfer of cell lines and other biological
materials between researchers and laboratories. Delays in or roadblocks
to research also arise out of efforts to work out the intellectual property
implications of shared materials and technology. Transfers may, for ex-
ample, be forestalled by disputes over "downstream" rights. As troubling
are claims that graduate students are being exploited, by, for example,
being assigned projects that advance a supervisor's commercial interests
rather than projects that best meet the student's intellectual interests and
educational needs. One even hears tales of graduates whose thesis com-
pletions were delayed so that they could continue to work on a
professor's commercially promising studies. And professors who spin
off companies to exploit their discoveries may hire their best graduate
students rather than direct them to academic careers.
I don't want to exaggerate any of these claimed costs to university
tech transfer, but I think we have to be aware that these are concerns that
some university faculty voice; that they have led some faculty to oppose
efforts like the University of Michigan's Life Science Initiative, and that
none of these concerns is completely fanciful. Problems with excessive
secrecy, publication delay, difficulties in securing or transferring biologi-
cal materials and the exploitation of graduate students have all been
described in the literature. So it was that when several years ago LSVSP
cosponsored a forum dealing with some of these issues, we had as a
theme "Facing the Brave New World." And this is what we must do. We
have in the modern life sciences tremendous potential for good for the
sciences, for the university and for the larger society. This potential is
being realized every day, at the University of Michigan, in the state's
Life Sciences Corridor, throughout the United States, and within foreign
countries. At the same time, there are red flags that signal real dangers. It
wasn't likely that Jesse Gelsinger would die in gene therapy, but he did.
Altered genes from genetically modified corn weren't expected to be
incorporated in native Mexican maize, but this has apparently happened.
Lots of other untoward outcomes are not likely, but they may occur. We
must work to anticipate them and try to minimize the likelihood they
will come to pass. We won't always succeed. But absent horrendous bad
luck, the fruits of life science research should far exceed its costs.
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MATT MOCK: Thank you very much Professor Lempert. And
thanks everybody for coming today. If you're registered for our banquet,
it begins tonight at the Campus Inn, at six-thirty. Thanks again. Have a
good night.
